Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  24 May 2022  Page 1 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Title Page  
Protocol Title:  A Phase 2b Dose Ranging Study to Evaluate the 
Efficacy and Safety of Rozibafusp Alfa (AMG 570 ) 
in Subjects With Active Systemic Lupus 
Erythematosus (SLE) With Inadequate Response 
to Standard of Care (SOC) Therapy  
Short Protocol Title:  Safety and Efficacy of AMG 570 in Subjects With 
Active Systemic Lupus Erythematosus (SLE)  
Protocol Number:  20170588  
Investigational Product:  Rozibafusp Alfa (AMG 570)  
Sponsor  Name of Sponsor:  Amgen Inc.  
Address:  One Amgen Center Drive,  
Thousand Oaks, CA, 91320, USA  
Telephone 
Number:  +1 (805) 447 -1000  
Protocol 
Approver  Name:  MD 
Function:  Vice President Global Development  
Key 
Sponsor 
Contact  
 Name:  MD, PhD  
Address:  One Amgen Center Drive,  
Thousand Oaks, CA, 91320, USA  
Telephone 
Number:  
Email Address:  
EudraCT Number:  2019 -000328 -16 
NCT Number:  04058028  
Protocol Date:  Document Version  Date  
Original  26 February 2019  
Amendment 1  28 February 2020  
Amendment 2  13 October 2020  
Superseding 
Amendment 2  11 November 2020  
Amendment 3 24 May 2022  
 
Version/Date:  
 Data Element Standards Version  
6.1 
 
 

Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  24 May 2022  Page 2 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Confidentiality Notice  
This document contains confidential information of Amgen Inc.  
This document must not be disclosed to anyone other than the site study staff and 
members of the institutional review board/independent ethics committee/institutional 
scientific review board or equivalent.  
The information in this document cannot be used for any purpose other than the 
evaluation or conduct of the clinical investigation without the prio r written consent of 
Amgen Inc.  
If you have questions regarding how this document may be used or shared, call the 
Amgen Medical Information number: US sites, 1 - 800-77-AMGEN; Canadian sites, 
1-866-50-AMGEN; for all other countries, call 1 -800-772-6436 ; Amg en’s general 
number in the US, 1 -805-447-1000.  
Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  24 May 2022  Page 3 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Investigator’s Agreement:  
I have read the attached protocol entitled A Phase 2b Dose Ranging Study to Evaluate 
the Efficacy and Safety of Rozibafusp Alfa (AMG 570) in Subjects With A ctive Systemic 
Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) 
Therapy , dated 24 May 2022 , and agree to abide by all provisions set forth therein.  
I agree to comply with the International Council for Harmonisation (ICH) Tri partite 
Guideline on Good Clinical Practice (GCP), Declaration of Helsinki, and applicable 
national or regional regulations/guidelines.  
I agree to ensure that Financial Disclosure Statements will be completed by: me 
(including, if applicable, my spouse or legal partner and dependent children) and my 
sub investigators (including , if applicable, their spouses or legal partners and dependent 
children) at the start of the study and for up to 1 year after the study is completed, if 
there are changes that affect my financial disclosure status.  
I agree to ensure that the confidential information contained in this document will not be 
used for any purpose other than the evaluation or conduct of the clinical investigation 
without the prior written consent of Amgen In c. 
 
_______________________________  
Signature  
_______________________________   ____________________________  
Name of Investigator      Date (DD Month YYYY)  
Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  24 May 2022  Page 4 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Table of Contents  
Table of Contents  ................................ ................................ ................................ ... 4 
1. Protocol Synopsis  ................................ ................................ ................................ . 10 
2. Study Schema and Schedule of Activities  ................................ .............................  18 
2.1 Study Schema  ................................ ................................ ...........................  18 
2.2 Schedule of Activities  ................................ ................................ ................  19 
3. Introduction  ................................ ................................ ................................ ...........  28 
3.1 Study Rationale  ................................ ................................ .........................  28 
3.2 Background  ................................ ................................ ...............................  28 
3.2.1  Disease  ................................ ................................ .....................  28 
3.2.2  Amgen Investigational Product Background:  
AMG  570 ................................ ................................ ...................  29 
3.3 Clinical Studies With AMG 570  ................................ ................................ .. 29 
3.3.1  First in Human (FIH) Study 20140322  ................................ ....... 29 
3.3.1.1  FIH Study 20140322 – Clinical 
Pharmacokinetics  ................................ ....................  30 
3.3.1.2  FIH Study 20140322 – Clinical 
Pharmacodynamics  ................................ .................  30 
3.3.2  Amgen Study 20160344  ................................ ............................  30 
3.3.3  Amgen Study 20150196  ................................ ............................  31 
3.4 Toxicology  ................................ ................................ ................................ . 31 
3.5 Benefit/Risk Assessment  ................................ ................................ ...........  31 
3.5.1  Therapeutic Context  ................................ ................................ .. 32 
3.5.2  Key Benefits  ................................ ................................ ..............  32 
3.5.3  Key Risks  ................................ ................................ ..................  32 
4. Objectives, Endpoints and Hypothesis  ................................ ................................ .. 34 
4.1 Objectives and Endpoints  ................................ ................................ ..........  34 
4.2 Hypothesis  ................................ ................................ ................................  38 
5. Study Design  ................................ ................................ ................................ ........  38 
5.1 Overall Design  ................................ ................................ ..........................  38 
5.2 Number of Subjects  ................................ ................................ ...................  40 
5.2.1  Replacement of Subjects  ................................ ...........................  40 
5.2.2  Number of Sites  ................................ ................................ .........  40 
5.3 End of Study  ................................ ................................ .............................  40 
5.3.1  End of Study Definition  ................................ ..............................  40 
5.3.2  Study Duration for Subjects  ................................ .......................  41 
5.4 Justification for Investigational Product Dose  ................................ ............  41 
5.5 Patient Input on Study Design  ................................ ................................ ... 43 
6. Study Population  ................................ ................................ ................................ .. 43 
6.1 Inclusion Criteria Screening Visit  ................................ ..............................  44 
Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  24 May 2022  Page 5 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
6.2 Exclusion Criteria Screening Visit  ................................ .............................  45 
6.3 Inclusion Criteria Baseline/Day 1 Visit ................................ .......................  49 
6.4 Subject Enrollment  ................................ ................................ ....................  49 
6.5 Screen Failures  ................................ ................................ .........................  50 
7. Treatments  ................................ ................................ ................................ ...........  50 
7.1 Treatment Procedures ................................ ................................ ...............  51 
7.1.1  Investigational Products  ................................ ............................  51 
7.1.2  Non-investigational Products  ................................ .....................  53 
7.1.3  Medical Devices  ................................ ................................ ........  53 
7.1.4  Other Therapies  ................................ ................................ ........  53 
7.1.4.1  Immunosuppressants/Immunomodulators  ...............  53 
7.1.4.2  Oral, Intramuscular, and Intravenous 
Corticosteroids  ................................ ........................  53 
7.1.4.3  Topical Corticosteroids and Topical 
Calcineurin Inhibitors  ................................ ...............  54 
7.1.4.4  Non-steroidal Anti -inflammatory Drugs 
(NSAIDs) and Other Analgesic Therapies  ...............  54 
7.1.4.5  Anti-proteinuria Agents  ................................ ............  54 
7.1.5  Other Treatment Procedures  ................................ .....................  54 
7.1.5.1  Home Health Care Visits  ................................ .........  54 
7.1.6  Product Complaints  ................................ ................................ ... 55 
7.1.7  Excluded Treatments, Medical Devices, and/or 
Procedures During Study Period  ................................ ...............  56 
7.2 Method of Treatment Assignment  ................................ .............................  56 
7.3 Blinding  ................................ ................................ ................................ ..... 56 
7.3.1  Site Personnel Access to Individual Treatment 
Assignments  ................................ ................................ .............  57 
7.3.2  Access to Individual Subject Treatment Assignments 
by Amgen or Designees  ................................ ............................  57 
7.3.3  Unblinding Procedure For Investigators  ................................ ..... 58 
7.4 Dose Modification  ................................ ................................ ......................  58 
7.4.1  Dose -cohort Study Escalation/De -escalation and 
Stopping Rules  ................................ ................................ ..........  58 
7.4.2  Dosage Adjustments, Delays, Rules for Withholding or 
Restarting, Permanent Discontinuation  ................................ ..... 58 
7.4.2.1  Amgen Investigational Product:  AMG 570 
or Placebo  ................................ ...............................  58 
7.4.2.2  Non-Amgen Non -Investigational Product:  
SLE Standard of Care Therapy and Oral 
Corticosteroids  ................................ ........................  58 
7.4.3  Hepatotoxicity Stopping and Rechallenge Rules  .......................  59 
7.5 Preparation/Handling/Storage/Accountability  ................................ ............  59 
7.6 Treatment Compliance  ................................ ................................ ..............  59 
7.7 Treatment of Overdose  ................................ ................................ .............  59 
Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  24 May 2022  Page 6 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
7.8 Prior and Concomitant Treatment  ................................ .............................  59 
7.8.1  Prior Treatment  ................................ ................................ .........  59 
7.8.2  Concomitant Treatment  ................................ .............................  59 
8. Discontinuation Criteria  ................................ ................................ .........................  60 
8.1 Discontinuation of Investigational Product  ................................ .................  60 
8.2 Discontinuation From the Study  ................................ ................................  61 
8.2.1  Reasons for Removal From Study  ................................ .............  61 
8.3 Lost to Follow -up ................................ ................................ .......................  62 
9. Study Assessments and Procedures  ................................ ................................ .... 62 
9.1 General Study Periods  ................................ ................................ ..............  62 
9.1.1  Screening, Enrollment and/or Randomization  ............................  62 
9.1.2  Treatment Period  ................................ ................................ ....... 64 
9.1.3  Safety Follow -up ................................ ................................ ........  64 
9.1.4  Long -term Follow -up ................................ ................................ .. 64 
9.1.5  End of Study  ................................ ................................ ..............  64 
9.1.5.1  End of Study for Individual Subject  ..........................  64 
9.1.5.2  End of Study  ................................ ...........................  65 
9.2 Description of General Study Assessments and Procedures  .....................  65 
9.2.1  General Assessments  ................................ ...............................  65 
9.2.1.1  Informed Consent  ................................ ....................  65 
9.2.1.2  Demographics  ................................ .........................  65 
9.2.1.3  Medical History  ................................ ........................  65 
9.2.1.4  Physical Examination  ................................ ..............  65 
9.2.1.5  Concomitant Medications  ................................ ........  65 
9.2.1.6  Physical Measurements  ................................ ..........  65 
9.2.1.7  Substance Abuse History  ................................ ........  66 
9.2.2  Efficacy Assessments  ................................ ................................  66 
9.2.2.1  Hybrid Systemic Lupus Erythematosus 
Disease Activity Index  ................................ .............  66 
9.2.2.2  British Isles Lupus Assessment Group 
Index  ................................ ................................ ....... 67 
9.2.2.3  Cutaneous Lupus Erythematosus Disease 
Area and Severity Index  ................................ ..........  67 
9.2.2.4  Photography  ................................ ............................  67 
9.2.2.5  Swollen and Tender Joint Count  .............................  67 
9.2.2.6  Physician Global Assessment – Visual 
Analogue Scale  ................................ .......................  68 
9.2.2.7  SELENA -SLEDA I Flare Index  ................................ . 69 
9.2.2.8  BILAG Flare Index  ................................ ...................  69 
9.2.2.9  Lupus Low Disease Activity State (LLDAS)  .............  69 
9.2.2.10  Systemic Lupus International 
Collaborating Clinics/American College of 
Rheumatology Damage Index  ................................ . 69 
Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  24 May 2022  Page 7 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
9.2.2.11  Systemic Lupus Erythematosus 
Responder Index  ................................ .....................  69 
9.2.2.12  BICLA Index Response  ................................ ...........  70 
9.2.3  Safety Assessments  ................................ ................................ .. 70 
9.2.3.1  Adverse Events and Serious Adverse 
Events  ................................ ................................ ..... 71 
9.2.3.2  Vital Signs  ................................ ...............................  73 
9.2.4  Clinical Laboratory Assessments  ................................ ...............  74 
9.2.4.2  Pregnancy Testing  ................................ ..................  74 
9.2.4.3  Tuberculosis Testing  ................................ ...............  75 
9.2.4.4  HIV Antibodies, Hepatitis B, and 
Hepatitis  C Testing  ................................ ..................  75 
9.2.5  Pharmacokinetic Assessments  ................................ ..................  75 
9.2.6  Pharmacodynamic Assessments  ................................ ...............  76 
9.2.6.1  Biomarker Assessment During the Study  ................  76 
9.2.7  Pharmacogenetic Assessments ................................ .................  76 
9.2.9  Biomarker Development  ................................ ............................  77 
9.2.10  Clinical Outcome Assessments:  Patient Reported 
Outcomes  ................................ ................................ ..................  77 
9.2.10.1  Medical Outcomes Short Form -36 
Questionnaire Version  2 ................................ ..........  77 
9.2.10.2  Patient -Reported Outcome Measurement 
Information System Fatigue Short Form 7a 
Instrument (PROMIS Fatigue SF 7A)  ......................  77 
9.2.10.3  LupusQoL  ................................ ...............................  78 
9.2.10.4  Patient Global Assessment  ................................ ..... 78 
10. Statistical Considerations  ................................ ................................ ......................  80 
10.1  Sample Size Determination  ................................ ................................ ....... 80 
10.2  Analysis Sets, Subgroups, and Covariates  ................................ ................  80 

Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  24 May 2022  Page 8 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
10.2.1  Analysis Sets  ................................ ................................ .............  80 
10.2.1.1  Full Analysis Set  ................................ ......................  80 
10.2.1.2  Safety Analysis Set  ................................ .................  80 
10.2.1.3  PK Concentration Analysis Set  ................................  80 
10.2.1.4  PK Parameter Analysis Set  ................................ ..... 81 
10.2.1.5  PD Analysis Set  ................................ ......................  81 
10.2.2  Covariates  ................................ ................................ .................  81 
10.2.3  Subgroups  ................................ ................................ .................  81 
10.3  Statistical Analyses  ................................ ................................ ...................  81 
10.3.1  Planned Analyses  ................................ ................................ ...... 82 
10.3.1.1  Interim Analysis and Early Stopping 
Guidelines  ................................ ...............................  82 
10.3.1.2  Primary Analysis  ................................ .....................  83 
10.3.1.3  Final Analysis  ................................ ..........................  83 
10.3.2  Methods of Analyses  ................................ ................................ . 83 
10.3.2.1  General Considerations  ................................ ...........  83 
10.3.2.2  Efficacy Analyses  ................................ ....................  84 
10.3.2.3  Safety Analyses  ................................ ......................  84 
10.3.2.4  Other Analyses  ................................ ........................  85 
11. References  ................................ ................................ ................................ ...........  86 
12. Appendices  ................................ ................................ ................................ ...........  88 
12.1  Appendix 1.  List of Abbreviations and Definitions of Terms  ......................  89 
12.2  Appendix 2.  Clinical Laboratory Tests  ................................ ......................  92 
12.3  Appendix 3.  Study Governance Considerations  ................................ ....... 95 
12.4  Appendix 4.  Safety Events:  Definitions and Procedures for 
Recording, Evaluating, Follow -up and Reporting  ................................ ..... 103 
12.5  Appendix 5.  Contraceptive Guidance and Collection of 
Pregnancy and Lactation Information  ................................ ......................  111 
12.6  Appendix 6.  Sample Storage and Destruction  ................................ ........  116 
12.7  Appendix 7.  Hepatotoxicity Stopping Rules:  Suggested Actions 
and Follow -up Assessments and Investigational Product 
Rechallenge Guidelines  ................................ ................................ ..........  118 
 

Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  24 May 2022  Page 9 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
List of Tables  
Table  1-1.  Analyses Schedule:  Decisions at each Interim Analysis,  Primary 
Analysis, and Final Analysis  ................................ ................................ ... 16 
Table  2-1.  Schedule of Activities – Treatment Period  ................................ ...................  19 
Table  2-2.  Schedule of Activities – Safety Follow -up Perioda ................................ ........  25 
Table 7 -1.  Investigational Products  ................................ ................................ ...............  52 
Table 12 -1.  Analyte Listinga ................................ ................................ ..........................  93 
Table  12-2.  Conditions for Withholding and/or Permanent Discontinuation of 
Amgen Investigational Product and Other Protocol -required 
Therapies Due to Potential Hepatotoxicity  ................................ ............  119 
List of Figures  
Figure 2 -1.  Study Schema  ................................ ................................ ............................  18 
Figure  6-1.  Screening and Enrollment  ................................ ................................ ..........  44 
Figure  12-1.  Sample Electronic Serious Adverse Event Contingency Report 
Form  ................................ ................................ ................................ ..... 108 
Figure 12-2.  Pregnancy Notification Form  ................................ ................................ .. 114 
Figure  12-3.  Lactation Notification Form  ................................ ................................ ..... 115 
 

Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  24 May 2022  Page 10 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
1. Protocol Synopsis  
Protocol Title:   A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of 
Rozibafusp Alfa (AMG 570) in Subjects With Active Systemic Lupus Erythematosus 
(SLE) With Inadequate Response to Standard of Care (SOC) Therapy  
Short Protocol Title:   Safety and Efficacy of AMG 570 in Subjects With Active Systemic 
Lupus Erythematosus (SLE)  
Study Phase:   2b 
Indication:   systemic lupus erythematosus (SLE)  
Rationale : 
This is a phase 2b dose -ranging study to assess efficacy and safety of rozibafusp alfa 
(AMG  570) in subjects with active SLE.  AMG 570 could be a viable treatment option for 
SLE patients who are not responding to current standard of care.  
Objectives/Endpoints  
Objectives  Endpoints  
Primary  
 Evaluate the efficacy of AMG 570 
at week 52 as measured by the 
Systemic Lupus Erythematosus  
(SLE)  Responder Index (SRI -4)  SRI-4 response at week 52  
The primary estimand is the difference in SRI -4 response between each AMG  570 
dose group and placebo at week 52 for all subjects with SLE with inadequate 
response to SOC therapy who are randomized, regardless of investigational product  
discontinuation; sub jects using more than protocol -allowed therapies will be 
considered as non -responders.   
Secondary  
 Evaluate the efficacy of AMG  570 
at week  24  SRI-4 response at week 24  
 British Isles Lupus Assessment 
Group ( BILAG ) based Combined Lupus 
Assessment (BICLA) response at 
week  24 
 Evaluate the efficacy of AMG  570 
at week 52   Lupus Low Disease Activity State 
(LLDAS) response at week  52 
 BICLA response at week  52 
 Evaluate the efficacy of AMG  570 
as measured by SRI -4 response  
with oral corticosteroid 
(OCS) -tapering   SRI-4 response at week  52 with 
reduction of OCS to  7.5 mg/day by 
week 44 and sustained through week  52 
in subjects with a baseline OCS dose 
 10 mg/day  
Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  24 May 2022  Page 11 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Objectives  Endpoints  
 Evaluate the efficacy of AMG  570 
on disease flares   Annualize d moderate and severe flare 
rate (as measured by SELENA -SLEDAI 
Flare Index) over 52  weeks  
 Annualized severe flare rate (as 
measured by SELENA -SLEDAI Flare 
Index) over 52  weeks  
 Annualized flare rate (as measured by 
BILAG score designation of “worse” or 
“new ” resulting in a B score in  2 organs 
or an A score in  1 organ) over 
52 weeks  
 Evaluate the efficacy of AMG  570 
on joints and skin   Total tender and swollen joint count 
(limited  to hands and wrists ):   50 
improvement from baseline at week  12, 
24, 36, and 52 in subjects with  6 tender 
and swollen joints in hands and wrists at 
baseline  
 Cutaneous Lupus Erythematosus Area 
and Severity Index (CLASI) activity 
score :   50 improvement from 
baseline at week 12, 24, 36, and 52 in 
subjects with a CLASI activity score  8 
at baseline  
 Describe the efficacy of AMG  570 
using patient reported outcomes   Patient -Reported Outcome 
Measurement Information System  
Fatigue Short Form 7a Instrument 
(PROMIS -Fatigue SF7A) score and 
change from baseline at week 12, 24, 
36, 44, and 52  
 Medical Outcomes Short Form 36 
version 2 Questionnaire (SF -36v2) 
change from baseline in the physical 
component  score , mental component 
score individual domains of the 
Medical Outcomes Short Form 36 
version 2 questionnaire  (SF-36v2 ) at 
week 12, 24, 36, 44, and 52  
 Lupus  Quality of Life questionnaire  
(Lupus QoL) score and change from 
baseline at week 12, 24, 36, 44, and 52  
 Patient Global Assessment (PtGA) score 
and change from baseline at week 12, 
24, 36,  44, and 52  
Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  24 May 2022  Page 12 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Objectives  Endpoints  
 Characterize the safety of 
AMG  570  Treatment -emergent adverse events  
 Serious adverse events  
 Clinically significant changes in 
laboratory values and vital signs  
 To characterize the 
pharmacokinetics (PK) of AMG  570  Trough serum concentrations and 
terminal elimination half -life of AMG  570 
Exploratory  

Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  24 May 2022  Page 13 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Objectives  Endpoints  
Hypothesis  
AMG 570 administered for 52  weeks will be well tolerated and have greater efficacy than 
placebo as measured by Systemic Lupus Erythematosus Responder Index  (SRI-4) 

Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  24 May 2022  Page 14 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
response at week 52 in subjects with active SLE and an inadequate response to 
standard of care therapy.  
Overall Design  
This is a Bayesian adaptive phase 2b, multi -center, double -blind, randomized, 
placebo -controlled, 52 -week, dose -ranging study in subjects with active SLE and 
inadequate response to SOC therapies including oral corticosteroids ( OCS ), 
immunosuppressants, and immunomodulators.  Subjects will be randomized to receive 
either placebo or 1 of 3  doses of AMG 570 with the last dose at week 50.  Treatment  
will be administered every 2  weeks (Q2W).   Study duration for a single subject will be 
52 weeks plus the screening period and safety follow -up period.  Tapering of OCS from 
the baseline dose is allow ed up to  week 44 at the discretion of the investigator .  The 
first interim analysis (IA) will be executed after the first 40  enrolled subjects have had the 
opportunity to complete the week 24 assessment.  Additional IAs may be executed after 
approximately every 32 newly enrolled subjects have had the opportun ity to complete 
the week 24 assessment.  The last IA will occur when all 320 subjects are randomized 
and have had the opportunity to complete the week 24 assessment.  This IA will be 
referred to as the ‘all -subjects -week -24 IA’.  The purpose and analyses p lanned at each 
IA are listed in Table  1-1. 
Number of Subjects  
Approximately 320 subjects will be enrolled.  Because enrollment can be stopped if early 
stopping rules for futility are met, the actual sample size could be smaller.  
Summary of Subject Eligibility Criteria  
Eligible subjects must be between the ages of 18 and 75 years of age, inclusive, and be 
able to provide informed consent.  Subjects must fulfill the classification criteria for SLE 
according to the 2019 European League Against Rheumatism (EULAR)/American 
College of Rheumatology (ACR) classification criteria for SLE, with antinuclear antibody 
 1:80 by immunofluorescence on Hep -2 cells being present at screening.  In addition, at 
screening, subjects must have a Hybrid Systemic Lupus Erythematosus Disease 
Activity Index  (hSLEDAI ) ≥ 6 and a clinical hSLEDAI  4.  Subjects must be on a stable 
dose of OCS (  20mg/day of prednisone or equivalent) for  2 weeks prior to screening 
and stable dose of other standard treatment for SLE such as 
immunosuppressants/immunom odulators for  8 weeks prior to screening.  Subjects with 
active or unstable neuropsychiatric SLE or unstable lupus nephritis, or any disease other 
Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  24 May 2022  Page 15 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
than SLE requiring treatment with oral or parenteral corticosteroids for more than 
2 weeks within 6  weeks o f the screening visit or any clinically significant concurrent 
medical conditions and/or significant laboratory abnormalities will not be eligible 
(Section  6.2).  Female subjects must not be pregnant or breastfeeding or plan to 
become pregnant or breastfeed during treatment or for at least 10 additional weeks after 
the last dose of investigati onal product in the study.  
For a full list of eligibility criteria, please refer to Sections  6.1 to 6.3. 
Treatments  
AMG 570 and placebo will be manufactured and packaged by Amgen Inc. and 
distributed using Amgen clinical investigational product distribution procedures.  Both are 
liquid formulations presented in identical glass vials and stored in the same manner.  
AMG 570 or placebo will be administered by subcutaneous (SC) injection Q2W by the 
Principal Investigator (PI) or appropriately  trained designee.  
Procedures  
Written informed consent must be obtained from all subjects (or his/her legally 
authorized representative) before any study -specific screening procedures are 
performed.  The following procedures will occur per the Schedule  of Activities: medical 
history; physical examination; physical measures; vital signs; prior and concomitant 
medication assessment; tuberculosis testing; urinalysis; and blood draw for serum 
chemistry, hematology, Human Immunodeficiency Virus (HIV) antibod ies, hepatitis B 
and C testing, , biomarker development, and pharmacogenetics 
sampling.  Women of childbearing potential will have pregnancy tests performed at 
screening and at regular intervals during the study.  Disease assessments  (hSLEDAI, 
BILAG, Physician Global Assessment [ PGA ], swollen and tender joints count, 
Cutaneous Lupus Erythematosus Area and Severity Index  [CLASI ], photography of 
skin lesions in selected cases, and patient reported outcomes) will also be obtained.  
Safety assessments including adverse events, serious adverse events, and clinically 
significant changes in laboratory values and vital signs will be performed throughout the 
entire study including the safety follow -up. 
For a full list of study procedures , including  the timing of each procedure, please refer to  
Section  9.2 and the Schedule of Activities in Table  2-2. 

Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  24 May 2022  Page 16 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Statistical Considerations  
A total of approximately 320 subjects will be randomized to receive AMG 570 at 70  mg 
Q2W, 280 mg Q2W, 420  mg Q2W, or placebo.  The approximate sample size of 320 is 
chosen to provide 80% power to detect ≥ 25% absolute improvement for at least  1 
AMG  570 dose group relative to place bo in the primary endpoint of SRI -4 response rate 
at week 52 at a significance level of 0.025 (1 -sided) using a Bayesian Hierarchical 
Model, assuming a 40% response rate in the placebo group.  
Randomization will be stratified by geographic region and screen ing hSLEDAI score 
( 10 or < 10) and start with a fixed and equal allocation (1:1:1:1).  At the time of the IAs 
(if before full enrollment), the randomization probability for each of the 3 active doses 
may be updated based on clinical efficacy, while the r andomization allocation probability 
to placebo will be kept constant, ie, 25% .  IAs will be conducted as described in 
Table  1-1.  IAs will be implemented by an Independent Biostatistics Group (IBG) as 
described in Appendix 3  with decision rules specified in Section  10.3.1.1 . 
The primary analysis of the p rimary endpoint, SRI -4 at week 52, will be based on a 
Bayesian Hierarchical Model which borrows dynamically in order to share  information 
across the 3  active AMG 570 treatment groups while controlling the overall type I error at 
the 1 -sided 2.5% level acro ss multiple comparisons.  
Categorical variables will be summarized using the number and percent of subjects 
falling into each category.  All continuous variables will be summarized using mean, 
standard error or standard deviation, median, minimum, maximum, and number of 
subjects with observations.  Safety endpoints will be summarized descriptively.  
Table  1-1.  Analyses Schedule:  Decisions at each Interim Analysis,  
Primary Analysis, and Fina l Analysis  
Time point  Adaptive Decision  Number of subjects with 
opportunity to complete week 24  
1st IA  RAR  40 
2nd IA Futility, RAR  72 
3rd IA Futility, RAR  104 
4th IA Futility, RAR  136 
5th IA Futility, RAR  168 
6th IA Futility, RAR  200 
7th IAa Futility, RAR  232 
Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  24 May 2022  Page 17 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Last IAb Administrative Success  320 
Primary Analysis  Not applicable  All subjects have had the opportunity 
to complete week 52  
Final Analysis  Not applicable  All subjects reach EOS  
IA  interim analysis; RAR  response adaptive randomization; EOS  end of study  
a Interim analyses  are planned after every 32 subjects are randomized and have had the opportunity 
to complete the week 24 assessment until full enrollment .  Number of IAs will depend on the actual 
enrollment rate.  
b Last IA is the all -subjects -week -24 IA.  The administrative success analysis at the last IA will not result in 
any adaptive decision for the ongoing study.  
Refer to Section  10 for a full description of the statistical analysis methods.  
Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  24 May 2022   Page 18 of 121 
 
CONFIDE NTIAL  FORM -001520, v.22, 05 February 2018   
2. Study Schema and Schedule of Activities  
2.1 Study Schema  
Figure 2-1.  Study Schema  
 
 
EOS   end of study; IA   interim analysis; Q2W   every 2  weeks; RAR  Response Adaptive Randomization.  
 

Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  24 May 2022   Page 19 of 121 
 
CONFIDE NTIAL  FORM -001520, v.22, 05 February 2018   
2.2 Schedule of Activities  
Table  2-1.  Schedule of Activities – Treatment Period  
 Study Week  Screening  Treatment Period  
 
Baseline  
visit/Day  1 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52/ET  
Study Day ± 
Visit 
Window  Scr visit   1 (pre -rand)  1 (pre -dose)  1 (dose)  15 ±3  29 ±3  43 ±3  57 ±3  71 ±3  85 ±3  99 ±3  113 ±3  127 ±3  141 ±3  155 ±3  169 ±3  183 ±3  197 ±3  211 ±3  225 ±3  239 ±3  253 ±3  267 ±3  281 ±3  295 ±3  309 ±3  323 ±3  337 ±3  351 ±3  365 ±3  
GENERAL AND SAFETY ASSESSMENTS  
Informed 
consent  X                                                          
Eligibility  X X                                                         
Demographics  X                                                          
Physical exam  X  X   X  X  X  X  X  X  X  X  X  X  X  X  X 
2019 EULAR / 
ACR criteria  X                              
Height  X                                                          
Weight  X  X     X   X   X   X   X   X   X   X   X   X   X   X   X 
Medical 
historya X  X                                                       
Vital signs  X  X   X X X X X X X X X X X X X X X X X X X X X X X X X X 
Chest X -rayb X                                                          
Adverse events     X X X X X X X X X X X X X X X X X X X X X X X X X X X 
Serious 
adverse 
eventsc X X X X X X X X X X X X X X X X X X X X X X X X X X X X 
Page 1 of 5  
Footnotes defined on last page of the table.  
Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  24 May 2022   Page 20 of 121 
 
CONFIDE NTIAL  FORM -001520, v.22, 05 February 2018   
Table 2 -1.  Schedule of Activiti es – Treatment Period  
 Study Week  Screening  Treatment Period  
 
Baseline  
visit/Day  1 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52/ET  
Study Day ± Visit 
Window  Scr visit   1 (pre -rand)  1 (pre -dose)  1 (dose)  15 ±3  29 ±3  43 ±3  57 ±3  71 ±3  85 ±3  99 ±3  113 ±3  127 ±3  141 ±3  155 ±3  169 ±3  183 ±3  197 ±3  211 ±3  225 ±3  239 ±3  253 ±3  267 ±3  281 ±3  295 ±3  309 ±3  323 ±3  337 ±3  351 ±3  365 ±3  
Concomitant 
medication 
review  X X    X X X X X X X X X X X X X X X X X X X X X X X X X X 
GENERAL AND SAFETY ASSESSMENTS (Continued)  
Randomizationd   X                                                       
Home Health 
Visite               X  X  X  X  X  X  X  X  
LABORATORY ASSESSMENTS   
Serum pregnancy 
test X                              
Urine  pregnancy 
test   X     X   X   X   X   X   X   X   X   X   X   X   X   X 
Tuberculosis testf X                                                         
Hepatitis B & Cg X                                                         
HIV serology  X                              
Blood SLE SOC 
drug levelsh X                                                         
Antinuclear 
antibody  X                                                         
Page 2 of 5  
Footnotes defined on last page of the table.  

Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  24 May 2022   Page 21 of 121 
 
CONFIDE NTIAL  FORM -001520, v.22, 05 February 2018   
Table 2 -1.  Schedule of Activities – Treatment Period  
 Study Week  Screening  Treatment Period  
 
Baseline  
visit/Day  1 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52/ET  
Study Day ± Visit 
Window  Scr visit  1 (pre -rand)  1 (pre -dose)  1 (dose)  15 ±3  29 ±3  43 ±3  57 ±3  71 ±3  85 ±3  99 ±3  113 ±3  127 ±3  141 ±3  155 ±3  169 ±3  183 ±3  197 ±3  211 ±3  225 ±3  239 ±3  253 ±3  267 ±3  281 ±3  295 ±3  309 ±3  323 ±3  337 ±3  351 ±3  365 ±3  
Coagulation 
testingk X  X             X              X 
Hematologyi X  X     X   X   X   X    X   X   X   X   X   X   X   X   X 
ESRl X  X   X  X  X  X  X  X  X  X  X  X  X  X  X 
Chemistryi X  X     X   X   X   X  X   X   X   X   X   X   X  X   X 
LABORATORY ASSESSMENTS (Continued)  
Urinalysism X  X     X   X   X   X   X   X   X   X   X   X   X   X   X 
Urine protein/ 
creatininem X  X     X   X   X   X   X   X   X   X   X   X   X   X   X 
SLE CLINICAL ASSESSMENTS  
Tender/swollen 
joint countn X  X     X   X   X   X   X   X   X   X   X   X   X   X   X 
PGA VASo X  X     X   X   X   X   X   X   X   X   X   X   X   X   X 
hSLEDAI  X  X     X   X   X   X   X   X   X   X   X   X   X   X   X 
Clinical hSLEDAI  X X                                                        
SELENA -SLEDAI 
Flare Index    X   X  X  X  X  X  X  X  X  X  X  X  X  X 
BILAG  X  X     X   X   X   X   X   X   X   X   X   X   X   X   X 
Page 3 of 5  
Footnotes defined on last p age of the table.  

Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  24 May 2022   Page 22 of 121 
 
CONFIDE NTIAL  FORM -001520, v.22, 05 February 2018   
Table 2 -1.  Schedule of Activities – Treatment Period  
 Study Week  Screening Treatment Period  
 
Baseline  
visit/Da y
1 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52/ET  
Study Day ± 
Visit Window  Scr visit  1 (pre -rand)  1 (pre -dose)  1 (dose)  15 ±3  29 ±3  43 ±3  57 ±3  71 ±3  85 ±3  99 ±3  113 ±3 127 ±3  141 ±3  155 ±3  169 ±3  183 ±3  197 ±3  211 ±3  225 ±3  239 ±3  253 ±3  267 ±3  281 ±3  295 ±3  309 ±3  323 ±3  337 ±3  351 ±3  365 ±3  
CLASI activity  
and damage  X  X     X   X   X   X   X   X   X   X   X   X   X   X   X 
SDI   X             X              X 
Photographyp   X             X           X                           X 
IMMUNOGENICITY  
BIOMARKER AND PHARMACOGENETICS  
Biomarker  
development  
samplei     
X     X       X           X           X       X      X 
Pharmaco - 
genetics i, s      X                                                       
CLINICAL OUTCOME ASSESSMENTS:  PATIENT REPORTED OUTCOMES  
SF-36v2t     X     X       X           X           X       X       X 
PROMIS -Fatiguet     X     X       X           X           X       X       X 
LupusQoLt     X     X       X           X           X       X       X 
Patient Global  
Assessment  
(PtGA)t   
X   X    X      X      X    X    X 
Page 4 of 5  
Footnotes are defined on last page of the table.  

Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  24 May 2022   Page 23 of 121 
 
CONFIDE NTIAL  FORM -001520, v.22, 05 February 2018   
Table 2 -1.  Schedule of Activities – Treatment Period  
 Study Week  Screening Treatment Period  
 
Baseline  
visit/Day  1 
 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52/ET  
Study Day ± 
Visit Window  Scr visit  1 (pre -rand)  1 (pre -dose)  1 (dose)  15 ±3  29 ±3  43 ±3  57 ±3  71 ±3  85 ±3  99 ±3  113 ±3  127 ±3  141 ±3  155 ±3 169 ±3  183 ±3  197 ±3  211 ±3  225 ±3  239 ±3  253 ±3  267 ±3  281 ±3  295 ±3  309 ±3  323 ±3  337 ±3  351 ±3  365 ±3  
INVESTIGATIONAL PRODUCT ADMINISTRATION  
Investigational  
Product  
(AMG   570/ 
placebo)u     
  X X X X X X X X X X X X X X X X X X X X X X X X X X   
PHARMACOKINETIC ASSESSMENTS  
PK samplesi, q     X     X   X   X   X   X   X        X     X       X 
Page 5 of 5  
ACR  = American College of Rheumatology; aPTT   activated partial thrombop lastin time; BILAG = British Isles Lupus 
Assessment Group; CLASI = Cutaneous Lupus Erythematosus Disease and Severity Index; Clinical hSLEDAI = hybrid SLEDAI assessment score without the 
inclusion of points attributable to any laboratory parameter, includi ng urine and immunologic parameters;  eCRF  = electronic Case Report Form; ESR  erythrocyte 
sedimentation rate;  ET = early termination visit; EULAR  = European League Against Rheumatism; HBcAb = hepatitis B core antibody ; HBsAg = hepatitis B surface 
antigen ; HIV = Human Immunodeficiency Virus; INR = international normalized ratio;  PCR = polymerase chain reaction;  
PD = pharmacodynamics; PGA = Physician Global Assessment; PK  = pharmacokinetic; PPD  = purified protein der ivative; PROMIS  = Patient -reported Outcomes 
Measures Information System; PT  = prothrombin time; PTT  = partial thromboplastin time; Lupus QoL  Lupus Q uality of Life questionnaire ; ; 
SDI = Systemic Lupus International Collaborating Cli nic/American College of Rheumatology Damage Index; Scr  = screening; SF -36v2  = Medical Outcomes Short 
Form 36 version 2 questionnaire; SLE  = systemic lupus erythematosus; hSLEDAI  = Hybrid Systemic Lupus Erythematosus Disease Activity Index; VAS  = visual 
analogue scale.  
a Including substance abuse history.  
b Only for subjects with a positive tuberculosis test (ie, positive PPD [purified protein derivative] or positive or indetermin ate QuantiFERON® -TB or T -spot test).  
c After end of study , serious adverse events suspected to be related to investigational product will be reported to Amgen.  Please refer to Section  9.2.3.1.1.3  
or additi onal details.   
d Randomization may occur at any time after confirmation of all eligibility criteria, but the maximum time between initiation o f screening and randomization is 33  days.  
e In addition to administration of investigational product, safety asse ssments including vital signs, adverse events, serious adverse events, and concomitant 
medications review will be collected.  Home health care visits will be optional after week 20 for subjects who do not experience any adverse effects from 
investigational  product administration.  
f Either a centrally  or locally  performed QuantiFERON®-TB or locally performed PPD or T -spot test will be done during screening per Section  6.2 criterion 206 . 

Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  24 May 2022   Page 24 of 121 
 
CONFIDE NTIAL  FORM -001520, v.22, 05 February 2018   
g For subjects with HBsAg negative, HBcAb positive and undetectable viral DNA by PCR; and for subjects with HCVAb positive and undetectable viral RNA by PCR, 
serum viral DNA (H epatitis B virus) or RNA (Hepatitis C virus) will be monitored by PCR in peripheral blood at approximately  every 3 months during treatment 
period, and up to a minimum of  16 weeks after last administration of  the investigational product .  
h Blood levels wil l be measured for the following: azathioprine, mycophenolate mofetil and hydroxychloroquine.  
i Blood samples must be collected prior to administration of investigational product.  
j Lupus reflex will be done if aPTT is prolonged.  
k PT/INR and aPTT (in case of drug -induced liver injury [DILI] events, fibrinogen and D -dimers will also be included).  
l ESR will be performed at a local laboratory.  
m Clean catch urine specimen required.  
n Tender and swollen joint counts will be performed  as described in Section  9.2.2.5 . 
o Should be completed by a health care provider before assessing the hSLEDAI and BILAG scores. See Section  9.2.2.6 . 
p Whenever possible and only in subjects with a CLASI activity score ≥ 8 at screening per Section  9.2.2.4 . 
q If a subject discontinues investigational product prior to completing week 52 visit, they should be encouraged to maintain th e pla nned scheduled assessment for 
monthly efficacy and safety visits through week 52 (Table  2-1). and PK samples should be collected at the first 4 visits after 
investigational product discontinuation.  
s DNA will be extracted only if subject provides additional consent for pharmacogenetics testing.  
t Patient reported outcomes should be completed as described in Section  9.2.10 . 
u Investigational product (AMG 570 or placebo) will be administered as described in Section  7.1.1 .  Subjects will be observed for at least 30 minutes at the site or by the 
home health care provider following investigational product administration.  

Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  24 May 2022   Page 25 of 121 
 
CONFIDE NTIAL  FORM -001520, v.22, 05 February 2018   
Table  2-2.  Schedule of Activities – Safety Follow -up Perioda 
Safety Follow -up Week  Visit Window  4 Weeks  5 days 
after last IP dose  4 Weeks  5 days 
after prior safety 
follow -up visit 4 Weeks  5 days 
after prior safety 
follow -up visit 4 Weeks  5 days 
after prior safety  
follow -up visit 
EOS  
GENERAL AND SAFETY ASSESSMENTS  
Vital signs  X X X X 
Adverse events  X X X X 
Serious adverse eventsb X X X X 
Concomitant medications review  X X X X 
LABORATORY ASSESSMENTS   
Urine pregnancy  test X X   
Hematology   
X  
X 
Hepatitis B and Cc   X   
IMMUNOGENICITY  
PHARMACOKINETIC ASSESSMENTS  
Pharmacokinetic Samples  X X X X 
EOS   end of study ; IP  investigational product ; PCR   polymerase chain reaction  
a This table applies for subjects who have completed the planned 52 -week treatment period.  Subjects are required to attend as many follow -up visits as 
necessary to ensure a minimum of 16 weeks of safety follow -up after the last administration of the investi gational product.  
b After end of study , serious adverse events suspected to be related to investigational product will be reported to Amgen.  Please refer to Section  9.2.3.1.1.3  
for additional details.   
c For subjects who require monitoring, PCR test to assess viral load should be performed at approximately every 3 months from baseline and up to a minimum 
of 16 weeks  after the last administration of the investigational product .  See Section  6.2 criterion 208.  
  
 
 

Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  24 May 2022   Page 26 of 121 
CONFIDE NTIAL  FORM -001520, v.22, 05 February 2018   

Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  24 May 2022   Page 27 of 121 
CONFIDE NTIAL  FORM -001520, v.22, 05 February 2018   
 

Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  24 May  2022  Page 28 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
3. Introduction  
3.1 Study Rationale  
This is a phase 2 b dose -ranging study to assess efficacy and safety of rozibafusp alfa 
(AMG 570) in subjects with active systemic lupus erythematosus (SLE).  
This study will help determine if AMG 570 could be a useful therapeutic agent in the 
current treatment landscape where subjects have ongoing disease activity despite 
treatment with standard of care therapies.  
Three dose levels of AMG 570 (70  mg subcutaneous [ SC] every 2  weeks [Q2W ], 
280 mg SC Q2W, and 420  mg SC Q2W) were selected based on pharmacokinetic 
(PK)/pharmacodynamic (PD) modeling and analysis of emerging PK, B cell activating 
factor (BAFF) inhibition (ie, % change in % naïve B -cells), and inducible co -stimulator 
ligand (ICOSL) % receptor occupancy (RO) data from previous studies (AMG 570 
Investigator’s Brochure  [IB]).  These dose regimens are proposed to promote 
characterization of exposure -response relationships in this phase  2b SLE study and 
inform d ose selection for future studies.  
3.2 Background  
3.2.1  Disease  
Systemic lupus erythematosus is a multisystem autoimmune disease of unknown cause 
with diverse clinical manifestations that disproportionately affects minorities (eg, in the 
United States [US], blacks and Hispanics) and women of childbearing potential 
(Rhaman  and Isenberg, 2008; Kotzin, 1996).  In the US, moderate to severe SLE is 
estimated to affect one -third of the more than 250,000 patients diagnosed with lupus.  
SLE disease activity may vary from mild episodes to severe, even fatal outcomes with 
symptoms varying widely in individuals over time and characterized by periods of 
remission and flare.  SLE can affect the skin (rash), musculoskeletal system (arthritis) 
nervous system (seizures, psych osis), lungs (pleuritis, pneumonitis), and the blood 
(venous or arterial thrombosis, anemia, thrombocytopenia, and leukopenia).  In addition, 
approximately 65% of patients will develop lupus nephritis that can range from mild 
glomerulonephritis to severe d iffuse proliferative glomerulonephritis (Adams  et al, 2006).  
Current treatment options include antimalarials, corticosteroids  (CS), and other 
immunomodulators/immunosuppressants, and few biologics (including Benlysta), which 
have limited efficacy and may h ave toxicities that impede a patient’s ability to remain on 
therapy.   Therefore, significant need exists for effective therapies with limited toxicities.  
SLE is both clinically and immunologically heterogenous; however, the presence of 
Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  24 May  2022  Page 29 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
class -switched, hyp ermutated immunoglobulin  G (IgG) autoantibodies implicate immune 
dysregulation as a driving force for disease pathogenesis, with T cells playing a role in 
the development of autoantibody production by B cells.  
3.2.2  Amgen Investigational Product Background:  AMG  570 
AMG 570 is a bispecific IgG2 antibody -peptide conjugate  inhibiting both ICOSL and 
BAFF.  AMG 570 contains 2 tandem copies of BAFF -binding peptides fused to the 
C-terminus of a fully human IgG2 against ICOSL.  In terms of anti -BAFF effect, 
AMG  570 has similar binding affinity and cellular potency to relevant BAFF inhibitors.  
AMG  570 binds and inhibits cynomolgus monkey ICOSL and BAFF, but not rodent 
ICOSL.  A mouse surrogate ICOSL/BAFF bispecific molecule showed dual -target 
inhibition in vivo and was more efficacious than single ICOSL or BAFF inhibitors in the 
mouse NZB/NZW lupus model (AMG 570 Investigator’s Brochure).  Thus, we 
hypothesize that targeting both ICOSL and BAFF by AMG 570 will achieve a large effect 
size in the treatment of autoantib ody associated diseases, such as SLE.  
3.3 Clinical Studies With AMG 570  
3.3.1  First in Human (FIH) Study 20140322  
In the first in human (FIH) study in healthy volunteers, a total of 56  subjects were 
enrolled and randomized to receive AMG  570 or placebo; 42  subjects received AMG  570 
(6 per dosing cohort; dose range:  7 to 700  mg), and 14  subjects received placebo.  Four 
subjects (7.1%, AMG  570 group) discontinued from the study; of these, 3  subjects 
(5.4%) were lost to follow -up and 1  subject (1.8%) withdrew consent.  AMG  570 was 
generally well tolerated with most adverse events being mild in severity.  One subject 
from the 7  mg cohort had a serious adverse event of injury, which was considered not 
related to investigational product.  No subject had any clinically sign ificant, 
life-threatening, or fatal adverse event.  No dose limiting toxicities or withdrawals due to 
adverse events were reported.  
The FIH study included 2 humoral immune status stopping rules that accounted for the 
potential of AMG 570 to decrease total circulating B cells and/or serum IgG levels.  If a 
single subject in the FIH study satisfied the humoral immune status stopping rules, 
further studies with AMG 570 would shift from healthy volunteers to patients.  No subject 
satisfied these rules during th e course of the study.  
Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  24 May  2022  Page 30 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
3.3.1.1  FIH Study 20140322 – Clinical Pharmacokinetics  
The PK of AMG 570 were assessed in the FIH study.  
After a single SC dose, AMG  570 exposure was greater than dose proportional in the 
dose range of 7 to 700  mg.  However, exposures across  the dose range from 210 to 
700 mg SC suggested that approximately dose -proportional exposure as assessed by 
maximum concentration (C max) may be observed in the dose range of 210 to 700  mg. 
3.3.1.2  FIH Study 20140322 – Clinical Pharmacodynamics  
A validated, semi -quantitative flow cytometry assay was developed to monitor the PD 
properties of the constituent arms of the bispecific in whole blood specimens.  
The effect of AMG  570 on ICOSL receptor occupancy was substantial with more than 
90% receptor occupancy on total  B cells at 8  days after dosing in 420  mg and 700  mg 
AMG  570 dose groups.  A prominent effect of AMG  570 was observed on B  cell 
populations, with a decreased percentage of naïve and increased percentage of memory 
B cells.  No treatment effect was observed on serum IgG, IgM, natural killer cells, and 
T cells.  
3.3.2  Amgen Study 20160344  
The safety, tolerability, and PK of single doses of AMG  570 was evaluated in healthy 
Japanese subjects in Study 20160344.  A total of 12 subjects were enrolled and 
randomized to rec eive a single dose of AMG 570 210 or 420  mg SC (6 subjects per 
cohort).  One subject (8.3%, AMG 570 420  mg group) withdrew consent and 
discontinued from the study.  AMG 570 was generally well tolerated with 2 adverse 
events being mild (grade 1) in severity  and considered not related to investigational 
product.  No subject had serious, life -threatening, or fatal adverse events.  
Following a single SC dose of AMG 570 210 or 420  mg in healthy Japanese subjects, 
mean C max, and AUC inf increased 2.4 - and 3.9 -fold, respectively, for a 2 -fold increase in 
dose.  
Inducible co -stimulator ligand receptor occupancy was > 85% on total peripheral B cells 
at 8 days after dosing in both AMG 570 210 and 420  mg treatment groups.  A prominent 
effect o f AMG 570 was observed on B cell populations, with a reduction of naïve B cells 
and an increase in memory B cells.  
One subject (8.3%) had pre -existing anti -AMG 570 antibodies at baseline and 
11 subjects (91.7%) developed anti -AMG 570 antibodies after dosin g; the effect of 
anti-AMG 570 antibodies on the PK after a single SC dose of AMG 570 could not be 
Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  24 May  2022  Page 31 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
determined.  There was no association between AMG 570 binding antibodies and any 
adverse events.  
3.3.3  Amgen Study 20150196  
The safety, tolerability, and PK of mult iple ascending doses of AMG  570 was evaluated 
in subjects with rheumatoid arthritis (RA) in Study 20150196.  The study had 4 cohorts, 
each receiving 6 doses of AMG 570 ranging from 70 to 420  mg SC given Q2W  based on 
cohort.  A total of 32 subjects were pla nned (8 per cohort); 34 subjects were treated as 
9 subjects were enrolled in both cohorts 1 and 4 (7 subjects received AMG  570 and 
2 received placebo).  There were no deaths or drug -related serious adverse events, 
dose -limiting toxicities, or withdrawals d ue to adverse events .  In general, AMG  570 had 
an acceptable safety profile at the doses tested.  
3.4 Toxicology  
The AMG  570 safety profile was evaluated in 3 - and 6 -month Good Laboratory Practice 
(GLP) repeat -dose toxicology studies in the cynomolgus monkey as  well as in several in 
vitro test systems.  In both the 3 -month toxicology study with an 8 -month recovery 
(30, 100, and 200  mg/kg, 13  weekly SC injections) and 6 -month study (100  and 
200 mg/kg, 26  weekly SC injections), the no -observed -adverse effect -level (NOAEL) 
was 200  mg/kg.  AMG  570 pharmacolog y-related effects (ie, decreased B  cells, IgG , and 
lymphoid depletion of the lymphoid tissues ) were observed at all dose levels.  In the 
3-month study, all changes were shown to be reversible within 8 months afte r the end of 
the dosing phase.  Increased reticulocyte counts and subsequently increased red blood 
cell (RBC) mass were observed in a limited number of animals (4  animals in total; 
1 animal at 100  mg/kg in the 3 -month study and 1 and 2  animals at 100 and 2 00 mg/kg, 
respectively, in the 6 -month study) but no adverse consequences were observed.  
All the clinical dose levels in the ongoing and planned clinical studies are supported by 
adequate exposure margins based on the NOAEL (200  mg/kg) from the 3 -and 6 -month 
GLP repeat -dose toxicology studies in the cynomolgus monkey (NOAEL exposure in the 
monkey corresponded to ≥ 16-fold above exposures expected/observed at clinical 
doses).   A detailed description of nonclinical safety studies is provided in the 
AMG  570 Investigator’s Brochure . 
3.5 Benefit/Risk Assessment  
The following benefit -risk assessment supports the conduct of this clinical trial.  
Reference should be made to the AMG 570 Investigator’s Brochure (IB) for further data 
on AMG 570.  
Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  24 May  2022  Page 32 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
3.5.1  Therapeutic  Context  
Systemic  Lupus  Erythematosus  is a chronic autoimmune disease with no known cure 
and unpredictable disease flares that can lead to progressive disability, marked by 
moderate or severe exacerbations and sometimes fatal outcomes.  Inflammation can 
arise in almost any major organ system of the body leading to manifestations such as 
rash, arthritis, bone tissue death, leukopenia, seizures, psychosis, pleuritis, pneumonitis, 
thromboses, anemia, nephritis and renal failure.  Current tre atment options include 
antimalarials, CS, immunomodulators, immunosuppressants, and few biologics 
(including Benlysta) , these therapies have limited efficacy and may have toxicities that 
impede a patient’s ability to remain on therapy.  A substantial unmet  medical need exists 
for these patients who have active disease despite SOC therapy.  
3.5.2  Key Benefits  
Phase 1 studies for AMG 570 have completed, and predicate evidence indicates 
potential biological and/or clinical benefits in lupus patients upon targeting either ICOSL 
or BAFF in isolation (Cheng et al, 2018; Zhang et al, 2018; Doria et al, 2018; 
Sullivan  et al, 2016;  Furie et al, 2011; Navarra et al, 2011; Chandran et al, 2007).  
3.5.3  Key Risks  
The safety, tolerability, and PK/PD of single ascending doses of AMG  570 were 
evaluated in the FIH Study 20140322 in healthy subjects.  A total of 56  subjects received 
blinded investigational product at SC doses up to 700  mg.  All subjects receiving dose 
levels up to 700  mg SC in the single ascending dose study demonstr ated acceptable 
safety and tolerability with no drug -related severe, life -threatening, or fatal events 
reported.  All adverse events were of mild to moderate severity .  Safety, tolerability, and 
PK of multiple ascending doses of AMG  570 were evaluated in s ubjects with RA in 
Amgen Study 20150196.  There were no deaths or drug -related serious adverse events, 
dose -limiting toxicities, or withdrawals due to adverse events .  Adverse events occurring 
2 or more times include: headache, arthralgia, pain in extremit y, upper respiratory tract 
infection, dizziness, RA flare, and sciatica.  All these events were mild or moderate.  In 
general, AMG  570 was well tolerated at the doses tested.  
An additional assessment of potential side effects of multiple doses of AMG 570 i s 
based on the preclinical studies conducted to date and by observations of safety and 
tolerability of molecules that inhibit only ICOSL or BAFF.  Summaries of findings from 
the nonclinical studies with AMG 570 can be found in the AMG 570 IB.  No target or gans 
beyond pharmacologic effects of AMG 570 were identified up to the high dose in the 
Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  24 May  2022  Page 33 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
GLP cynomolgus monkey toxicology study (200  mg/kg:  11 to 64.5 times higher than 
planned clinical doses [70 to 420  mg]).  
Potential side effects of AMG 570 could also be  related to the biological nature of the 
molecule and mode of administration.  
Please refer to the AMG 570 IB, Section 7 for a description of these potential side 
effects.  
 
Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number :  20170588  
Date:  24 May 2022  Page 34 of 121 
 
CONFIDENTIAL  FORM -001520, v22, 05 February 2018   
4. Objectives, Endpoints and Hypothesis  
4.1 Objectives and Endpoints  
Objectives  Endpoints  
Primary  
 Evaluate the efficacy of AMG  570 at 
week 52 as measured by the Systemic 
Lupus Erythematosus  (SLE)  
Responder Index (SRI -4)  SRI-4 response at week 52  
The primary estimand is the difference in SRI -4 response between each AMG  570 
dose group and placebo at week 52 for all subjects with SLE with inadequate 
response to SOC therapy who are randomized regardless of investigational product  
discontinuation; subjects using more than protocol -allowed therapie s will be 
considered as non -responders.   
Secondary  
 Evaluate the efficacy of AMG  570 at 
week 24   SRI-4 response at week 24  
 British Isles Lupus Assessment 
Group  (BILAG ) based Combined 
Lupus Assessment (BICLA) 
response at week 24  
 Evaluate the efficacy of AMG 570 at 
week 52   Lupus Low Disease Activity State 
(LLDAS) response at week 52  
 BICLA response at week 52  
 Evaluate the efficacy of AMG 570 as 
measured by SRI -4 response with oral 
corticosteroid (OCS) -tapering   SRI-4 response at week 52 with 
reduction of OCS to  7.5 mg/day by 
week  44 and sustained through 
week  52 in subjects with a baseline 
OCS dose  10 mg/day  
 Evaluate the efficacy of AMG 570 on 
disease flares   Annualized moderate and severe 
flare rate (as measured  by 
SELENA -SLEDAI Flare Index) over 
52 weeks  
 Annualized severe flare rate (as 
measured by SELENA -SLEDAI Flare 
Index) over 52  weeks  
 Annualized flare rate (as measured 
by BILAG score designation of 
“worse” or “new” resulting in a B 
score in  2 organs or an A score in 
 1 organ) over 52  weeks  
 Evaluate the efficacy of AMG 570 on 
joints and skin   Total tender and swollen joint count 
(limited  to hands and wrists ):   50 
improvement from baseline at week 
Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number :  20170588  
Date:  24 May 2022  Page 35 of 121 
 
CONFIDENTIAL  FORM -001520, v22, 05 February 2018   
Objectives  Endpoints  
12, 24, 36, and 52 in subjects with 
 6 tender and swollen  joints in 
hands and wrists at baseline  
 Cutaneous Lupus Erythematosus 
Area and Severity Index (CLASI) 
activity score:    50 improvement 
from baseline at week 12, 24, 36, 
and 52 in subjects with a CLASI 
activity score  8 at baseline  
 Describe the efficacy  of AMG 570 
using patient reported outcomes   Patient -Reported Outcome 
Measurement Information System  
Fatigue Short Form 7a Instrument 
(PROMIS -Fatigue SF7A) score and 
change from baseline at week 12, 24, 
36, 44, and 52  
 Medical Outcomes Short Form 36 
version 2 Questionnaire (SF -36v2) 
change from baseline in the 
physical component score , mental 
component score  individual 
domains of the Medical Outcomes 
Short Form 36 version 2 
questionnaire  (SF-36v2 ) at week 
12, 24, 36, 44, and 52  
 Lupus Quality of Life questionn aire 
(Lupus QoL) score and change from 
baseline at week 12, 24, 36, 44, and 
52 
 Patient Global Assessment (PtGA) 
score and change from baseline at 
week 12, 24, 36, 44, and 52  
 Characterize the safety of AMG 570   Treatment -emergent adverse events  
 Serious adverse events  
 Clinically significant changes in 
laboratory values and vital signs  
 To characterize the pharmacokinetics 
(PK) of AMG 570   Trough serum concentrations and 
terminal elimination half -life of 
AMG  570 
Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number :  20170588  
Date:  24 May 2022  Page 36 of 121 
 
CONFIDENTIAL  FORM -001520, v22, 05 February 2018   
Objectives  Endpoints  
Exploratory  

Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number :  20170588  
Date:  24 May 2022  Page 37 of 121 
 
CONFIDENTIAL  FORM -001520, v22, 05 February 2018   
Objectives  Endpoints  
 

Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number :  20170588  
Date:  24 May 2022  Page 38 of 121 
 
CONFIDENTIAL  FORM -001520, v22, 05 February 2018   
4.2 Hypothesis  
AMG 570 administered for 52  weeks will be well tolerated and have greater efficacy than 
placebo as measured by Systemic Lupus Erythematosus Responder Index  (SRI-4) 
response at week 52 in subjects with active SLE and an inadequate response to SOC 
therapy.  
5. Study Design  
5.1 Overall Design  
This is a Bayesian adaptive phase 2b, multi -center, double -blind, randomized,  
 placebo -controlled, 52 -week, dose -ranging study in subjects with active SLE and 
inadequate response to SOC therapies including oral corticosteroids ( OCS ), 
immunosuppressants, and immunomodulators.  Previous biologic use is allowed with an 
adequate washout period (see Exclusion Criterion 215).  
Approximately 320  subjects will be enrolled and randomized to receive AMG 570 SC at 
70 mg Q2W,  280 mg Q2W, 420  mg Q2W, or placebo.  The randomization starts as 
1:1:1:1 and then could be adapted at each interim analysis (IA) (if before full enrollment) 
based on the clinical efficacy (Response Adaptive Randomization [RAR]) for allocating 
more subject s to more efficacious doses and fewer subjects to less efficacious doses.  
The randomization allocation probability for placebo group will be kept constant at 25%.   
Randomization will be stratified by geographic region (North  America  + Western Europe 
vs re st of the world [ROW]) and screening  Hybrid Systemic Lupus Erythematosus 
Disease Activity Index  (hSLEDAI ) score ( 10 or <  10). 
Study duration for a single subject will be 52  weeks (treatment period) plus the screening 
period and safety follow -up period.  Investigational product will be administered Q2W 
with the final dose at week  50.  If a subject discontinues investigational product prior to 
completing week 52 visit, the subject will be encouraged to continue in the study and 
maintain the planned schedule d assessment for monthly efficacy and safety visits  
through week 52  (Table  2-1).  Subjects are required to attend as many follow -up 
visits as necessary to ensure a minimum of 16 weeks of safety follow -up after the 
last administration of the investigational product .  For subjects who discontinue 
investigational product prior to  week 36, the safety follow -up visits will be 
included with in the 52 -week  period  and no additional safety follow -up visits will be 
required .  Immunogenicity  and PK samples should be 
collected at the first 4 visits after investigational product discontinuation.  

Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number :  20170588  
Date:  24 May 2022  Page 39 of 121 
 
CONFIDENTIAL  FORM -001520, v22, 05 February 2018   
Subjects will undergo a screen ing visit to confirm eligibility requirements.  Baseline/day  1 
visit should not occur prior to confirmation of subject’s SLE -related  eligibility by the 
adjudication team and must occur up to 33  days from the screening visit.  At 
baseline/day 1 visit, prior  to randomization, the subject must present with  disease activity 
(defined by clinical hSLEDAI score  4) and stability and compliance with OCS and other 
immunosuppressant/immunomodulator doses (by reviewing medication history).  
Subjects may be randomized  at any time after confirmation of all eligibility criteria, but 
the maximum time between initiation of screening and randomization is 33  days.  
Subjects who do not meet all the eligibility requirements at the baseline/day  1 visit will be 
considered screen  failures.  Subjects may be allowed to rescreen as detailed in 
Section  9.1.1. 
After randomization, adjudication reviews will be completed throughout the study 
period on blinded endpoint data from enrollment to week 52 for all randomized 
subjects and for all vi sits.  This includes review of all efficacy -related endpoint 
data.  
Immunosuppressant/immunomodulator dose should remain stable through week 52.  
For OCS, initiation of,  or temporary increases in OCS are allowed from weeks 0 to 8, 
provided that return to ba seline dose occur within the subsequent 2  weeks, as outlined 
in Section  7.1.4.2 .  OCS can be tapered at the investigator’ s discretion but shall not be 
changed during the last 8  weeks (week 44 to 52) of the 52 -week treatment period.  
Subjects listed below will be allowed to continue the study but will be considered 
treatment failures for primary efficacy endpoint analyses for the subsequent time points. 
These subjects  will also be allowed to continue investigational product at the 
investigator's discretion, except subjects who initiate any 
immunosuppressant/immunomodulator listed in Section 7.1.7  (treatments 
a through  i). 
 Subjects requiring initiation or increase in OCS dose  5 mg/day (prednisone or 
equivalent), or intramuscular (IM) CS or intravenous (IV) CS at any time point 
during the study, subjects requiring initiation or increase in OCS dose  5 mg/day 
(prednisone or equivalent) after week 10, or subjects requiring initiation or increase 
in OCS dose  5 mg/day (prednisone or equivalent) from week 0 to we ek 8 who 
cannot return to their baseline dose within the following 2  weeks ( Section  7.1.4.2 ). 
 Subjects requiring either dose increases of the current 
immunosuppressants/immunomodulators or initiation of new 
immunosuppressant/immunomodulator(s) at any time point during the study 
(Section  7.1.7 ). 
Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number :  20170588  
Date:  24 May 2022  Page 40 of 121 
 
CONFIDENTIAL  FORM -001520, v22, 05 February 2018   
This study will utilize adaptive design elements based on the results of planned IAs:  
 IAs will be conducted by an Independent Biostatistics Group (IBG) and will be 
reviewed by a Data Monitoring Committee (DMC), both external to Amgen.  The 
study team, investigators and subjects will remain blinded to the results of the IAs. 
 Adaptive randomi zation begins after a fixed allocation period.  After each IA (if before 
full enrollment), the randomization probability for each of the 3 active doses may be 
changed based on clinical efficacy, while the randomization probability for placebo is 
kept const ant, ie,  25%.  
 Efficacy is assessed against predefined early stopping rules for futility from the 
second IA until before the last IA.  If futility is triggered, the study could be 
terminated, eg, continued enrollment and follow -up activities for previously enrolled 
subjects would be stopped, etc.  
 Efficacy is assessed against predefined rules for administrative success only at the 
last IA.  If administrative success is determined, downstream activities may be 
planned/initiated (eg, a phase 3 study), but the e xecution of this study would not be 
stopped or altered.  
5.2 Number of Subjects  
Approximately 320 subjects will be enrolled in the study; however, the actual sample 
size could be smaller as the study can be stopped earlier if futility is reached at IAs.  
Participants in this clinical investigation shall be referred to as “subjects .”  For the 
sample size justification, see Section  10.1. 
5.2.1  Replacement of Subjects  
Subjects who are withdrawn or removed from treatment or the study will not be replaced.  
5.2.2  Number of Sites  
Approximately 150 investigative sites globally will be included in the study.  Sites that do 
not enroll subjects within 6 months of site initiation may be considered for closure.  
5.3 End of Study  
5.3.1  End of Study Definition  
Primary Completion:   The primary completion date is defined as the date when the last 
subject is assessed or receives an interv ention for the final collection of data for the 
primary endpoint(s), for the purposes of conducting the primary analysis, whether the 
study concluded as planned in the protocol or was terminated early.  
If the study concludes prior to the primary completion  date originally planned in the 
protocol (ie, early termination of the study), then the primary completion will be the date 
when the last subject is assessed or receives an intervention for evaluation in the study 
(ie, last subject last visit).  
Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number :  20170588  
Date:  24 May 2022  Page 41 of 121 
 
CONFIDENTIAL  FORM -001520, v22, 05 February 2018   
End of Stud y:  The end of study date is defined as the date when the last subject 
across all sites is assessed or receives an intervention for evaluation in the study (ie, last 
subject last visit), following any additional parts in the study (eg, safety follow -up), a s 
applicable.  
5.3.2  Study Duration for Subjects  
Study duration for a single subject will be 52  weeks plus the screening period (up to 
33 calendar days) and safety follow -up period ( a minimum of  16 weeks after the last 
administration of the investigational product ). 
If a subject discontinues investigational product prior to completing week 52 visit, 
the subject will be encouraged to continue in the study and maintain the planned 
scheduled assessment for monthly efficacy and safety visits through week 52  
(Table  2-1).   
For subjects who discontinue investigational product prior  to or at  week 36, the 
safety follow -up visits will be included within the 52 -week  period  and no additional 
safety follow -up visits will be required.   Subjects who discontinue investigational 
product after week 36 are required to attend as many follow -up visits as necessary 
to ensure a minimum of 16 weeks of safety follow -up period afte r the last 
administration of the investigational product ( Table  2-2).   
Subjects have completed the study when:  1) have completed  52-week  treatment 
period regardless of investigational product  compliance , and 2) have completed a 
minimum of  16 weeks  of safety follow -up after the last administration of the 
investigational product.   
5.4 Justification for Investigational Product Dose  
Three dose l evels of AMG 570 (ie, 70, 280, and 420  mg) were chosen for the study.  
Preclinical and clinical data supporting the safety of a 420  mg SC Q2W dose are as 
follows: the NOAEL from nonclinical 6 -month toxicology studies of 200  mg/kg SC 
weekly, corresponding t o a maximum concentration (C max) of 2490  g/mL, and area 
under the curve from time 0 to 7 days (AUC 0-7d) of 13800  g•day/mL.  These exposures 
are 16 -fold and 23 -fold higher than the predicted steady -state mean C max and AUC 0-14d, 
in humans at the 420  mg SC Q2W dose.  Predicted steady -state AUC 0-14d from the 
420 mg SC Q2W dosing regimen is also anticipated to be within the range of the 
exposures observed in previous AMG  570 clinical studies.  Multiple doses up to 420  mg 
are expected to be well tolerated in su bjects with moderate to severe SLE as it was 
Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number :  20170588  
Date:  24 May 2022  Page 42 of 121 
 
CONFIDENTIAL  FORM -001520, v22, 05 February 2018   
shown in healthy subjects following single dose administration up to 700  mg SC.  
Multiple dose administration up to 420  mg Q2W X 6 (Study  20150196) in subjects with 
RA was also well tolerated.  Exposure (AUC 0-inf) after a single dose of 700  mg was 35% 
higher than the projected steady -state exposure (AUC 0-14d) of 420  mg Q2W at 
steady -state.  Thus, the highest selected dose is predicted to result in exposures that are 
16- to 23 -fold lower than those achieved at the  NOAEL dose in preclinical toxicology 
studies and are lower than what was achieved with the 700  mg SC dose in humans, 
which was generally well tolerated.  
The 3 dose levels were also chosen with the intent to characterize the dose -response 
and exposure -response relationships and to inform dose selection for the phase  3 
program.  The dose selection strategy integrates the 2 targets of AMG 570.  Impact of 
BAFF inhibition on naïve B cell reduction and efficacy in the SLE patient population was 
previously demons trated for BAFF inhibitors (eg, Benlysta) (Arthritis & Rheumatism, 
2009).  Impact of inhibition of ICOSL was previously demonstrated for AMG 557 
(Sullivan et al, 2016), where maximal inhibition of the anti -KLH IgG response occurred at 
doses associated with  ICOSL saturation.  
The dosing regimens for this phase 2b study were selected using PK/PD modeling and 
simulation based on available data from the single ascending dose study in healthy 
subjects (Study 20140322) and multiple ascending dose study in RA subjects 
(Study  20150196).  
The PK/PD analysis was based on biologic changes consistent with BAFF inhibition 
(ie, % change in % naïve B cells) and modeling of the AMG 570 Exposure -ICOSL 
% receptor occupancy relationship.  
The highest planned dose of 420  mg Q 2W was chosen to evaluate attainment of 
maximal coverage of both targets.  This dose is predicted to achieve maximal reduction 
in % change naïve B cells and achieve maximal saturation of ICOSL (mean percent 
receptor occupancy of > 90%) in ~98% of simulated  subjects at steady -state trough.  
The lowest planned dose of 70  mg Q2W will provide additional dose -ranging information 
for characterization of the dose -response and exposure -response relationships.  This 
dose is predicted to achieve maximal reduction in %  change naïve B cells and achieve 
minimal saturation of ICOSL (mean percent receptor occupancy of 50% to 90% in ~80% 
of simulated subjects) at steady -state trough.  Efficacy at this dose may also allow 
comparison of AMG 570 to the efficacy associated with BAFF inhibitors (ie, Benlysta).  
Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number :  20170588  
Date:  24 May 2022  Page 43 of 121 
 
CONFIDENTIAL  FORM -001520, v22, 05 February 2018   
The dose of 280  mg SC Q2W is predicted to achieve maximal reduction in naïve B cells 
and near maximal ICOSL coverage (mean percent receptor occupancy of > 90% in 
~90% of simulated subjects at steady -state trough).  
Overall, the safety of the selected doses is supported by the clinical and preclinical data, 
and the 3  doses have been selected to evaluate dose -response and exposure -response 
relationships.  
5.5 Patient Input on Study Design  
Patient input was obtained for this stud y in various international regions.  Patients were 
able to understand and comment on the requirements for study participation.  
6. Study Population  
Screening:  Investigators will be expected to maintain a screening log of all potential 
study candidates tha t includes limited information about the potential candidate (eg, date 
of screening).  This log may be completed and updated via an Interactive Response 
Technology (IRT) system.  Eligibility criteria will be evaluated at screening visit and at 
baseline/day  1 visit, prior to randomization.  
The screening visit will confirm all eligibility requirements described in Section  6.1 and 
6.2 and Table  2-1.  All SLE -related screening criteria will be reviewed by the adjudication 
team.  The site will be notified by electronic communication of the results of this review 
and baseline/visit 1 should not occur prior to this notification.  Subjects who do not meet 
the eligibility criteria will be considered screen fails but may be eligible for rescreening as 
described in Section  9.1.1 . 
The baseline/day 1 visit will occur up to 33 calendar days following the screening visit (it 
can be earlier if all eligibility requirements for screening visit are met).  Baseline/day 1 
visit will confirm eligibility requirements prior to randomization, as described in 
Section  6.3.  Subject who meet all eligibility criteria  may proceed to randomization and 
dosing.  Subjects who do not meet criteria may be eligible for rescreening as described 
in Section  9.1.1 . 
Before any study -specific activities/procedures, the appropriate written informed consent 
must be obtained (see Section  12.3). 
Prosp ective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions will not be provided.  
Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number :  20170588  
Date:  24 May 2022  Page 44 of 121 
 
CONFIDENTIAL  FORM -001520, v22, 05 February 2018   
Figure  6-1.  Screening and Enrollment  
 
PD = pharmacodynamic; PK  = pharmacokinetic; SLE  = systemic lupus erythematosus   
6.1 Inclusion Criteria Screening Visit  
Subjects are eligible to be included in the study only if all the following criteria apply:  
101 Subject has provided informed consent prior to initiation of any study -specific 
activities/procedures.  
102 Age  18 years  to  75 years at screening visit.  
103 Fulfills classification criteria for SLE according to the 2019 European League 
Against Rheumatism (EULAR)/American College of Rheumatology (ACR) 
classification criteria for SLE (Aringer et al, 2019), with antinuclear antibody 
 1:80 by immunofluorescence on Hep -2 cells being present at screening.  
104 Hybrid SLEDAI score  6 points with a "Clinical" hSLEDAI score  4 points . 
The "Clinical" hSLEDAI is the hSLEDAI assessment score without the inclusion 
of points attributable to laboratory results , including urine or immunologic 
parameters .  
Additional protocol -specific rules are applied at screening and throughout the 
study, as follows:  
 Arthritis:  Arthritis (at least 3 tender and swollen joints) must involve joints in 
the hands or wrists for the hSLEDAI scoring.  
 Alopecia:  Subjects should have hair loss without scarring; should neither 
have alopecia areata nor androgenic alop ecia; and should have a CLASI 
activity score for alopecia  2. 
 Oral ulcers:  Ulcers location and appearance must be documented by the 
investigator.  
 Scleritis and Episcleritis:  the presence of stable SLE -related scleritis and 
episcleritis (ie, that will likely not require initiation/increase in 
immunosuppressants/immunomodulators as outlined in the 

Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number :  20170588  
Date:  24 May 2022  Page 45 of 121 
 
CONFIDENTIAL  FORM -001520, v22, 05 February 2018   
inclusion/exclusion criteria) must be documented by an ophthalmologist and 
other causes excluded.  
 Renal:  subjects with urine protein/creatinine ratio  3000 m g/g (or equivalent 
method) in a clear catch spot urine sample can enroll and be scored in the 
hSLEDAI, provided the subject has a clinical hSLEDAI  4 and did not 
receive induction treatment for nephritis within the last year.  
 Pleurisy and Pericarditis: symptoms of pleurisy and pericarditis must be 
accompanied by objective findings to be scored in the hSLEDAI.  
105 Unless there is a documented intolerance , subjects m ust be taking:   
 Only  1 of the following SLE treatments:  anti -malarial  (hydroxychloroquine, 
chloroquine, or quinacrine), azathioprine, methotrexate, leflunomide,  
mycophenolate mofetil/acid mycophenolic, or  dapsone.   
OR 
 2 of the above -mentioned SLE treatments in which 1 must be  anti-malarial 
(hydroxychloroquine, chloroquine, or quinacrine).  
Treatment  should be taken for  12 weeks prior to screening and must be a 
stable dose for  8 weeks prior to screening.   
106 For subjects taking OCS, dose must be  20 mg/day of prednisone or OCS 
equivalent, and the dose must be stable at baseline visit for  2 weeks prior to 
screening visit.  
6.2 Exclusion Criteria Screening Visit  
Subjects are excluded from the study if any of the following criteria apply:  
Disease Related  
201 Urine protein creatinine ratio  3000  mg/g (or equivalent) at screening or 
induction therapy for lupus nephritis within 1 year prior to screening visit.  
202 Active CNS lupus within 1 year prior to screening including, but not limited to, 
aseptic meningitis, ataxia, CNS vasculitis, cranial neuropathy, demyelinating 
syndrome, optic neuritis, psychosis, seiz ures, or transverse myelitis.  
Other Medical Conditions  
203 Diagnosis of any inflammatory joint or skin disease other than SLE (confirmed 
accurate by the PI) currently present or within 1 year prior to screening which 
would interfere with SLE disease assessment  based on investigator judgment.  
204 Any disease other than SLE that has required treatment with oral or parenteral 
CS for > 2 weeks within 6  weeks prior to screening.  
205 Active infection (including chronic or localized infections), OR infection  for which 
anti-infectives were initiated  within 4  weeks prior to screening OR presence of 
serious infection, defined as requiring hospitalization or IV anti-infectives within 
8 weeks prior to screening.  
Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number :  20170588  
Date:  24 May 2022  Page 46 of 121 
 
CONFIDENTIAL  FORM -001520, v22, 05 February 2018   
206 Active tuberculosis or latent tuberculosis with no documented past hi story of 
adequate treatment per local standard of care.  
207 Positive test for tuberculosis during screening defined as:  either positive or 
indeterminate QuantiFERON®-TB OR T -spot test OR positive purified protein 
derivative (PPD) (  5 mm of induration at 48 t o 72 hours after test is placed).  
 Subjects with a positive PPD and a history of Bacillus Calmette -Guérin 
vaccination are allowed to enroll with a negative QuantiFERON®-TB or 
T-Spot test.  
 Indeterminate QuantiFERON®-TB or T -spot test can be repeated once, ba sed 
on investigator judgment.  Subjects can enroll if second result is negative.  
Subjects with persistent indeterminate or positive test results should proceed 
as below.  
 Subjects with a positive PPD test (without a history of Bacillus 
Calmette -Guérin vacc ination) or a positive or indeterminate 
QuantiFERON®-TB or T -Spot test (including repeated results when 
performed) are allowed to enroll if they meet ALL the following criteria at 
screening:  
 no symptoms per tuberculosis worksheet provided by Amgen  
 document ed history of adequate TB treatment or prophylactic treatment 
for latent TB (completed per local standard of care prior to the start of 
investigational product)  
 no known exposure to a case of active tuberculosis after most recent 
treatment/prophylaxis  
 ches t X-ray with no new radiographic findings suggestive of active TB (to 
be read by local facility)  
Note:  1) these tests do not need to be repeated at the time of rescreening, 
unless rescreening occurs  12 months from screening visit or subject’s 
medical/epidemiologic history suggests newly acquired infection or 
recent contact with TB cases and 2) repeat testing of an indeterminate 
QuantiFERON test using the T -spot test may be performed.  
208 Positive for hep atitis B surface antigen (HBsAg); or positive for hepatitis B core 
antibody (HBcAb) in the presence of detectable viral DNA in peripheral blood, 
assessed by polymerase chain reaction (PCR).  Subjects positive for HBcAb 
without detectable viral DNA by PCR a re allowed to enroll, provided the subject 
undergoes monitoring of viral DNA by PCR at approximately  every 3 months 
during the treatment period, up to a minimum of  16 weeks after last 
administration of the investigational product .  If viral DNA becomes 
detectable during the study period, the subject should  be evaluated by an 
hepatologist before stopping the treatment to evaluate the need to start specific 
hepatitis B treatment before investigational product discontinuation.  A history of 
hepatitis B vacc ination without history of hepatitis B infection (ie, positive 
hepatitis B surface antibody (HBsAb), negative HBsAg and negative HBcAb) is 
allowed.  
Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number :  20170588  
Date:  24 May 2022  Page 47 of 121 
 
CONFIDENTIAL  FORM -001520, v22, 05 February 2018   
Positive for hepatitis C antibody in the presence of detectable viral ribonucleic 
acid (RNA) in peripheral b lood, assessed by PCR.  Subjects positive for hepatitis 
C antibody without detectable viral RNA by PCR are allowed to enroll, provided 
the subjects undergo monitoring of viral RNA by PCR at approximately  every 
3 months during treatment period up to  a minim um of  16 weeks after  last 
administration of  the investigational product .  If viral RNA become detectable 
during the study period, the subject should be evaluated by an hepatologist 
before stopping the treatment to evaluate the need to start specific hepati tis C 
treatment before investigational product discontinuation.  
Note:   these tests do not need to be repeated at the time of rescreening, unless 
rescreening occurs  12 months from screening or there is evidence or suspicion 
of recent infection.  
209 Known hist ory of HIV or positive serology for HIV antibodies at screening.  
Note: these tests do not need to be repeated at the time of rescreening, unless 
rescreening occurs  12 months from screening or there is evidence or suspicion 
of recent infection.  
210 Presence o f 1 or more significant concurrent medical conditions per investigator 
judgment, including but not limited to the following:  
 poorly controlled diabetes or hypertension  
 symptomatic heart failure (New York Heart Association class III or IV)  
 myocardial infarc tion or unstable angina pectoris within the past 12 months 
prior to screening  
 severe chronic pulmonary disease requiring oxygen therapy  
 multiple sclerosis or any other demyelinating disease  
 major chronic inflammatory disease or connective tissue disease ot her than 
SLE (eg, RA, Primary Sjogren Syndrome, Mixed  Connective Tissue Disease ) 
Note:  Subjects with positive antiphospholipid antibodies or diagnosis of 
antiphospholipid antibody syndrome according to the revised Sapporo 
classification criteria (Miyakis et al, 2006) can enroll in the study provided they 
have no current or past histor y of thrombotic events and meet all the other 
eligibility criteria.  
211 Any history of malignancy  with the following exceptions:  
 resolved non -melanoma skin cancers > 5 years prior to screening  
 resolved cervical carcinoma > 5 years prior to screening  
 resolved malignant colon polyps > 5 years prior to screening  
Prior/Concomitant Therapy  
212 Currently receiving or had treatment with :  cyclophosphamide, chlorambucil, 
nitrogen mustard, or any other alkylating agent within 6 months prior to 
Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number :  20170588  
Date:  24 May 2022  Page 48 of 121 
 
CONFIDENTIAL  FORM -001520, v22, 05 February 2018   
screening; sirolimus or oral calcineurin inhibitors (eg, cyclosporine, tacrolimus, 
voclosporin)  or thalidomide  within 4  weeks prior screening.  
213 Currently receiving or had treatment with a Janus kinase ( JAK) inhibitor within 
1 month prior to screening.  
214 Currently receiving or had treatme nt with an immune checkpoint inhibitor (eg, 
PD-1 inhibitor, PD -L1 inhibitor, CTLA -4 inhibitor).  
Note:   Abatacept is not considered a CTLA -4 inhibitor and is referred to below.  
215 Current or previous treatment with a biologic agent with 
immunosuppressive/immun omodulatory activity  for SLE or other conditions 
as follows: rituximab within 6 months prior to screening; abatacept,  belimumab , 
and anifrolumab within the past 3 months prior to screening; other biologics 
within less than 5  drug half -lives or within the period of pharmacodynamic 
activity , when relevant , prior to screening.  
216 Subjects who have received intra -articular, intra -lesional, or systemic 
corticosteroid injections within 6  weeks prior to screening.  
217 Subjects who have received live vaccines within 5  weeks prior to screening, or 
plan to receive live vaccines during the treatment period and up to 16  weeks after 
last administration  of the investigational  product.  
Prior/Concurrent Clinical Study Experience  
218 Currently  receiving treatment in another investigat ional device or drug study.  
219 Ending a treatment with an investigational drug or investigational device less 
than 5 drug  half-lives from the last dose of the investigational product or within 
the period of its pharmacodynamic activity when relevant , at screening.  
220 Subject previously randomized in this study.  
Diagnostic Assessments  
221 Presence of laboratory abnormalities at screening including the following:  
 Aspartate aminotransferase (AST) or alanine aminotransferase (ALT)  
> 2 x upper limit of normal (ULN)  
 Serum total bilirubin (TBL) ≥ 1. 2 mg/dL (≥ 26  mol/L) except for 
Gilbert ’s Syndrome  
 Hemoglobin < 8  g/dL (< 80  g/L) 
 Platelet count < 75,000/mm3 (75 x 109/L) 
 White blood cell count < 2000  cells/mm3 (2 x 109/L) 
 Absolute neutrophil count (ANC) < 1,000/mm3 (1 x 109/L) 
 Calculated glomerular filtration rate of  30 mL/min/1.73  m2 using the 
Modification of Diet in Renal Disease (MDRD) formula  
Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number :  20170588  
Date:  24 May 2022  Page 49 of 121 
 
CONFIDENTIAL  FORM -001520, v22, 05 February 2018   
222 Any other laboratory abnormality, which in the opinion of the investigator or 
Central Review Team, poses a safety risk, will  prevent the subject from 
completing the study or will interfere with the interpretation of the study results, or 
might cause the study to be detrimental to the subject.  
Other Exclusions  
223 Female subject is pregnant or breastfeeding or planning to become pre gnant or 
breastfeed during treatment and for at least 10 additional weeks after the last 
dose of investigational product.  
224 Female subjects of childbearing potential unwilling to use 1 highly effective 
method of contraception during treatment and for at leas t 10 additional weeks 
after the last dose of investigational product administration.  Refer to 
Section  12.5 for additional contraceptive information.  
225 Female subjects of childbearing potential with a positive pregnancy test (serum 
pregnancy test required at screening , and urine pregnancy test required  at 
day 1 visit).  
226 Subject has known sensitivity to any of the products to be administered during 
dosing.  
227 Subject likely to not be available to complete all protocol -required study visits or 
procedures, and/or to comply with all required study procedu res (eg, Clinical 
Outcome Assessments) to the best of the subject and investigator’s knowledge.  
228 History or evidence of any other clinically significant disorder, condition or 
disease (with the exception of those outlined above) that, in the opinion of the 
investigator or Central Review Team would pose a risk to subject safety or 
interfere with the study evaluation, procedures, or completion.  
6.3 Inclusion Criteria Baseline/Day 1 Visit  
Baseline/day 1 visit should occur after confirmation of SLE-related eligibility by the 
adjudication t eam and up to 33  days after screening visit.  At baseline/day 1 visit, the 
following 2  criteria should be assessed prior to randomization:    
107 Stability of SLE treatments:  OCS and other immunosuppressants/ 
immunomodulators d oses must be stable since screening visit, by reviewing 
subject’s medication history.  
108 Disease activity:   active disease as indicated by clinical hSLEDAI score  4 must 
be observed (clinical hSLEDAI score is the hSLEDAI assessment score without 
the inclusio n of points attributable to laboratory results).  
6.4 Subject Enrollment  
Before subjects begin participation in any study -specific activities/procedures, Amgen 
requires a copy of the site’s written institutional review board/independent ethics 
Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number :  20170588  
Date:  24 May 2022  Page 50 of 121 
 
CONFIDENTIAL  FORM -001520, v22, 05 February 2018   
committee (IRB/IEC) approval of the protocol, informed consent form, and all other 
subject information as applicable (see Section  12.3). 
The subject must personally sign and date the IRB/IEC and Amgen approved informed 
consent before commencem ent of study -specific procedures.  
A subject is considered enrolled when the investigator decides and all eligibility criteria 
(from screening visit and baseline/day 1 visit) are met.  The investigator is to document 
this decision and date, in the subject’s  medical record and in the enrollment case report 
form (CRF).  At baseline/day 1 visit, if the subject meets all eligibility criteria , he/she is 
subsequently enrolled and randomized to a treatment regimen.  Subjects who meet 
screening visit eligibility but  do not meet baseline/day 1 visit eligibility criteria are 
considered screen fails.  Subjects may rescreen up to 2 times, as described in 
Section  9.1.1 . 
Each subject who enters into the screening period for the study (defined as the point at 
which the subject signs the informed consent  form) receives a unique subject 
identification number before any study -related activities/procedures are performed.  The 
subject identification number will be assigned by IRT.  This number will be used to 
identify the subject throughout the clinical study  and must be used on all study 
documentation related to that subject.  
The subject identification number must remain constant throughout the entire clinical 
study; it must not be changed after initial assignment, including if a subject is 
rescreened.  This number will not necessarily be the same as the randomization number 
assigned for the study.  
6.5 Screen Failures  
Screen failures are defined as subjects who consent to participate in the clinical study 
but are not subsequently enrolled in the study.  A mini mal set of screen failure 
information will be collected that includes demography, screen failure details, eligibility 
criteria, and any serious adverse events.  
Individuals who do not meet the criteria for participation in this study (screen failure) may 
be rescreened up to 2 additional times.  Refer to Section  9.1.1 . 
7. Treatments  
Investigational product is  defined as any investigational product(s), non -investigational 
product(s), placebo, or medical device(s) intended to be administered to a study subject 
according to the study protocol.  
Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number :  20170588  
Date:  24 May 2022  Page 51 of 121 
 
CONFIDENTIAL  FORM -001520, v22, 05 February 2018   
Note that in several countries, investigational product and non -invest igational product 
are referred to as investigational medicinal product and non -investigational medicinal 
product, respectively.  
The Investigational Product Instruction Manual (IPIM), a document external to this 
protocol, contains detailed information regar ding the storage, preparation, destruction, 
and administration of each treatment shown in Section  7.1.1  below.  
7.1 Treatment Procedures  
7.1.1  Investigational Products  
AMG 570 will be manufactured and packaged by Amgen Inc . and distributed using 
Amgen cl inical investigational product distribution procedures.  AMG 570  is a clear 
colorless sterile solution  which  will be packaged in open -label 5  mL glass vials 
containing 70  mg/ml of AMG 570 formulated with 
 Placebo will be presented in identical 
containers and stored/packaged the same as AMG 570, but will not contain AMG 570 
protein .  All AMG  570 and placebo will be shipped to the study site and should be stored 
the same as AMG 570 at 2C to 8C with limited exposure to light.  
For more information regarding investigational product handling and preparation please 
see the study -specific IPIM which is provided as a separate document.  

Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  24 May 2022   Page 52 of 121 
 
CONFIDENTIAL  FORM -001520, v22, 05 February 2018   
Table 7-1.  Investigational Products  
Investigational Product Name  Amgen Investigational Product:   AMG 570a Placebo  
Dosage Formulation  Clear colorless sterile solution  in 5 mL glass vials 
containing 70  mg/mL of AMG 570  Placebo will be presented in identical containers, 
and stored/packaged the same as AMG  570 
Unit Dose Strength(s)/  
Dosage Level(s) and Dosage Frequency  70 mg/Q2W  
280 mg/Q2W  
420 mg/Q2W   
Route of Administration  SC injection   
Accountability   Total volume of preparation, quantity 
administered start date, start time, and box 
number of AMG 570 is to be recorded on each 
subject's CRF.   
Dosing Instructions  PI or designee will administer product in subject’s 
abdomen.  Dosing must be administered on day 
of scheduled visit after all clinical assessments 
have been completed.  No dose adjustments for 
weight or restrictions with food intake are 
required.   
CRF  Case Report Form; PI   Principal Investigator; SC   subcutaneous; Q2W   every 2  weeks  
aAMG 570 will be manufactured and packaged by Amgen and distributed using Amgen clinical investigational product distribution procedures.  
 
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 53 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
7.1.2  Non-investigational Product s 
No non -investigational products will be used.  
7.1.3  Medical Devices  
There are no investigational medical devices used in this study.  
Non-investigational medical devices may be used in the conduct of this study as part of 
standard care.  
Non-investigational, non -Amgen medical devices (eg, syringes, sterile needles), that are 
commercially available are not usually provided  or reimbursed by Amgen (except, for 
example, if required by local regulation).  The investigator will be responsible fo r 
obtaining supplies of these devices.  
7.1.4  Other Therapies  
7.1.4.1  Immunosuppressants/Immunomodulators  
Subjects should receive stable doses of immunomodulators and/or immunosuppressants 
agents from  8 weeks prior to screening through week 52.  If a subject requires a higher 
dose of an immunosuppressant/immunomodulator or requires a new 
immunosuppressant/immunomodulator at any time during the study period (other than 
CS, see below), the subject may co ntinue the study but will be considered treatment  
failures for primary efficacy endpoint analyses  for the subsequent time points.   
These subjects will also be allowed to continue investigational product at the 
investigator's discretion, except subjects who  initiate any 
immunosuppressant/immunomodulator listed in Section 7.1.7  (treatments 
a through  i). 
Subjects may reduce dosage in immunomodulators and/or immunosuppressants if the 
subject develops unacceptable side effects or abnormal laboratory values attributable to 
these medications.  
7.1.4.2  Oral, Intramuscular , and Intravenous Corticosteroids  
Initiation or temporary increases in the OCS dosage are not en couraged but are allowed 
if initiated at any time between weeks 0 to 8 with a return to baseline dose within the 
subsequent 2  weeks.  In such cases, initiation or temporary increase of OCS is limited to 
a dose  5 mg/day of prednisone (or equivalent).  Sub jects who require higher dose 
increase of OCS  (> 5 mg/day of prednisone or equivalent ), or IM CS or IV CS, or those 
who cannot return to baseline dose within the following 2  weeks or subjects who require 
initiation or CS dose increase at any time point after week 10 can continue the study or 
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 54 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
investigational product  at the investigator's discretion  but will be considered 
treatment failures for the primary efficacy endpoint.  
Subjects may begin tapering OCS up to the week 44 assessment with initiation of 
tapering based upon clinical judgment of the treating physician.  The tapering schedule 
should be directed at the discretion of the investigator but should generally not be 
tapered more than 10% to 20% of the prior dose per week.  Between weeks 44 and 52, 
the OCS dosing should again remain stable.  
7.1.4.3  Topical Corticosteroids and Topical Calcineurin Inhibitors  
Subjects who are using topical CS or topical calcineurin inhibitors must remain on a 
stable regimen but may discontinue topical corticosteroids at any tim e if clinically 
indicated.  
7.1.4.4  Non-steroidal Anti -inflammatory Drugs (NSAIDs) and Other 
Analgesic Therapies  
Subjects taking non -steroidal anti -inflammatory drugs (NSAIDs) or other analgesic 
therapies should remain on stable dose from day 1 through week 52.  NS AIDs or other 
analgesic therapies used for SLE disease activity should be held for 24  hours prior to the 
scheduled monthly efficacy assessments.  Subjects can return to their regular doses 
immediately after the clinical visit is complete.  Discontinuation or reduction of NSAIDs or 
other analgesic therapy dose during the study is allowed based on the investigator’s 
judgment.  Initiation or increases in the NSAIDs or other analgesic therapy dose during 
the study are allowed if:  1) not initiated within 24  hours of the scheduled monthly 
efficacy assessments , 2) the subject returns to baseline dose within the subsequent 
2 weeks, and 3) it is not within 2  weeks prior to the week 52 visit.  
7.1.4.5  Anti-proteinuria Agents  
Subjects with SLE -related proteinuria taking anti -proteinuria agents (eg, angiotensin II 
receptor blockers, angiotensin -converting enzyme inhibitors), should remain on stable 
dose through week 52.  Discontinuation or dose reduction of anti -proteinuria agents 
during the study is allowed in case of intoleran ce or toxicity.  Initiation or dose increase 
of anti -proteinuria agents (eg, angiotensin II receptor blockers, angiotensin -converting 
enzyme inhibitors) for the purpose of SLE -related proteinuria during the study should be 
avoided.  
7.1.5  Other Treatment Procedur es 
7.1.5.1  Home Health Care Visits  
Section 7.1.5.1 is not applicable for participating sites in Bulgaria.  
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 55 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
If permitted by national and/or local regulations, the investigator may utilize a qualified 
home health care service provider, selected and approved by the sponsor, for 
investigational product administration.  This service can be offered to subjects that have 
not experienced adverse events considered to be related to investigational product that 
in the opinion of the investigator may pose a risk for home heal th care administration of 
investigational product.  The study may include up to 8  home visits, including weeks 22, 
26, 30, 34, 38, 42, 46, and 50.   
 
.  In addition to 
admini stration of investigational product, safety assessments including vital signs, 
adverse events, serious adverse events, and concomitant medications review will be 
collected.  
Home health care staff must be included on the study delegation log (authorized by the 
investigator) before any study -related tasks to be conducted by each home health care 
provider are started.  In addition, study -specific training including requirements for 
recording source documentation for the home health care provider, must be compl eted 
before they conduct any study -related tasks.  
Following home health care visit, all the information collected will be documented on the 
home health care services visit worksheet and forwarded to the investigator.   
A comprehensive list of all home heal th care services, as well as mandatory procedural 
and data collection requirements, will be separately provided in a home health care 
manual.  
7.1.6  Product Complaints  
A product complaint is any written, electronic, or oral communication that alleges 
deficien cies related to the identity, quality, durability, reliability, safety, effectiveness, or 
performance of a drug, combination product,  or device  after it is released for 
distribution to market or clinic by either (1) Amgen or (2) distributors or partners for 
whom Amgen manufactures the material.  This includes  all components distributed 
with the drug, such as packaging drug containers, delivery systems, labeling, and 
inserts.  This includes  AMG 570/placebo provisioned and/or repackaged/modified by  
Amgen.  
Any product complaint(s) associated with an investigational product supplied by Amgen  
are to be reported according to the instructions provided in the IPIM.  

Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 56 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
7.1.7  Excluded Treatments, Medical Devices, and/or Procedures During 
Study Period  
Subjects wh o are receiving treatments listed below are allowed to remain in the 
study at the investigator’s discretion.  Subjects are also allowed to continue 
investigational product at the investigator’s discretion except those  who initiate 
any treatment  listed below from a through  i:   
a. investigational therapies or commercially available biologic agents with 
immunosuppressive/immunomodulatory activity  for SLE or other conditions (eg, 
rituximab or belimumab)  
b. cytotoxic agents including: chlorambucil, cyclophosphamide, nitrogen mustard, or 
other alkylating agents  
c. thalidomide  
d. sirolimus  
e. oral calcineurin inhibitors (eg, tacrolimus, cyclosporine, etc.)  
f. T cell depleting agents (eg, antithymocyte globulin, Campath)  
g. recombinant IL -2 (eg, Proleukin)  
h.  JAK inhibi tors  
i. live vaccines  
j. intra-articular, IM, or IV CS, including adrenocorticotropic hormone  
k. intra-articular hyaluronic acid injections  
 
7.2 Method of Treatment Assignment  
Subjects who meet all eligibility criteria will be randomized to receive AMG 570 at 70 mg 
Q2W, 280  mg Q2W, 420  mg Q2W, or placebo in a double -blind manner.  The 
randomization starts as 1:1:1:1 and then could be adapted at each IA (if before full 
enrollment) based on the clinical efficacy (RAR) for allocating more subjects to more 
efficaci ous doses and fewer subjects to less efficacious doses.  The randomization 
allocation probability for placebo group will be kept constant at 25%.  The randomization 
will be  stratified by geographic region (North America + Western Europe vs ROW) and 
screeni ng hSLEDAI score (≥ 10 or <  10). 
Each randomized subject will receive a single, unique randomization number via IRT at 
randomization.  The randomization date is to be documented in the subject’s medical 
record as registered in the IRT and on the enrollment  CRF.  
7.3 Blinding  
This is a double -blind study.  Treatment assignment will be blinded to all subjects, site 
personnel, and Amgen as described below . 
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 57 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
7.3.1  Site Personnel Access to Individual Treatment Assignments  
A subject’s treatment assignment is to only be  unblinded by the investigator when 
knowledge of the treatment is essential for the further management of the subject on this 
study or may potentially impact the safety of the subject.  Unblinding at the study site for 
any other reason will be considered a  protocol deviation.  It is encouraged that the  
Amgen Trial Manager be notified before the blind is broken unless the investigator 
believes that identification of the investigational product is required for a medical 
emergency.  If this is not possible, th e Amgen Trial Manager must be notified within 
24 hours after breaking the blind.  The date and reason that the blind was broken must 
be recorded in the source documentation and CRF, as applicable.  Continuation of such 
subjects in the study should be discu ssed with the medical monitor.  
7.3.2  Access to Individual Subject Treatment Assignments by Amgen or 
Designees  
Blinded individuals will not have access to unblinded information until the study is 
formally unblinded.  Unblinding and potentially unblinding inform ation is not to be 
distributed to the study team, investigators or subjects prior to the study being formally 
unblinded which will occur at the final analysis except as specified (eg, Section  7.3.2 ).  
Otherwise, if unblinding  occurs, only the subject an d investigators will have access to 
what investigational product treatment was received and Amgen will not have access to 
this information.  
Individual subject treatment assignments will be maintained by the IRT System.  Any 
unplanned unblinding occurring d uring the study period will be documented and reported 
in the final clinical study report.  Staff from Clinical Supply Chain, Biological Sample 
Management, PK and Drug Metabolism, Clinical Pharmacology Modelling and 
Simulation, Clinical Immunology, Departm ent of Molecular Sciences and Computational 
Biology, Safety, internal team, and Global Biostatistical Science departments who are 
responsible for tracking, assaying, or analyzing biological samples during the conduct of 
this study are considered to be unbl inded to the treatment assignments in this study.  
These individuals will not have access to subject level clinical data apart from the  
samples they are assaying and analyzing during the course of the study.  If 
exposure -response analysis is performed, the  exposure -response analysis team, 
including Clinical Pharmacology Modeling and Simulation (CPMS) and Global 
Biostatistics Sciences, who are independent of the study team, may be unblinded.  If 
needed by the Development/Therapeutic Area (TA) Head to make de cisions after 
receiving DMC recommendations at IAs, pre -specified independent biostatistician(s), 
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 58 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
programmer(s), and/or CPMS scientist(s) outside the study team may be unblinded to 
carry out ad -hoc analyses as requested by the Development/TA Head at IAs (d etails will 
be specified in data access plan for IA).  
7.3.3  Unblinding Procedure For Investigators  
A subject's treatment assignment must only be unblinded when this knowledge is 
essential for management of the subject.  Before unblinding, the investigator (or si te) 
should contact Amgen.  In the interest of subject safety, where this is not possible, the 
investigator must contact Amgen within 1 working day of the unblinding event.  The 
actual treatment assignment must only be shared to those who require it for tre atment of 
the subject and should not be recorded in the CRF.  The IRT system will assign each 
subject, at each dispensing visit, with individually numbered Investigational Product  
containers.  This unique number will form the basis of the unblinding information.  For 
unblinding, only authorized staff assigned with access to the unblinding module in the 
IRT can obtain unblinding information.  For further details on access and unblinding, 
refer to the IRT Manual.  
Contact details for emergency unblinding : 
Amgen, Inc.  
Address: One Amgen Center Drive  
Thousand Oaks, CA 91320, USA  
Telephone: +1 (805) 447 -1000  
7.4 Dose Modification  
7.4.1  Dose -cohort Study Escalation/De -escalation and Stopping Rules  
All subjects will receive a fixed dose of the investigational product (AMG 570/placebo ).  
No dose adjustments will be allowed.  
7.4.2  Dosage Adjustments, Delays, Rules for Withholding or Restarting, 
Permanent Discontinuation  
7.4.2.1  Amgen Investigational Product:  AMG 570 or Placebo  
No dose adjustments will be allowed . 
7.4.2.2  Non-Amgen Non-Investigational Product:  SLE Standard of Care 
Therapy and Oral Corticosteroids  
The reason for dose change of OCS ( Section  7.1.4.2 ) and/or other medications including 
for SLE SOC therapies ( Section  7.1.4 ; anti-malarials,  azathi oprine, methotrexate, 
leflunomide , mycophenolate mofetil, or dapsone) is to be recorded on each subject’s 
CRF(s).  
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 59 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
7.4.3  Hepatotoxicity Stopping and Rechallenge Rules  
Refer to Section  12.7 for details regarding drug -induced liver injury guidelines, as 
specified in the Guidance for Industry Drug -Induced Liver Injury:  Premarketing Clinical 
Evaluation, July 2009 .  This will be used for stopping and rechallenge with the agent.  
7.5 Preparation/Handling/Storage/Accountability  
Guidance and information on preparation, handling, storage, ac countability, destruction, 
or return of the investigational product during the study are provided in the IPIM.  
7.6 Treatment Compliance  
Subjects will receive the 26 doses of investigational product (AMG 570 or placebo) at the 
research facility or via home health care visits, administered by qualified study personnel 
for the duration of the study.  The investigational product will be administered Q2W and 
dosing should occur within a visit window of ± 3 business days from the scheduled 
dosing date.  There sho uld also be a minimum of 11  days between administrations of 
investigational product .  If any scheduled dose after study day 1 is delayed 7 or more 
calendar days from the scheduled visit date, this will be considered a missed dose and 
recorded as such on th e CRF.  The next dose is to be given on the next scheduled visit 
date (based on study day  1).  Subjects will be observed  for at least 30 minutes following 
dose administration.  Vital signs, adverse events, serious adverse events, concomitant 
medications an d efficacy assessments will be obtained prior to administration of the 
investigational product.  
7.7 Treatment of Overdose  
The effects of overdose of this product are not known.  
7.8 Prior and Concomitant Treatment  
7.8.1  Prior Treatment  
Prior therapies that were being taken/used from time of initial diagnosis with SLE 
through the date of randomization will be collected.  For prior therapies, collect therapy 
name, indication, dose, unit, frequency, start date, and stop date.  
7.8.2  Concomitant Treatment  
Throughout the stu dy, investigators may prescribe any concomitant medications or 
treatments deemed necessary to provide adequate supportive care except for those 
listed in Section  7.1.7 . 
Concomitant therapies are to be collected from randomization through the end of the 
safety follow -up period.  For conc omitant therapies, collect therapy name, indication, 
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 60 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
dose, unit, frequency, start date, and stop date.  Guidelines for immunomodulators, 
immunosuppressants, and OCS are provided in Section  7.1.4.1  through  Section  7.1.4.5 . 
8. Discontinuation Criteria  
Subjects have the right to withdraw from investigational product and/or other 
protocol -required therapies, protocol procedures, or the study as a whole at any time 
and for any reason without prejudice to their future medical care by the physician or at 
the institution.  The investigator and/or sponsor can decide to withdraw a subjec t(s) from 
investigational product, device, and/or other protocol -required therapies, protocol 
procedures, or the study as a whole at any time prior to study completion for the reasons 
listed in Sections  8.1, 8.2, and 8.2.1 . 
8.1 Discontinuation of Investigati onal Product  
Subjects (or a legally acceptable representative) can decline to continue receiving 
investigational product and/or other therapies or procedures at any time during the study 
but continue participation in the study.  If this occurs, the inves tigator is to discuss with 
the subject the appropriate processes for discontinuation from investigational product or 
other therapies and must discuss with the subject the possibilities for continuation of the 
Schedule of Activities (see Table  2-1 and Table  2-2) including different options of 
follow -up (eg, in person, by phone/mail, through family/friends, in 
correspondence/communication with other treating physici ans, from the review of 
medical records) and collection of data, including endpoints and adverse events, as 
applicable and must document this decision in the subject’s medical records.  Subjects 
who have discontinued investigational product and/or therapie s or procedures should not 
be automatically removed from the study  and will be encouraged to maintain the planned 
scheduled assessments for monthly efficacy and safety visits ( Table  2-1 and Table  2-2) 
to allow safety surveillanc e and collection of outcome data up to week 52 or for a 
minimum of 16  weeks after the last dose of investigational product (see Section  9.1.2  for 
additional details).  
Subjects may be eligible for continued treatment with Amgen investigational product(s) 
and/or other therapies by a separate protocol or as provided for by the local country’s 
regulatory mechanism, based on parameters consistent with Section  12.3. 
Reasons for removal from protocol -required investigational product(s) or procedural 
assessments may include any of the following:    
 Decision by Sponsor  
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 61 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
 Lost to follow -up 
 Death  
 Ineligibility determined  
 Protocol deviation  
 Non-compliance  
 Adverse event  
 Subject request  
 Pregnancy  
 Disease flare  
8.2 Discontinuation From the Study  
Withdrawal of consent for a study means that the subject does not wish to receive 
further protocol -required therapies or procedures, and the subject does not wish to or is 
unable to continue further study participation.  Subject data up to withdrawal of consent 
will be included in the analysis of the study, and where permitted, publicly availab le data 
can be included after withdrawal of consent.  The investigator is to discuss with the 
subject appropriate procedures for withdrawal from the study and must document the 
subject’s decision to withdraw in the subject’s medical records.  
If a subject w ithdraws from the study, he/she may request destruction of any samples 
taken and not tested, and the investigator must notify Amgen accordingly 
(see Section  12.6 for further details).  Refer to the Schedule of Activities ( Section  2) for 
data to be collected at the time of study discontinuation and follow -up and for any further 
evaluations that need to be completed.  
8.2.1  Reasons for Removal From Study  
Reasons for  removal of a subject from the study are:    
 Decision by sponsor  
 Withdrawal of consent from study  
 Death  
 Lost to follow -up 
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 62 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
8.3 Lost to Follow -up 
A subject will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by the study site.  
The following actions must be taken if a subject fails to return to the clinic for a required 
study visit:  
 The site must attempt to contact the subject and reschedule the missed visit as soon 
as possible and counsel the subject on the importance of maintaining the assigned 
visit schedule and ascertain whether or not the subject wishes to and/or is able to 
continue in the study.  
 In cases in which the subject is deemed lost to follow -up, the investigator or 
designee must make every effort to regain contact with the subject (where possible, 
3 telephone calls and, if necessary, a certified letter to the  subject’s last known 
mailing address or local equivalent methods).  These contact attempts are to be 
documented in the subject’s medical record.  
 If the subject continues to be unreachable, he/she will be considered to have 
withdrawn from the study with a primary reason of lost to follow -up.  
 For subjects who are lost to follow -up, the investigator can search publicly available 
records where permitted to ascertain survival status.  This ensures that the data 
set(s) produced as an outcome of the study is/are  as comprehensive as possible.  
9. Study Assessments and Procedures  
Study procedures and their time points are summarized in the Schedule of Activities  
(Section  2). 
As protocol waivers or exemptions are not allowed if an enrolled subject is subsequently 
determined to be ineligible for the s tudy, this must be discussed with the sponsor 
immediately upon occurrence or awareness to determine if the subject is to continue or 
discontinue investigational product.  
Adherence to the study design requirements, including those specified in the Schedule 
of Activities ( Section  2), is essential an d required for study conduct.  
9.1 General Study Periods  
9.1.1  Screening, Enrollment and/or Randomization  
Informed consent must be obtained before completing any screening procedure or 
discontinuation of standard therapy for any disallowed therapy.  After the sub ject has 
signed the informed consent form, the site will register the subject in the IRT and screen 
the subject in order to assess eligibility for participation.  The screening window is up to 
33 calendar days.  
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 63 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
All eligibility evaluations (at screening vis it and baseline/day 1 visits, prior to 
randomization) must be completed to confirm that potential subjects meet all eligibility 
criteria ( Section  6).  The investigator will maintain a screening log to record details of all 
subjects screened, to confirm eli gibility or record reasons for screening failure (see 
Section  6.5), as applicable.  If a lab retest is required, the sponso r should approve prior 
to being retested.  
A subject is considered enrolled when the investigator decides and all eligibility criteria 
(from screening visit and baseline/day 1 visit) are met.  The investigator is to document 
this decision and date, in the s ubject’s medical record and in/on the enrollment CRF.  At 
baseline/day 1 visit, if the subject meets all eligibility criteria, he/she is subsequently 
enrolled and randomized to a treatment regimen.  
If a subject has not met all eligibility criteria either d uring or at the end of the screening 
period (maximum 33  days), the subject will be registered in IRT as a screen fail.  
Subjects should always complete the 33 -day screening period before being considered 
for re -screening.  At that point, subjects may be re screened, as follows:  
 Subjects who do not meet the hSLEDAI criteria (total hSLEDAI score  6 at 
screening visit or clinical hSLEDAI score  4 at baseline/day 1 visit) must wait at 
least 2  weeks before rescreening.  
 Subjects who have not maintained stable OC S dosing at day 1 will be required to 
wait at least 2  weeks prior to rescreening ( Section  6.1). 
 Subjects who have not maintained stable immunosuppressant/immunomodulatory 
dosing at day 1 will be required to wait at least 8  weeks prior to rescreening 
(Section  6.1).  
 Subjects who met eligib ility criteria but were not able to enroll within the screening 
period (within the 33  days), can rescreen immediately.  
Once the subject is registered as rescreened, a new 33-day screening window will 
begin.  All procedures noted in Section  6, including the informed consent and all 
laboratory parameters ( Section  9.2.4 ) must be repeated with the following exception:  
 tuberculosis screening tests (QuantiFERON®-T, T-spot test OR PPD), serologies for 
hepatitis B virus, hepatitis  C virus a nd HIV may not be repeated provided that 
rescreening occurs  12 months of screening visit (where those test results were 
negative) and there is no patient’s medical/epidemiological history suggestive of 
infection or recent exposure to cases of infection.  
Screen fail subjects may be eligible for re -screening up to 2 times . 
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 64 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
9.1.2  Treatment Period  
The 52 -week treatment period is the study period following randomization to the planned 
week 52 visit (regardless of investigational product compliance) .   
Visits will occur per the Schedule of Activities ( Sectio n 2.2).  On -study visits may be 
completed within ± 3 business days of the scheduled visits.  The date o f the first dose of 
investigational product is defined as day 1.  All subsequent doses and study visits will be 
scheduled based on the day 1 date.  The investigational product is to be administered 
following the completion of all other study required proce dures for that visit.  
9.1.3  Safety Follow -up 
Following last administration of  the investigational product , a minimum of 16-weeks 
of safety follow -up assessments is required to ensure safety surveillance of 
subjects in the study.    
For subjects who discontinue investigational product prior  to or at  week 36, the 
safety follow -up visits will be included within the 52 -week period  and no additional 
safety follow -up visits will be required  (Table  2-1).  Subjects who discontinue 
investigational product after week 36 are required to attend as many follow -up 
visits as necessary to ensure a minimum of 16 weeks of safety follow -up period 
after the last administration of the investigational product  (Table  2-2).   
 and PK samples should be collected during the first 
4 safety follow -up visit s after last administration of the investigational product.  
Subjects who are unwilling or unable to complete the follow -up visits as scheduled will 
be contacted by phone and may be requested to provide documentation from their 
primary  provider.  
9.1.4  Long -term Follow -up 
Not applicable to this study.  
9.1.5  End of Study  
9.1.5.1  End of Study for Individual Subject  
The end of study for an individual subject is defined as the last day the protocol -specific 
procedures are conducted for an individual subject.  An individual subject has  
completed the study when: 1) ha s completed  52-week treatment period regardless 
of investigational product  compliance, and 2) ha s completed a minimum of 
16 weeks  of safety follow -up after the last administration of the investigation al 
product.   

Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 65 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
9.1.5.2  End of Study  
The end of study is defined as the date when the last subject across all sites is assessed 
or receives an intervention for evaluation in the study (ie, last subject last visit), following 
any additional parts in the study (eg, safety follow -up), as applicable.  
9.2 Description of General Study Assessments and Procedures  
The sections below provide a description of the individual study procedures for required 
time points.  
9.2.1  General Assessments   
9.2.1.1  Informed Consent  
All subjects mus t sign and personally date the IRB/IEC approved informed consent 
before any study -specific procedures are performed.  
9.2.1.2  Demographics  
Demographic data collection including sex, age, race, and ethnicity will be collected in 
order to study their possible ass ociation with subject safety and treatment effectiveness.  
Additionally, the correlation between specific demographic data and PK, PD, and 
biomarkers may be explored.  
9.2.1.3  Medical History  
The Investigator or designee will collect a relevant medical, psychia tric, and surgical 
history that started within 5 years of enrollment or as necessary to describe chronic or 
co-morbid conditions prior to enrollment through the start of the adverse event reporting 
period.  Medical history will include information on the s ubject's concurrent medical 
conditions.  Findings are to be recorded on the medical history CRF.  In addition to the 
medical history above, SLE history must date back to the original diagnosis.  The current 
toxicity grade and severity will be collected for  each condition that has not resolved.  
9.2.1.4  Physical Examination  
Physical examination will be performed as per SOA.  Physical examination findings 
should be recorded on the appropriate CRF (eg, medical history, event).  
9.2.1.5  Concomitant Medications  
All concomitant  medications including over -the-counter products and vitamins 
administered while the subject is on study will be recorded on the eCRF.  
9.2.1.6  Physical Measurements  
Height in centimeters should be measured without shoes.  Weight in kilograms should 
be measured without shoes.  
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 66 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
9.2.1.7  Substance Abuse History  
Obtain a detailed history of prior and/or concurrent use of alcohol and tobacco.  
Note:  Subjects who are taking methotrexate should be advised to limit alcohol 
consumption to no more than 4 ounces per week.  
9.2.2  Efficacy Assessments  
Efficacy assessments are recommended to be performed prior to obtaining any blood 
samples.  Data will be captured on paper source.  Data will be entered into the study 
database.  It is highly recommended that the same investigator pe rforms efficacy 
assessments at every timepoint for a given subject.  
9.2.2.1  Hybrid Systemic Lupus Erythematosus Disease Activity Index  
The hSLEDAI is a global index that evaluates disease activity and includes 24 items 
collecting specific manifestations in 9 orga n systems: neurological, musculoskeletal, 
renal, mucocutaneous, general, heart, respiratory, vascular, and hematological.  The 
maximum score is 105.  Hybrid SLEDAI is the index score used during the validation of 
the SRI (Navarra et al, 2011; Furie et al, 2011).  The hSLEDAI is identical to the 
SELENA -SLEDAI score except for the scoring of proteinuria, which uses the SLEDAI -2K 
definition (proteinuria is scored 4 points if proteinuria is >  0.5 grams/24  hours [or 
equivalent urine protein/creatinine ratio]).  The hSLEDAI differs from SLEDAI -2K in 2 
main aspects:  the hSLEDAI  includes scleritis and episcleritis for visual disturbances 
assessments and scores arthritis only if > 2 joints manifest signs of inflammation.  In the 
hSLEDAI score, inflammation is strict ly defined as the presence of tenderness plus one 
of the following: swelling, effusion, warmth or erythema.  Unlike SLEDAI -2K, the 
presence of tenderness alone is not sufficient and at least 3 joints, and not only 2, must 
be affected.  In this study, for h SLEDAI scoring purposes, arthritis is required to involve 
the small joints of hands and/or wrists.  Additionally, in this study, scleritis and episcleritis 
will be considered for scoring purposes in the hSLEDAI only if SLE -relatedness is 
confirmed by an op hthalmologist.  
A total hSLEDAI  6 is used for eligibility purposes, together with the presence of a 
clinical hSLEDAI  4.  A clinical hSLEDAI score is a hSLEDAI score without the inclusion 
of points attributable to laboratory results.  
Hybrid SLEDAI descri ptors will be scored based on a review of medical history, physical 
examination, and clinical laboratory findings.  Findings should reflect activity during the 
30 calendar days prior to the current visit.  
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 67 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
9.2.2.2  British Isles Lupus Assessment Group Index  
The British Isles Lupus Assessment Group ( BILAG ) index (BILAG 2004) evaluates 
disease activity in 9  separate organ systems and comprises a total of 97 items.  Each 
item is measured qualitatively by review of medical history and physical examination 
(yes/no, improv ing/same/worse/new) or quantitatively by measuring laboratory values.  
Based on these items, each of the 9  organ systems allocated an alphabetical score of A 
(most active), B (moderate activity), C (minor activity), D (no activity) or E (never 
present).  BILAG descriptors will be scored based on a review of medical history, 
physical examination, and clinical laboratory findings.  Findings should reflect activity 
during the 4 -week period prior to the current visit and should be related to the subject’s 
SLE.  
9.2.2.3  Cutaneous Lupus Erythematosus Disease Area and Severity Index  
The CLASI consists of 2 scores, the first summarizes the activity of the disease while the 
second is a measure of the damage done by the disease.  Activity is scored based on 
erythema, scale/hyp erkeratosis, mucous membrane involvement, acute hair loss and 
non-scarring alopecia.  Damage is scored in terms of dyspigmentation and scarring, 
including scarring alopecia.  Subjects are asked whether dyspigmentation due to 
cutaneous lupus lesion usually remains visible for more than 12 months, which is 
considered permanent.  If so, the dyspigmentation score is doubled.  The scores are 
calculated by simple addition based on the extent of the symptoms.  The CLASI is 
designed as a table where the rows denote  anatomical areas, while the columns score 
major clinical symptoms.  The extent of involvement for each of the skin symptoms is 
documented according to specific anatomic areas that are scored according to the worst 
affected lesion within that area for each  symptom.  
9.2.2.4  Photography  
In subjects who have a CLASI activity score  8 at screening, half body (from the neck 
down, anterior and posterior views) and cutaneous lupus lesion target area (global and 
close up excluding the face) photography will be taken and c ollected, if possible, per the 
photography manual.  Photographs will be taken by the study staff at the time points 
specified in the Schedule of Activities ( Section  2) and reviewed by vendor’s team for 
quality and to ensure subject’s de -identification before being rev iewed by Amgen 
external adjudicator to ensure the visual characteristics of the rash are consistent with 
the CLASI score assigned.  
9.2.2.5  Swollen and Tender  Joint Count  
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 68 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Swollen and tender joint counts will be performed as noted in the Schedule of Activities 
(Section 2). 
It is highly recommended that the same investigator /assessor  should perform the 
assessments throughout the study for a given  subject.  The initials of the joint assessor 
should be recorded in the CRF.  The score for each joint will be recorded on a paper 
source.  Data will be entered into the study database.  
Joints that have been replaced during the study, or have suffered trauma or received 
intra -articular injections,  are considered non -evaluable.   Joints from subjects with 
osteoar thritis or other condition that in the investigator’s opinion can cofound the 
assessment of lupus arthritis, are considered non -evaluable.  
Swollen Joint Count Assessments:  A total 28 joints will be scored for pres ence or 
absence of swelling.  A separated score for joints in the hands and wrists will be 
calculated.  
Tender Joint Count Assessments:  A total 28 joints will be scored for presence or 
absence of tenderness.  A separated score for joints in the hands and w rists will be 
calculated.  
Swollen and Tender Joint Count Assessments:  joints in hands and wrists will be scored 
for the simultaneous presence or absence of swelling and tenderness.  
9.2.2.6  Physician Global Assessment – Visual Analogue Scale  
The Physician Global Assessment (PGA ) is a visual analogue scale (VAS) using 3 
benchmarks for assessing disease activity over the last 4  weeks.  When scoring the 
PGA, the previous visit score should be noted, and the current score should be relative 
to that pr evious visit.  The score ranges from 0 to 3 with 3 indicating severe disease.  
This refers to the most severe possible disease and does not reflect the most severe 
ever seen in a particular subject, but the most severe disease ever seen in all SLE 
patients .  Therefore, a score of 3 should rarely be seen.  Any disease rated greater than 
2.5 is very severe.  The range of moderate disease covers approximately 1.5 to 2.4.  
Mild disease falls below 1.5.  
This is a global assessment, factoring in all aspects of th e subject’s lupus disease 
activity.  It should not reflect non -lupus medical conditions.  An increase of  0.3 points 
( 10% on the 3 point -VAS) from baseline is considered clinically significant worsening 
of disease.  This assessment will be completed by a health care provider (HCP) and 
should be done before assessing the hSLEDAI and BILAG.  The assessment will be 
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 69 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
recorded on a paper source with both sources using the same dimensions and 
benchmarks for the VAS.  Data will be transmitted or entered into the  study database.  
9.2.2.7  SELENA -SLEDAI Flare Index  
The SELENA -SLEDAI Flare Index will be used to evaluate the presence of 
mild-moderate and severe flares as detailed in Buyon et al, 2005.  An additional question 
will be added to the classic instrument if, based o n the investigators’ clinical judgment, 
the flare is mild or moderate.  
9.2.2.8  BILAG Flare Index  
The BILAG flare index will be derived from BILAG 2004, as measured by BILAG score 
designation of “worse” or “new” resulting in a B score in  2 organs or an A score in  1 
organ (Gordon et al, 2003).  
9.2.2.9  Lupus Low Disease Activity State (LLDAS)  
The LLDAS will be calculated as detailed in Franklyn et al, 2016.  
9.2.2.10  Systemic Lupus International Collaborating Clinics/American 
College of Rheumatology Damage  Index  
The Systemic Lupus International Collaborating Clinic/American College of 
Rheumatology Damage Index global score will be calculated as detailed in Gladman 
et al, 1996.  
9.2.2.11  Systemic Lupus Erythematosus Responder Index   
The SRI -4 will be calculated as det ailed in Luijten et al, 2012 .  A subject achieves 
SRI-4 response if all of the following criteria are met:    4-point reduction from 
baseline in hSLEDAI score, AND no new BILAG 2004  A score and no  1 new 
BILAG  B domain scores compared with baseline (eg, no B, C, D, or E scores at 
baseline becomes A or no more than 1 C, D , or E score at baseline becomes B) , 
AND no 0.3-point deterioration from baseline in PGA VAS score ( scale 0 to 3 ), AND 
no use of more than protocol -allowed therapies (ie, initiation or increase in OCS 
dose  5 mg/day prednisone [or equivalent] or IM CS or IV CS at any time point 
during the study; initiation or increase in OCS dose  5 mg/day prednisone [or 
equivalent] after week 10; initiation or increase in OCS dose  5 mg/day 
prednisone [or equivalent] between week  0 and week  8 that was not returned to 
baseline dose within the following 2 weeks; increase in current or initiation of new 
immunosuppressant/immunomodulator(s) at any time during the study).  The 
latest vis it date among hSLEDAI, BILAG , and PGA will be considered the SRI -4 
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 70 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
visit date.  In the case when all 3 visit dates are missing, the upper limit of the 
analytic window of this visit will be the SRI -4 visit date.  When all 4 criteria are met, 
the subject is a responder at that time point according to the SRI -4 definition.  
9.2.2.12  BICLA Index Response  
The BICLA response is defined as at least 1  gradation of improvement in baseline 
BILAG domain scores in all body systems with moderate or severe disease activity at 
entry (eg, all A [severe disease] domain scores falling to B [moderate], C [mild], or D [no 
activity], and all B domain scores falling to C or D); no new BILAG 2004 A domain score 
and no  1 new BILAG 2004 B domain scores compared with baseline; no worsening 
of the hSLEDAI score from baseline; no  0.3-point deterioration from baseline in 
PGA (scale 0 to  3); and no use of more than protocol -allowed therapies (ie, 
initiation or increase in OCS dose  5 mg/day prednisone [or equivalent] or IM CS 
or IV CS at any time point during the study; initiation or increase in OCS dose 
 5 mg/day prednisone [or equivalent] after week 10; initiation or increase in OCS 
dose  5 mg/day prednisone [or equivalent] between week 0 and week 8 that was 
not returned to basel ine dose within the following 2 weeks; increase in current or 
initiation of new  immunosuppressant/immunomodulator(s) at any time during the 
study); and no initiation of non -protocol treatment for SLE  (Wallace  et al, 2011; Wallace 
et al,  2014 ). 
9.2.3  Safety Ass essments  
Planned time points for all safety assessments are listed in the Schedule of Activities 
see Section  2.  The investigator may utilize a qualified home health care service provider 
selected by Amgen at up to 8 home visits (including weeks 22, 26, 30, 34, 38, 42, 46, 
and 50), for subjects that have not experienced adverse events considered to be related 
to investigational product that in the opinion of the investigator may pose a risk for home 
health care administration of investigational product (h ome health care visits are not 
applicable for participating sites in Bulgaria).   During those visits, in addition to 
administration of investigational product, safety assessments including vital signs, 
adverse events, serious adverse events, and concomitan t medications review will be 
collected, as described in Section  7.8.2 . 
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 71 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
9.2.3.1  Adverse Events  and Serious Adverse Events  
9.2.3.1.1  Time Period and Frequency for Collecting and Reporting Safety 
Event Information  
9.2.3.1.1.1  Adverse Events  
The adverse event grading scale to be used for this study will be the Common 
Terminology Criteria for Adverse Events (CTCAE) versio n 5 and is described in 
Section  12.4. 
The investigator is responsible for ensuring that all adverse events observed by the 
investigator or reported by the subject that occur after the first dose of investigational 
product (AMG 570/placebo) through the EOS are repo rted using the Event CRF.  
9.2.3.1.1.2  Serious Adverse Events  
The investigator is responsible for ensuring that all serious adverse events observed by 
the investigator or reported by the subject that occur after signing of the informed 
consent through the EOS are repor ted using the Event s CRF.  
All serious adverse events will be collected, recorded and reported to the sponsor or 
designee within 24  hours, as indicated in Section  12.4.  The investigator will submit any 
updated serious adverse event data to the sponsor within 24  hours of it being available.  
Since the criteria  the CTCAE grading scale differs from the regulatory criteria for serious 
adverse eve nts, if adverse events correspond to grade 4 CTCAE toxicity grading 
scale criteria (eg, laboratory abnormality reported as grade 4 without 
manifestation of life threatening status), it will be left to the investigator’s judgment to  
also report these  abnorm alities  as serious adverse events .  For any adverse event that 
applies to this situation, comprehensive documentation of the event’s severity 
must be recorded in the subject medical records . 
9.2.3.1.1.3  Serious Adverse Events After the Protocol -required Reporting 
Period 
After end of study,  there is no requirement to actively  monitor study subjects after the 
study has ended with regards to study subjects treated by the investigator.   
However, if the investigator becomes aware of serious adverse events  suspected to 
be re lated to the investigational product, then  these serious adverse events will be 
reported to Amgen within 24  hours following the investigator’s awareness  of the event.  
Serious adverse events reported outside of the protocol -required reporting period will be  
captured within the safety database as clinical trial cases and handled accordingly based 
on relationship to investigational product.   
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 72 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
If further safety related data is needed to fulfill any regulatory reporting 
requirements for a reportable event, then additional information may need to be 
collected from the subject’s records after the subject ends the study.  
9.2.3.1.2  Method of Detecting Adverse Events and Serious Adverse Events  
Care will be taken not to introduce bias when detecting adverse events and/or serious  
adverse events.  Open -ended and non -leading verbal questioning of the subject is the 
preferred method to inquire about adverse event occurrence.  
9.2.3.1.3  Follow -up of Adverse Events and Serious Adverse Events  
After the initial adverse event/serious adverse event report, the investigator is required to 
proactively follow each subject at subsequent visits/contacts.  All adverse events and 
serious adverse events will be followed until resolution, stabilization, un til the event is 
otherwise explained, or the subject is lost to follow -up (as defined in Section  8.3).  
Further information on follow -up procedures is given in Section  12.4. 
All new information for previously reported serious adverse events must be sent to 
Amgen within 24  hours following knowledge of th e new information.  If specifically 
requested, the investigator may need to provide additional follow -up information, such as 
discharge summaries, medical records, or extracts from the medical records.  
Information provided about the serious adverse event must be consistent with that 
recorded on the Event s CRF.  
9.2.3.1.4  Regulatory Reporting Requirements for Serious Adverse Events  
If a subject is permanently withdrawn from protocol -required therapies because of a 
serious adverse event, this information must be submit ted to Amgen.  
Prompt notification by the investigator to the sponsor of serious adverse events is 
essential so that legal obligations and ethical responsibilities towards the safety of 
subjects and the safety of an investigational product under clinical in vestigation are met.  
The sponsor has a legal responsibility to notify both the local regulatory authority and 
other regulatory agencies about the safety of an investigational product under clinical 
investigation.  The sponsor will comply with country -speci fic regulatory requirements 
relating to safety reporting to the regulatory authority, IRBs/IECs, and investigators.  
Individual safety reports must be prepared for suspected unexpected serious adverse 
reactions according to local regulatory requirements and  sponsor policy and forwarded 
to investigators as necessary.  
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 73 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
An investigator who receives an individual safety report describing a serious adverse 
event or other specific safety information (eg, summary or listing of serious adverse 
events) from the sponso r will file it along with the IB and will notify the IRB/IEC, if 
appropriate according to local requirements.  
To comply with worldwide reporting regulations for serious adverse events, the treatment 
assignment of subjects who develop serious, unexpected, a nd related adverse events 
may be unblinded by Amgen before submission to regulatory authorities.  Aggregate 
analyses may also be unblinded by the Safety Assessment Team as appropriate.  
Investigators will receive notification of related serious adverse eve nts reports sent to 
regulatory authorities in accordance with local requirements.  
9.2.3.1.5  Safety Monitoring Plan  
Subject safety will be routinely monitored as defined in Amgen’s safety surveillance and 
signal management processes.  
9.2.3.1.6  Pregnancy and Lactation  
Details o f all pregnancies and/or lactation in female subjects will be collected after the 
start of investigational product through the EOS . 
If a pregnancy is reported, the investigator is to inform Amgen within 24  hours of learning 
of the pregnancy and/or lactatio n and is to follow the procedures outlined in 
Section  12.5.  Amgen Global Patient Safety will follow -up with the investigator regarding 
additional information that may be requested.  
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered serious adverse events.  
Further details regarding pregnancy and lactation are provided in Section  12.5. 
9.2.3.2  Vital Signs  
The following measurements must be performed: systolic/diastolic blood pressure, heart 
rate, respiratory rate, and temperature.  Subject must be in a supine or seated position in 
a rested an d calm state for at least 5 minutes before blood pressure assessments are 
conducted.  The position selected for a subject should be the same that is used 
throughout the study and documented on the vital sign CRF.  The temperature location 
should be oral or  tympanic (with oral preferred).  Once a location for temperature 
assessment is selected for a subject, the location should be the same throughout the 
study and documented on the vital signs CRF.  Record all measurements on the vital 
signs CRF . 
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 74 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
9.2.4  Clinical Laboratory Assessments  
Refer to Section  12.2 for the list of clinical laboratory tests to be performed and to the 
Schedule of Activities ( Section 2) for the timing and frequency.  
The investigator is responsible for reviewin g laboratory test results and recording any 
clinically relevant changes occurring during the study in the Event CRF.  The investigator 
must determine whether an abnormal value in an individual study subject represents a 
clinically significant change from t he subject’s baseline values.  In general, abnormal 
laboratory findings without clinical significance (based on the investigator's judgment) 
are not to be recorded as adverse events.  However, laboratory value changes that 
require treatment or adjustment i n current therapy are considered adverse events.  
Where applicable, clinical sequelae (not the laboratory abnormality) are to be recorded 
as the adverse event.  
All protocol -required laboratory assessments, as defined in Section  12.2, must be 
conducted in accordance with the laboratory manual and  the Schedule of Activities . 
After baseline, PK/PD parameters that could unblind the study will not be reported to 
investigative sites or other blinded personnel unt il the study has been unblinded.  
9.2.4.2  Pregnancy Testing  
A highly sensitive serum pregnancy test should be completed at screening and a highly 
sensitive urine pregnancy test should be completed at the Day 1 visit  for females of 
childbearing potential.  
Note:  Females who have undergone a bilateral tubal ligation/occlusion should have 
pregnancy testing per protocol requirements.  (If a female subject, or the partner of a 
male subject, becomes pregnant it must be reported on the Pregnancy Notification 
Work sheet, see Section  12.5).  Refer to Section  12.5 for contraceptive requirements.  
Additional pregnancy testing using a high sensitivity urine pregnancy test should be 
performed at monthly intervals during the treatment period and at the first 2 safety 
follow -up visits.  

Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 75 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Additional on -treatment pregnancy testing may be performed at the investigator’s 
discretion or as required per local laws and regulations.  
9.2.4.3  Tuberculosis Testing  
All subjects must receive either a PPD, QuantiFERON-TB, or T -spot test at screening.  
9.2.4.3.1  Purified Protein Derivative  
The PPD test must be read by a trained health care professional 48 to 72  hours after the 
test is placed.  The PPD reader must be identified on the delegation of  authority for this 
responsibility.  PPD test kits will not be provided by the sponsor and must be procured 
locally.  
9.2.4.3.2  QuantiFERON-TB or T -spot Testing  
If a QuantiFERON-TB test is performed for eligibility, the test can be performed 
centrally with test kit s provided , or locally using a local kit procured by the site .  If a 
T-spot test is performed for eligibility, the test will be performed locally with test kits 
procured locally.  
9.2.4.4  HIV Antibodies, Hepatitis B, and Hepatitis  C Testing  
Hepatitis B surface anti gen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C 
(HCAb), and HIV antibodies will be assessed at screening.  If the results show a 
negative HBsAg and positive for HBcAb, quantification of hepatitis B virus DNA by PCR 
is necessary.  Similarly, if the results show a positive HCAb, a quantification of hepatitis 
C virus RNA by PCR is necessary.  The above  mentioned PCR test results must be 
negative at screening for the subject to be eligible for this study.  
9.2.5  Pharmacokinetic Assessments  
All subjects ran domized to treatment with AMG 570 will have PK samples assessed.  
Blood samples of approximately 4 mL will be collected for measurement of serum 
concentrations of AMG 570 as specified in the Schedule of Activities ( Table  2-1 and 
Table  2-2).  A maximum of 2 samples may be collected at additional time points during 
the study if warranted and agreed upon between the investigator and the sponsor.  
Instructions for the collection and handling of biological samples will be provided by the 
sponsor.  The actual date and time (24 -hour clock time) of each sampl e will be recorded .  
Drug concentration information that may unblind the study will not be reported to 
investigative study centers or blinded personnel until the study has been unblinded.  
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 76 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
9.2.6  Pharmacodynamic Assessments  
Blood samples for PD assessments will be collected as specified in the Schedule of 
Activities ( Table  2-1 and Table  2-2). 
9.2.6.1  Biomarker Assessment During the Study  
Blood samples will be collected for measurement of  
 
 at time points indicated in the Schedule of Activities 
(Table  2-1 and Table  2-2). 
9.2.7  Pharmacogenetic Assessments  
If the subject consents to the optional pharmacogenetic portion of this study, DNA 
analyses may be performed.  These optional pharmacogenetic analyses focus on 
inherited genetic variation s to evaluate their possible correlation to the disease and/or 
responsiveness to the therapies used in this study.  The goals of the optional studies 
include the use of genetic markers to help in the investigation of inflammatory conditions 
and/or to ident ify subjects who may have positive or negative response to AMG 570.  No 
additional samples are collected for this part of the study.  For subjects who consent to 
this/these analysis/analyses, DNA may be extracted.  
The final disposition of samples will be d escribed in Section  12.6. 

Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 77 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
9.2.9  Biomarker Development  
Biomarkers are objectively measured and evaluated indicators of normal biologic 
processes, pathogenic processes, or pharmacologic responses to a therapeutic 
interventi on. 
The development of biomarkers can be useful to identify disease subtypes, guide 
therapy, and/or predict disease severity.  
Amgen may attempt to develop test(s) designed to identify subjects most likely to 
respond positively or negatively to AMG 570.  
Blood samples are to be collected for biomarker development at the time points 
specified in the Schedule of Activities ( Table  2-1 and Table  2-2). 
9.2.10  Clinical Outcome Assessments:  Patient Re ported Outcomes  
Patient reported outcomes should be completed by the patient  alone before being 
clinically evaluated by the study nurse or physician.  
The assessments will be recorded directly into the electronic tablet which will serve as 
the source documentation and will not be transposed to a CRF.  
9.2.10.1  Medical Outcomes Short Form -36 Questionnaire Version  2 
The SF -36v2 (acute version) Health Survey ( Ware et al, 2000 ) contains 36 items and is 
a revised version of the SF -36 Health Survey.  The SF -36v2 acute  version is a 
patient -reported generic measure of health status.  This survey yields assessments of 
8 domains of health -related quality of life: 1) limitations in physical activities because of 
health problems; 2) limitations in social activities because o f physical or emotional 
problems; 3) limitations in usual role activities because of physical health problems; 
4) bodily pain; 5) general mental health (psychological distress and well -being); 
6) limitations in usual role activities because of emotional pr oblems; 7) vitality (energy 
and fatigue); and 8) general health perceptions.  The scores from the 8 domains will be 
evaluated independently and aggregated into 2 norm -based summary component 
measures of physical and mental health.  The recall period is the  past 7  days.  
This survey takes approximately 10 to 15 minutes to complete.  
9.2.10.2  Patient -Reported Outcome Measurement Information System 
Fatigue Short Form 7a Instrument (PROMIS Fatigue SF 7A)  
The PROMIS Fatigue Short Form 7a is a 7 -item instrument originally c onstructed by the 
PROMIS Fatigue team to represent the range of the fatigue trait (PROMIS  Fatigue 
Scoring Manual).  It assesses the experience of fatigue as well as its impact on physical, 
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 78 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
mental, and social activities.  Both psychometric properties and cl inical input were used 
in the development of the short form from the PROMIS item bank.  Estimates of 
responsiveness and minimally important differences have been reported for the 4 item 
PROMIS Fatigue instrument in SLE patients (Katz et al, 2019).  The PRO MIS Fatigue 
has also been able to differentiate disease activity in other rheumatologic diseases 
(Wohlfahrt et al, 2019).  
The PROMIS Fatigue Short Form 7a takes 1 to 2 minutes to complete.  
9.2.10.3  LupusQoL  
The Lupus Quality of Life questionnaire  (LupusQoL ) is a SL E-specific health -related 
quality of life instrument (Jolly et al, 2010; McElhone et al, 2007).  The LupusQoL 
consists of 8 domains: physical health (8  items), pain (3 items), planning (3 items), 
intimate relationships (2  items), burden to others (3 items) , emotional health (6 items), 
body image (5 items), and fatigue (4 items).  The final instrument has demonstrated 
good internal reliability (Cronbach's 0.88 to 0.95), good test -retest reliability (r 0.72 to 
0.93), good concurrent validity with the comparab le domains of the SF -36 (r 0.71 to 
0.79) and good discriminant validity for different levels of disease activity, measured by 
BILAG index, and damage (Systemic Lupus International Collaborating Clinics/ACR 
damage index) but not for all domains.  The instru ment also has acceptable ceiling 
effects and minimal floor effects.  
Subjects typically complete the LupusQoL in less than 10 minutes.  The scoring and the 
transformation of the scores takes approximately 5 minutes per subject.  
9.2.10.4  Patient Global Assessment  
The patient global assessment (PtGA) of disease activity typically assesses disease 
activity on a 10  cm numerical rating scale  (NRS ; 0 to 10 cm) .  The scale for the 
assessment ranges from “very well” (0) to “very poor” (10) (Furie et al, 2009).  The 
validity of the PtGA in SLE has been established (Khraishi et al, 2014; Liang et al, 1989).  
The PtGA scale has a 7 -day recall.  

Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 79 of 121 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   

Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 80 of 121 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
10. Statistical Considerations  
10.1 Sample Size Determination  
The approximate sample size of 320 subjects is chosen to provide 80% power to detect 
≥ 25% absolute improvement  for at least 1 AMG 570 dose group relative to placebo in 
the primary endpoint of SRI -4 response rate at week 52 at a significance level of 
0.025  (1-sided) using a Bayesian Hierarchical Model, assuming a 40% response rate in 
placebo group.  
Because enrollment can be stopped if early stopping rules for futility are met at an IA, 
the actual sample size could be smaller and cannot be pre -specified.  The approximate 
sample size of 320 ensures if there is no interim signal for early termination based on 
futility of all AMG 570 doses, the trial will have adequate power to achieve the primary 
objective once all subjects have had the opportunity to complete week  52. 
10.2 Analysis Sets, Subgroups, and Covariates  
10.2.1  Analysis Sets  
10.2.1.1  Full Analysis Set  
The Full Analys is Set (FAS) includes all subjects randomized in the study, with treatment 
assignment based on subjects’ randomized treatment assignment.  
10.2.1.2  Safety Analysis Set  
The Safety Analysis Set includes all randomized subjects who received at least 1 dose 
of investig ational product and will be used to perform safety analyses according to the 
actual treatment received.  
10.2.1.3  PK Concentration Analysis Set  
The PK Analysis Concentration Set is defined as the subset of subjects in the Safety 
Analysis Set who had at least 1 evalu able serum concentration (including results below 
the level of detection) of investigational product.  PK concentration data will be analyzed 
according to the actual treatment received.  

Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 81 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
10.2.1.4  PK Parameter Analysis Set  
The PK parameter analysis set is defined as the subset of subjects in the Safety 
Analysis Set who had at least one PK parameter adequately derived.  PK parameter will 
be analyzed according to the actual treatment received.  
10.2.1.5  PD Analysis Set  
The PD analysis set is defined as the subset of subjects in t he Safety Analysis Set who 
had at least one evaluable PD parameter measurement collected.  PD parameter will be 
analyzed according to the actual treatment received.  
10.2.2  Covariates  
The baseline covariates may include but are not limited to:  
 Age, region, race, sex 
 Baseline SLE disease activity  
 Baseline background medications (detectable vs undetectable baseline SLE SOC 
drug levels)  
Other covariates may be evaluated as necessary.  Stratification factors will be  included 
as covariates in the model or be used to examine treatment effect in subgroups.  If 
included as covariates in the model for treatment comparisons, the IRT value will be 
used to be consistent with the randomization scheme.  The impact of the basel ine 
covariates on the treatment effect may be explored and adjusted in the model for the 
primary and secondary endpoints as deemed necessary.  
10.2.3  Subgroups  
In addition to stratification factors, some covariates mentioned above may be used for 
further explo ration in subgroups.  For subgroup analysis, the value collected from 
source -verified eCRF will be used to reflect the true clinical relevance of the covariate.  
10.3 Statistical Analyses  
The statistical analysis plan (SAP) will be developed and finalized be fore any database 
lock.  To preserve study integrity, the primary analysis will be conducted after all 

Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 82 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
subjects have had the opportunity to complete week  52 and the final analysis will be 
conducted and reported following the EOS, as defined in Section  5.3.1 . 
10.3.1  Planned Analyses  
10.3.1.1  Interim Analysis and Early Stopping Guidelines  
Interim analyses will be conducted to allow adaptation of the randomization ratio to the 3 
AMG 570 treatment groups, holding the allocation to placebo constant at 25%, and 
assessing efficacy for early futility or administrative success decisions:  
 The study team, investigators, and subjects will remain blinded to the investigational 
product, changes in randomization alloc ation probabilities, and results of the interim 
analyses.  
 The first IA will be executed after the first enrolled 40 subjects are randomized and 
have had the opportunity to complete the week 24 assessment.  Subsequent IAs are 
scheduled after every additiona l 32 subjects are randomized and have had the 
opportunity to complete the week 24 assessment until full enrollment.  The last IA will 
occur when all 320 subjects are randomized and have had the opportunity to 
complete the week 24 assessment.  This IA will be referred to as the ‘all -subjects -
week -24’ IA.  
 Efficacy analyses will be performed at IAs to assess the likelihood of AMG  570 being 
superior to placebo by a clinically meaningful difference.  
 If this likelihood is unacceptably low for all dose levels, the  trial is recommended 
to stop for futility.  
 Additionally, at the ‘all -subjects -week -24 IA’, if this likelihood is sufficiently high at, at 
least 1 dose level, IA triggers an administrative success signal.  This would not alter 
ongoing or planned activities  of this phase  2b study, but downstream activities may 
be planned/initiated (eg, a phase  3 study).  Analysis planned at each IA are listed in  
Table  1-1. 
At IAs,  
 Beginning with the second IA and before the last IA, enrollment to the study may be 
stopped for futility if the posterior probabi lity of achieving a clinically meaningful 
difference in SRI -4 response rates of at least 15% between each active treatment 
group and placebo is below 2.5%.  
 Once all subjects have had the opportunity to complete the week 24 visit, the primary 
efficacy analy sis model, a Bayesian Hierarchical Model will be fitted to the week 52 
SRI-4 response data with longitudinal modeling of earlier visits week 16, 20, and 24 
to compute the predictive probability of success in a hypothetical, future phase  3 
study If the pred ictive probability of success in this hypothetical future phase  3 study 
is larger than 80% for any of the AMG 570 dose groups, downstream activities may 
be planned/initiated.  Regardless of the result of this IA, the conduct of the current 
study will not b e impacted; the current study will continue until all subjects have had 
the opportunity to complete the week 52 visit and safety follow -up. 
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 83 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
10.3.1.2  Primary Analysis  
The primary analysis will take place when all subjects have had the opportunity to 
complete week 52 . 
At primary analysis:  
 The efficacy goal of the study is to demonstrate the superiority of AMG 570 relative 
to placebo.  
 The primary analysis of the primary endpoint SRI -4 at week 52 is a Bayesian 
Hierarchical Model which borrows information dynamically acr oss the 3 active 
AMG  570 treatment groups while controlling the overall type I error at the 1 -sided 
2.5% level.  
 The null hypothesis will be rejected (ie, study will be claimed successful) if the 
posterior probability of superiority of any active AMG 570 tr eatment group is above 
0.981.  This threshold was chosen to preserve a simulated overall 1 -sided type I 
error rate to be less than 2.5%.  
10.3.1.3  Final Analysis  
The final analysis will be completed after study completion is reached, after the last 
subject reaches t he last visit during the safety follow -up period, and all data are collected 
for the study.  
10.3.2  Methods of Analyses  
10.3.2.1  General Considerations  
All categorical variables will be summarized using the number and percent of subjects 
falling into each category and all continuous variable will be summarized using mean, 
standard error or standard deviation, median, Q1, Q3, minimum, maximum, and number 
of subjects with observations.  Subgroup analyses (by certain demographic variables 
and stratification factors as appropriate) will be presented if deemed necessary.  Safety 
endpoints will be summarized descriptively.  
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 84 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
10.3.2.2  Efficacy Analyses  
Endpoint  Statistical Analysis Methods to Support Estimands  
Primary  Bayesian Hierarchical Model  will be used to evaluate primary efficacy 
estimand.  
Secondary  Bayesian Hierarchical Model/Generalized linear model will be used to 
evaluate secondary efficacy endpoints .  Details will be described in the 
SAP.  
Exploratory  Details of the analysis of exploratory endpoints will be specified  in the 
SAP.  
10.3.2.3  Safety Analyses  
10.3.2.3.1  Analyses of Primary Safety Endpoint(s)  
 
Endpoint  Statistical Analysis Methods  
Primary*  All safety analyses will be performed using the Safety Analysis Set 
based on subject’s actual treatment received.  Safety analysis will 
include analyses of AEs, clinical laboratory tests, vital signs, and 
 
*Safety endpoints are not primary endpoints for this study  
10.3.2.3.2  Adverse Events  
Subject incidence of all treatment -emergent adverse events will be tabulated by system 
organ class and preferred term.  Tables of fatal adverse events, serious adverse events, 
and adverse events leading to withdrawal from investigational product or other 
protocol -required therapies will also be provided.  
10.3.2.3.3  Laboratory Test Results  
Clinical la boratory test results and change from baseline will be summarized over time 
by each treatment group.  In addition, shift tables, from baseline to the worst on -study 
laboratory toxicity based on the latest version of CTCAE grading, will be presented.  
10.3.2.3.4  Vital Signs  
Vital sign data (observed and change from baseline) will be summarized using 
descriptive statistics by each treatment group.  
10.3.2.3.5  Physical Measurements  
Clinically significant findings from physical examinations will be listed by subject and 
assessed f or clinical significance  which will be included in the adverse event listings and 
summaries.  

Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 85 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
10.3.2.3.7  Exposure to Investigational Product  
Summary statistics will be provided for the total number of doses administered, total 
dose received, and total duration of investigational product exposure by treatment.  
10.3.2.3.8  Exposure to Other P rotocol -required Therapy  
Descriptive statistics of total dose (mg), dosage categories, duration of usage, number 
and percentage of subjects with dose modifications, and reasons for modification will be 
produced to describe the exposure by treatment group f rom baseline to end of study.  
10.3.2.3.9  Exposure to Concomitant Medication  
Number and proportion of subjects receiving therapies of interest will be summarized by 
preferred term or category for each treatment group as coded by latest version of the 
World Health Or ganization Drug dictionary.  
10.3.2.4  Other Analyses  
Serum concentrations will be summarized descriptively by treatment for each PK 
sampling time point using PK Concentration Analysis Set.  PK parameter (if deemed 
necessary) will be summarized with PK parameter an alysis set.  PD parameter (if 
deemed necessary) will be summarized with PD analysis set.  Medical history will be 
summarized by SOC and PT and tabulated by treatment group and total using the 
Safety Analysis Set according to the actual treatment received.  

Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 86 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
11. References  
AMG 570 Investigator’s Brochure.  Thousand Oaks, CA.  Amgen Inc.  
Adams A, MacDermott EJ, Lehman TJ. Pharmacotherapy of lupus nephritis in children: 
a recommended treatment approach. Drugs. 2006;66:1191 -1207.  
Aringer M, Costenbader K, Daikh D, et al.  2019 European League Against 
Rheumatism/American College of Rheumatology Classification Criteria for Systemic 
Lupus Erythematosus.  Arthritis & Rheum 2019 ; 71(9):1400 -1412  
Arthritis & Rheumatism (Arthritis Care & Research), Vol. 61, No. 9, Septe mber 15, 2009, 
pp 1168 -1178.  
Buyon JP, Petri MA, Kim MY, et. al. The effect of combined estrogen and progesterone 
hormone replacement therapy on disease activity in systemic lupus erythematosus: A 
randomized trial.  Ann Intern Med . 2005;142:953.  
Chandran V , Bhella S, Schentag C, Gladman DD. Functional assessment of chronic 
illness therapy -fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis . 
2007;66: 936 -939. 
Cheng LE, Amoura Z,Cheah B, et al. Brief Report: A Randomized, Double -Blind, 
Parallel -Group, Placebo -Controlled, Multiple -Dose Study to Evaluate AMG 557 in 
Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis. Arthritis 
Rheumatol. 2018 Jul;70(7):1071 -1076.  
Doria A, Stohl W, Schwarting A, et al. Efficacy and Safety of Subcutaneous Belimumab 
in Anti -Double -Stranded DNA -Positive, Hypocomplementemic Patients With Systemic 
Lupus Erythematosus. Arthritis Rheumatol. 2018 Aug;70(8):1256 -1264.  
Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a Lupu s Low 
Disease Activity State (LLDAS). Ann Rheum Dis. 2016 Sep;75(9):1615 -1621.  
Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo -controlled study of 
belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with 
systemic lupus erythematosus. Arthritis Rheum. 2011 Dec;63(12):3918 -30. 
Furie RA, Petri MA, Wallace DJ, et al. Novel evidence -based systemic lupus 
erythematosus responder index. Arthritis & Rheum. 2009;61(9):1143 -1151.  
Gladman D, Ginzler E, Goldsmith C, et al.   The development and initial validation of the 
systemic lupus international collaborating clinics/American College of Rheumatology 
Damage Index for Systemic Lupus Erythematosus. Arthritis Rheum.   
1996;39(3):363 -369. 
Gordon C,  Sutcliffe N, Skan J, et al. Definition and treatment of lupus flares measured by 
the BILAG index. Rheumatology. 2003;42(11):1372 -1379.  
Jolly M, Pickard AS, Wilke C et al. Lupus -specific health outcome measure for US 
patients: the LupusQoL -US version. Ann Rheum Dis. 2010;69:29 -33. 
Katz P, Pedro S, Alemao E, et al.  Estimates of responsiveness, minimally import 
differences and patient acceptable symptom state in five patient -reported outcomes 
measurement information system short forms in systemic lupus eryth ematosus.  ACR 
Open. 2019: 1 -8.  Doi 10.1002/acr2.11100.  
Khraishi M, Aslanov R, Dixit S, et al 2014. The validity of patient and physician global 
disease activity assessments of systemic lupus erythematosus: results from the lupus 
activity coring tool (LAS T) as compared to the Selena Sledai (SS) modification 
multicentre study. ACR 2014.  
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 87 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Kotzin BL. Systemic lupus erythematosus. Cell. 1996;85:303 -306. 
Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for 
the clinical assessment  of disease activity in systemic lupus erythematosus. Arthritis 
Rheum. 1989;32(9):1107 -18. 
Luijten KMAC, Tekstra J, Bijlsma JWJ, Bijl M.  The Systemic Lupus Erythematosus 
Responder Index (SRI):  A new SLE disease activity assessment.  Autoimmun Rev.  
2012; 11(5):326 -329. 
McElhone K, Abbott J, Shelmerdine J et al. Development and validation of a 
disease -specific health -related quality of life measure, the LupusQol, for adults with 
systemic lupus erythematosus. Arthritis Rheum. 2007;57:972 -979. 
Miyakis S, et a l. International consensus statement on an update of the classification 
criteria for definite antiphospholipid syndrome (APS). Journal of Thrombosis and 
Haemostasis, 2006; 4: 295 –306. 
Navarra SV, Guzmán RM, Gallacher AE, et al.  Efficacy and safety of beli mumab in 
patients with active systemic lupus erythematosus: a randomised, placebo -controlled, 
phase 3 trial. Lancet. 2011 Feb 26;377(9767):721 -731. 
Pisetsky DS, Clowse MEB, Criscione -Schreiber LG, et al.  A Novel System to Categorize 
the Symptoms of System ic Lupus Erythematosus. Arth Care Res. 2019; 71 (6): 735 -741. 
PROMIS Fatigue Scoring Manual. Accessed at 
http://www.healthmeasures.net/images/PROMIS/manuals/PROMIS_Fatigue_Scoring_M
anual.pdf on 29 Jan 2020  
Rhaman A and Isenberg DA. Systemic lupus erythemat osus. N Engl J Med. 2008;358: 
929-939. 
Sullivan BA, Tsuji W, Kivitz A, et al. Inducible T -cell co -stimulator ligand (ICOSL) 
blockade leads to selective inhibition of anti -KLH IgG responses in subjects with 
systemic lupus erythematosus. Lupus Science & Medi cine 2016;3: e000146.  
Wallace, D, Kalunian K, Petri, M, et al.  Efficacy and safety of epratuzumab in patients 
with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a 
phase IIb, randomised, double -blind, placebo -controlled, multice ntre study.  Ann Rheum 
Dis.  2014;73:183 -190. 
Wallace D, Strand V, Furie R, et al.  Evaluation of Treatment Success in Systemic Lupus 
Erythematosus Clinical Trials; Development of the British Isles Lupus Assessment 
Group -Based Composite Lupus Assessment En dpoint.  Arth Rheum.  2011;63 -s894 
ACR.  
Ware JE. SF -36 Health Survey Update. SPINE. 2000; 25:3130 -3139.  
Wohlfahrt A, Bingham CO, Marder W, et al. Responsiveness of patient -reported 
outcomes measurement information system measures in rheumatoid arthritis pa tients 
starting or switching a disease -modifying antirheumatic drug. Arth Car Res 2019: (4): 
521-529. 
Zhang F, Bae SC, Bass D, et al. A pivotal phase III, randomised, placebo -controlled 
study of belimumab in patients with systemic lupus erythematosus locat ed in China, 
Japan and South Korea. Ann Rheum Dis. 2018 Mar;77(3):355 -363. 
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 88 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
12. Appendices  
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 89 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
12.1 Appendix 1.  List of Abbreviations and Definitions of Terms  
 
Abbreviation or Term  Definition/Explanation  
ACR  American College of Rheumatology  
ALP alkaline phosphatase  
ALT alanine aminotransferase  
ANC  absolute neutrophil count  
AST aspartate aminotransferase  
AUC  area under the concentration -time curve  
BAFF  B cell activating factor  
BICLA  BILAG based Combined Lupus Assessment  
BILAG  British Isles Lupus Assessment Group  
CFR Code of Federal Regulations  
CLASI  Cutaneous Lupus Erythematosus Area and Severity Index  
Clinical hSLEDAI  hybrid  SLEDAI assessment score without the inclusion of points 
attributable to any laboratory  parameter,  including  urine and 
immunologic parameters .   
Cmax maximum observed concentration  
CNS  central nervous system  
CPK creatine phosphokinase  
CS corticosteroids  
CTCAE  common terminology criteria for adverse events  
DILI drug -induced liver injury  
DMC  data monitoring committee  
eCRF  electronic case report form  
EDC  electronic data capture  
End of Study for 
individual Subject  defined as the last day  that protocol -specified procedures are 
conducted for an individual subject  
End of Study (end of 
trial) defined as the date when the last subject is assessed or receives an 
intervention for evaluation in the study (ie, last subject last visit), 
following any additional parts in the study (eg,  safety follow  up), as 
applicable  
EOS  end of study  
Exposure -response 
analysis  mechanism -based modeling & simulation and statistical analyses 
based on individual pharmacokinetic [PK] exposure (eg, population 
pharmacokinetic modeling) and response, which may include 
biomarkers, pharmacodynamic (PD) effects, efficacy and safety 
endpoints.  
FAS Full Analysis Set  
FIH first in human  
FSH follicle stimulating hormone  
GCP  Good Clinical Practice  
GLP Good Laboratory Practices  
HBcAb  hepatitis B core antibody  
HCP  health care provider  
HBsAg  hepatitis B surface antigen  

Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 90 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Abbreviation or Term  Definition/Explanation  
HepCAb  hepatitis C antibody  
HIV Human Immunodeficiency Virus  
HRT hormonal replacement therapy  
hSLEDAI  Hybrid Systemic Lupus Erythematosus Disease Activity Index  
IA interim analysis  
IB Investigator’s Brochure  
IBG Independent Biostatistics Group  
ICF informed consent form  
ICH International Council for Harmonisation  
ICOS  inducible co -stimulator  
ICOSL  inducible co -stimulator ligand  
IEC Independent Ethics Committee  
Ig Immunoglobulin   
IL-2 Interleukin 2  
IM intramuscular  
INR international normalized ratio  
IPIM Investigational Product Instruction Manual  
IRB Institutional Review Boards  
IRT interactive response technology  
IV intravenous  
JAK janus kinase  
KLH Keyhole limpet hemocyanin  
LDH lactate dehydrogenase  
LLDAS  Lupus Low Disease Activity State  
LupusQoL  Lupus Quality of Life questionnaire  
MCTD  mixed connective tissue disease  
MDRD  Modification of Diet in Renal Disease  
NOAEL  
NSAID  no-observed -adverse -effect -level 
Non-steroidal Anti -inflammatory Drugs  
OCS  oral corticosteroids  
PCR  polymerase chain reaction  
PD pharmacodynamic  
PtGA  Patient Global Assessment  
PGA  Physician Global Assessment  
PI Principal Investigator  
PK pharmacokinetic  
PPD purified protein derivative  
PROMIS  Patient -Reported Outcome Measurement Information System  
PT preferred term  
Q2W  every 2  weeks  
Q4W  every 4  weeks  

Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 91 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Abbreviation or Term  Definition/Explanation  
QW once -weekly  
RA rheumatoid arthritis  
RAR  Response Adaptive Randomization  
RBC  red blood cell  
RO receptor occupancy  
ROW  rest of the world  
SAP Statistical Analysis Plan  
SC subcutaneous  
SDI Systemic Lupus International Collaborating Clinic / American College 
of Rheumatology Damage Index  
SF-36v2  Medical Outcomes Short Form 36 version 2 questionnaire  
SLE systemic lupus erythematosus  
SLEDAI -2K Systemic Lupus Erythematosus Disease Activity Index 2000  
SLICC  Systemic Lupus International Collaborating Clinics  
SOA  schedule of assessments  
SOC  standard of care  
Source Data  information from an original record or certified copy of the original 
record containing patient information for use in clinical research.   The 
information may include, but is not limited to, clinical findings, 
observations, or other activities in a clinical trial necessary for the 
reconstruction and evaluation of the trial.  Source data are contained  
in source documents (original records or certified copies).  (ICH 
Guideline [E6]).  Examples of source data include Subject 
identification, Randomization identification, and Stratification Value.  
SRI Systemic Lupus Erythematosus Responder Index  
study day 1  defined as the first day that protocol -specified investigational product 
is administered to the subject  
TBL total bilirubin  
ULN upper limit of normal  
VAS visual analogue scale  
 
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 92 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
12.2 Appendix 2.  Clinical Laboratory Tests  
Additional tests may be performed at any time during the study as determined necessary 
by the  investigator or required by local regulations.
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022   Page 93 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Table 12-1.  Analyte Listinga 
Central Laboratory: Chemistry  Central Laboratory: 
Coagulation  Central Laboratory: 
Urinalysis  Central Laboratory: 
Hematology  Central Laboratory:  
Other Labs  
Sodium  
Potassium  
Chloride  
Bicarbonate  
Total protein  
Albumin  
Calcium  
Adjusted calcium  
Magnesium  
Phosphorus  
Glucose  
BUN or Urea  
Creatinine  
Uric acid  
Total bilirubin  
Direct bilirubin  
ALP 
LDH 
AST (SGOT)  
ALT (SGPT)  
Creatinine clearance by MDRD  
GGT  
C-reactive protein  
Total Cholesterol  
HDL 
LDL 
Triglycerides  
Creatinine Phosphokinase  PT/INR 
aPTT  
Fibrinogenb 
D-dimerb Protein/creatinine ratio  
Specific gravity  
pH 
Blood  
Protein  
Glucose  
Bilirubin  
WBC  
RBC  
Epithelial cells  
Bacteria  
Casts  
Crystals  Central Laboratory : 
RBC  
Nucleated RBC  
Hemoglobin  
Hematocrit  
MCV  
MCH  
MCHC  
RDW  
Reticulocytes  
Platelets  
WBC  
Differential  
 Bands/stabs  
 Eosinophils  
 Basophils  
 Lymphocytes  
 Monocytes  
 Total neutrophils  
 Segmented neutrophils  
Local Laboratory : 
Erythrocyte sedimentation 
rate 
 Central Laboratory : 
Hep B surface antigen  
Hep B core antibody  
Hep B virus DNAc 
Hep C antibody  
Hep C virus RNAd 
Antinuclear antibody  
HIV antibody  
Serum pregnancy test  
QuantiFERON-TBf 
Local Laboratory : 
Urine Pregnancy  
T-spotf 
FSHg 
Coombs testh 
 
Footnotes defined on next page  

Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022   Page 94 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
ALP  alkaline phosphatase; ALT  alanine aminotransferase; aPTT  activated partial thromboplastin time; 
AST  aspartate aminotransferase; BUN   blood urea nitrogen; FSH  follicle  stimulating hormone; GGT  gamma glutamyl transpeptidase; HDL  high density 
lipoprotein; Hep  hepatitis; HIV   Human Immunodeficiency Virus;  INR  international normalized ratio; LDH  lactate dehydrogenase; 
LDL  low density liprop rotein; MCH  mean corpuscular hemoglobin; MCHC  mean corpuscular hemoglobin concentration; MCV  mean corpuscular volume; 
MDRD   Modification of Diet in Renal Disease; PD   pharmacodynamic; PK   pharmacokinetic; PT   prothrombin time; PTT  partial thromboplastin time; RBC   red 
blood cell count; RDW  Red cell distribution width; SGOT  serum glutamic -oxaloacetic transaminase; SGPT  serum glutamic -pyruvic transaminase; WBC   white 
blood cell count  
After baseline, PK/PD parameters that coul d unblind the study will not be reported to investigative sites or other blinded personnel until the study has been unblinded . 
a. Approval for applicable local lab testing may be granted by sponsor as needed in the event that central lab testing is unavai lable.   
b In case of drug -induced liver injury (DILI) events.   
c In case of Hep B surface antigen negative and Hep B core antibody positive.  
d In case of Hep C antibody positive.  
e Lupus reflex will be done if aPTT is prolonged.  
f For tuberculosis testing at  screening, QuantiFERON-TB OR T -spot test OR purified protein derivative  (PPD) test can be used.   QuantiFERON-TB can also be 
done locally.  
g In case the investigator needs to confirm postmenopausal status (and patient is not taking hormone replacement therapy). 
h For suspicion of hemolytic anemia (per the investigator’s judgment).  
 

Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 95 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
12.3 Appendix 3.  Study Governance Considerations  
Independent Data Monitoring  Committee  
An Independent Biostatistics Group (IBG) will perform the interim analysis and provide 
the interim report to an independent unblinded Data Monit oring Committee (DMC).  The 
DMC will review all available safety and efficacy  data periodically (Table 1-1).  The IBG 
and DMC will have access to subjects’ individual treatment assignments.  To minimize 
the potential introduction of bias to the conduct of the study, members of the DMC and  
Data Monitoring Group will not have any direct contact with study site personnel or 
subjects.  The DMC will communicate major safety concerns and recommendations 
regarding study modification or termination based on the safety and efficacy  parameters 
to Am gen in accordance with the DMC charter.  
Records of all meetings will be maintained by the DMC for the duration of the study.  
Records of all meetings will be transferred and stored in the trial master folder (TMF) at 
the conclusion of the study.  Further d etails are provided in the DMC charter.  
Regulatory and Ethical Considerations  
This study will be conducted in accordance with the protocol and with:  
 Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences International Ethical Guidelines  
 Applicable International Council  for Harmonisation (ICH) Good Clinical Practice 
(GCP) Guidelines  
 Applicable ICH laws and regulations  
The protocol, protocol ame ndments, informed consent form, IB, and other relevant 
documents (eg, subject recruitment advertisements) must be submitted to an  
Institutional Review Board (IRB)/Independent Ethics Committee (IEC) by the investigator  
and reviewed and approved by the IRB/I EC.  A copy of the written approval of the 
protocol and informed consent form must be received by Amgen before recruitment of 
subjects into the study and shipment of Amgen investigational product.  
Amgen may amend the protocol at any time.  The investigator  must submit and, where 
necessary, obtain approval from the IRB/IEC for all subsequent protocol amendments 
and changes to the informed consent document.  The investigator must send a copy of 
the approval letter from the IRB/IEC and amended protocol Investi gator’s Signature 
page to Amgen prior to implementation of the protocol amendment at their site.  
The investigator will be responsible for the following:  
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 96 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
 Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in ac cordance with the requirements, policies, and procedures 
established by the IRB/IEC  
 Obtaining annual IRB/IEC approval/renewal throughout the duration of the study.  
Copies of the investigator’s reports and the IRB/IEC continuance of approval 
must be sent t o Amgen  
 Notifying the IRB/IEC] of serious adverse events occurring at the site, deviations 
from the protocol or other adverse event reports received from Amgen, in 
accordance with local procedures  
 Overall conduct of the study at the site and adherence to r equirements of Title  21 
of the U.S. Code of Federal Regulations (CFR), ICH guidelines, the IRB/IEC, and 
all other applicable local regulations  
Recruitment Procedures  
Site staff will identify potential subjects from their existing patient population or may seek 
referral patients through existing professional networks or other community sources such 
as patient advocacy groups.   All patient facing materials must be reviewed/approved by 
the sponsor (Amgen Inc.) and the local IRB/IEC.  
Informed Consent Process  
An initial sample informed consent form is provided for the investigator to prepare the 
informed consent document to be used at his or her site.  Updates to the sample 
informed consent form are to be communicated formally in writing from the Amgen Trial 
Mana ger to the investigator.  The written informed consent form is to be prepared in the 
language(s) of the potential patient population.  
The investigator or his/her delegated representative will explain to the subject or his/her 
legally authorized representative the aims, methods, anticipated benefits, and potential 
hazards of the study before any protocol -specific screening procedures or any 
investigational product(s) is/are administered and answer all questions regarding the 
study.   
Subjects must  be informed that their participation is voluntary.  Subjects or his/her legally 
authorized representative will then be required to sign a statement of informed consent 
that meets the requirements of 21 CFR 50, local regulations, ICH guidelines, Health 
Insurance Portability and Accountability Act requirements, where applicable, and the 
IRB/IEC or study site.  
The medical record must include a statement that written informed consent was obtained 
before the subject was enrolled in the study and the date the w ritten consent was 
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 97 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
obtained.  The authorized person obtaining the informed consent must also sign the 
informed consent form.  
The investigator is also responsible for asking the subject if the subject has a primary 
care physician and if the subject agrees t o have his/her primary care physician informed 
of the subject’s participation in the clinical study unless it is a local requirement.  The 
investigator shall then inform the primary care physician.  If the subject agrees to such 
notification, the investiga tor is to inform the subject’s primary care physician of the 
subject’s participation in the clinical study.  If the subject does not have a primary care 
physician and the investigator will be acting in that capacity, the investigator is to 
document such in  the subject’s medical record.  
The acquisition of informed consent and the subject’s agreement or refusal of his/her 
notification of the primary care physician is to be documented in the subject’s medical 
records, and the informed consent form is to be sig ned and personally dated by the 
subject or his/her legally authorized representative and by the person who conducted the 
informed consent discussion.  Subject withdrawal of consent or discontinuation from 
investigational product and/or procedures must also  be documented in the subject’s 
medical records; refer to Section  8. 
Subjects must be re -consented to the most current version of the informed consent 
form(s) during their participation in the study.  
The original signed informed consent form is to be retained in accordance with 
institutional pol icy, and a copy of the informed consent form(s) must be provided to the 
subject or the subject’s legally authorized representative.  
A subject who is rescreened is not required to sign another informed consent form if the 
rescreening occurs within 33  days from the previous informed consent form signature 
date.  
The informed consent form (ICF) will contain a separate section that addresses the use 
of remaining mandatory samples for optional future research.  The investigator or 
authorized designee will explai n to each subject the objectives of the future research.  
Subjects will be told that they are free to refuse to participate and may withdraw their 
specimens at any time and for any reason during the storage period.  A separate 
signature will be required to  document a subject’s agreement to allow any remaining 
specimens to be used for future research.  Subjects who decline to participate will not 
provide this separate signature.  
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 98 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Data Protection/Subject Confidentiality  
The investigator must ensure that the subject’s confidentiality is maintained for 
documents submitted to Amgen.  
Subject will be assigned a unique identifier by the sponsor.  Any subject records or 
datasets that are transferred to the sponsor will contain the identifier only; subject names 
or any information which would make the subject identifiable will not be transferred.  
On the case report form ( CRF) demographics page, in addition to the unique subject 
identification number, include the age at time of enrollment.  
For serious adverse events r eported to Amgen, subjects are to be identified by their 
unique subject identification number, initials (for faxed reports, in accordance with local 
laws and regulations), and age (in accordance with local laws and regulations).  
Documents that are not subm itted to Amgen (eg, signed informed consent forms) are to 
be kept in confidence by the investigator, except as described below.  
In compliance with governmental regulations/ICH GCP Guidelines, it is required that the 
investigator and institution permit auth orized representatives of the company, of the 
regulatory agency(s), and the IRB/IEC direct access to review the subject’s original 
medical records for verification of study -related procedures and data.  Direct access 
includes examining, analyzing, verifyin g, and reproducing any records and reports that 
are important to the evaluation of the study.   
The investigator is obligated to inform and obtain the consent of the subject to permit 
such individuals to have access to his/her study -related records, includ ing personal 
information.  
Publication Policy  
To coordinate dissemination of data from this study, Amgen may facilitate the formation 
of a publication committee consisting of several investigators and appropriate Amgen 
staff, the governance and responsibili ties of which are set forth in a Publication Charter.  
The committee is expected to solicit input and assistance from other investigators and to 
collaborate with authors and Amgen staff, as appropriate, as defined in the Publication 
Charter.  Membership on  the committee (both for investigators and Amgen staff) does 
not guarantee authorship.  The criteria described below are to be met for every 
publication.  
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 99 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Authorship of any publications resulting from this study will be determined on the basis 
of the Unifor m Requirement for Manuscripts Submitted to Biomedical Journals 
International Committee of Medical Journal Editors Recommendations for the Conduct of 
Reporting, Editing, and Publications of Scholarly Work in Medical Journals, which states:  
Authorship credi t is to be based on:  (1) substantial contributions to conception and 
design, acquisition of data, or analysis and interpretation of data; (2) drafting the article 
or revising it critically for important intellectual content; (3) final approval of the vers ion to 
be published; and (4) agreement to be accountable for all aspects of the work in 
ensuring that questions related to the accuracy or integrity of any part of the work are 
appropriately investigated and resolved.  Authors need to meet conditions 1, 2,  3, and 4.  
When a large, multi -center group has conducted the work, the group is to identify the 
individuals who accept direct responsibility for the manuscript.  These individuals must 
fully meet the criteria for authorship defined above. Acquisition of f unding, collection of 
data, or general supervision of the research group, alone, does not justify authorship.  All 
persons designated as authors must qualify for authorship, and all those who qualify are 
to be listed.   Each author must have participated s ufficiently in the work to take public 
responsibility for appropriate portions of the content. All publications (eg, manuscripts, 
abstracts, oral/slide presentations, book chapters) based on this study must be 
submitted to Amgen for review.  The Clinical T rial Agreement among the institution, 
investigator, and Amgen will detail the procedures for, and timing of, Amgen’s review of 
publications.  
Investigator Signatory Obligations  
Each clinical study report is to be signed by the investigator or, in the case o f 
multi -center studies, the coordinating investigator.  
The coordinating investigator, identified by Amgen, will be any or all of the following:  
 A recognized expert in the therapeutic area  
 An Investigator who provided significant contributions to either the  design or 
interpretation of the study  
 An Investigator contributing a high number of eligible subjects  
Data Quality Assurance  
All subject data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically (eg, laboratory data, centrally or 
adjudicated data).  The investigator is responsible for verifying that data  entries are 
accurate and correct by physically or electronically signing the CRF.  
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 100 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.  
The investigator must permit study -related monitoring , audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.   
The sponsor or designee is responsible for the data management of this study including 
quality checking of the data.  
Clinical monitors will p erform ongoing source data verification to confirm that data 
entered into the CRF by authorized site personnel are accurate, complete, and verifiable  
from source documents; that the safety and rights of subjects are being protected; and 
that the study is b eing conducted in accordance with the currently approved protocol and 
any other study agreements, ICH GCP, and all applicable regulatory requirements per 
the sponsor’s monitoring plan.  
The investigator agrees to cooperate with the clinical monitor to ensu re that any 
problems detected in the course of these monitoring visits, including delays in 
completing CRFs, are resolved.  
The Amgen representative(s) and regulatory authority inspectors are responsible for 
contacting and visiting the investigator for the purpose of inspecting the facilities and, 
upon request, inspecting the various records of the clinical study (eg, CRFs and other 
pertinent data) provided that subject confidentiality is respected.  
In accordance with ICH GCP and the sponsor’s audit plans, t his study may be selected 
for audit by representatives from Amgen’s Global Research and Development 
Compliance and Audit function (or designees).  Inspection of site facilities (eg, 
pharmacy, protocol -required therapy storage areas, laboratories) and revie w of 
study -related records will occur to evaluate the study conduct and compliance with the 
protocol, ICH GCP, and applicable regulatory requirements.  
Retention of study documents will be governed by the Clinical Trial Agreement.  
All written information an d other material to be used by subjects and investigative staff 
must use vocabulary and language that are clearly understood.  
Source Documents  
The investigator is to maintain a list of appropriately qualified persons to whom he/she 
has delegated study duti es.  All persons authorized to make entries and/or corrections 
on CRFs will be included on the Amgen Delegation of Authority Form.  
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 101 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Source documents provide evidence for the existence of the subject and substantiate 
the integrity of the data collected.  Sou rce documents are filed at the investigator’s site.  
Source documents are original documents, data, and records from which the subject’s 
CRF data are obtained.  These include but are not limited to hospital records, clinical 
and office charts, laboratory an d pharmacy records, diaries, microfiches, radiographs, 
and correspondence.  Source documents may also include data captured in the 
Interactive Response Technology (IRT) system (if used, such as subject ID and 
randomization number) and CRF entries if the CR F is the site of the original recording  
(ie, there is no other written or electronic record of data, such as paper questionnaires 
for a clinical outcome assessment).  
Data reported on the CRF or entered in the electronic CRF that are transcribed from 
source  documents must be consistent with the source documents or the discrepancies 
must be explained.  The investigator may need to request previous medical records or 
transfer records, depending on the study.  Also, current medical records must be 
available.  
The Investigator and study staff are responsible for maintaining a comprehensive and 
centralized filing system of all study -related (essential) documentation, suitable for 
inspection at any time by representatives from Amgen and/or applicable regulatory 
authorities.  
To include the following:  
 Subject files containing completed CRFs, informed consent forms, and subject 
identification list  
 Study files containing the protocol with all amendments, IB, copies of prestudy 
documentation, and all correspondence to and  from the IRB/IEC and Amgen  
 Investigational product -related correspondence including Proof of Receipts, 
Investigational Product Accountability Record(s), Return of Investigational 
Product for Destruction Form(s), Final Investigational Product Reconciliatio n 
Statement, as applicable  
Retention of study documents will be governed by the Clinical Trial Agreement.  
Study and Site Closure  
Amgen or its designee may stop the study or study site participation in the study for 
medical, safety, regulatory, administrati ve, or other reasons consistent with applicable 
laws, regulations, and GCP.  
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 102 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Both Amgen and the Investigator reserve the right to terminate the Investigator’s 
participation in the study according to the Clinical Trial Agreement.  The investigator is to 
notify the IRB/IEC in writing of the study’s completion or early termination and send a 
copy of the notification to Amgen.  
Subjects may be eligible for continued treatment with Amgen investigational product(s) 
by an extension protocol or as provided for by th e local country’s regulatory mechanism.  
However, Amgen reserves the unilateral right, at its sole discretion, to determine 
whether to supply Amgen investigational product(s) and by what mechanism, after 
termination of the study and before the product(s) i s/are available commercially.  
Compensation  
Any arrangements for compensation to subjects for injury or illness that arises in the 
study are described in the Compensation for Injury section of the Informed Consent that 
is available as a separate document.  
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 103 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
12.4 Appendix 4.  Safety Events:  Definitions and Procedures for 
Recording, Evaluating, Follow -up and Reporting  
Definition of Adverse Event  
Adverse Event Definition  
 An adverse event is any untoward medical occurrence in a clinical study subject 
irrespective of a causal relationship with the investigational product.   
 Note: An adverse event can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease (new or 
exacerbated) temporally associated with the use  of a treatment, combination 
product, medical device or procedure.  
 Note:  Treatment -emergent adverse events will be defined in the SAP.  
 
Events Meeting the Adverse Event Definition  
 Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) 
or other safety assessments (eg, electrocardiogram, radiological scans, vital signs 
measurements), including those that worsen from baseline, that are considered 
clinically significant in the medical and scientific judgment of the investigator  
(ie, not related to progression of underlying disease).  
 Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition.  
 New conditions detected or diagnosed after investigational  product administration 
even though it may have been present before the start of the study.  
 Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
 Signs, symptoms, or the clinical sequelae of a suspected overdose of either 
investigational product or a concomitant medication.  Overdose per se will not be 
reported as an adverse event/serious adverse event unless it is an intentional 
overdose taken with possible suicidal/self -harming intent.  Such overdoses are to 
be reported r egardless of sequelae.  
 “Lack of efficacy” or “failure of expected pharmacological action” per se will not be 
reported as an adverse event or serious adverse event.  Such instances will be 
captured in the efficacy assessments.  However, the signs, symptoms,  and/or 
clinical sequelae resulting from lack of efficacy will be reported as adverse event 
or serious adverse event if they fulfill the definition of an adverse event or serious 
adverse event.   
 
Events NOT Meeting the Adverse Event Definition  
 Medical or  surgical procedure (eg, endoscopy, appendectomy):  the condition that 
leads to the procedure is the adverse event.  
 Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).  
 Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) 
present or detected at the start of the study that do not worsen.  
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 104 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Definition of Serious Adverse Event  
A Serious Adverse Event is defined as any untoward medical occurrence 
that, meets at least 1 of the following serious criteria:  
Results in death (fatal)  
Immediately life -threatening  
The term “life -threatening” in the definition of “serious” refers to an event in which 
the subject was at risk of death at the time of the event.  It does not refer to an 
event, which hypothetically might have caused death, if it were more severe.  
Requires in -patient hospitalization or prolongation of existing 
hospitalization  
In general, hospitalization signifies that the subject has been detained (usually 
involving at least an overnight stay) at the hospital or emergency ward for 
observation and/or treatment that would not have been appropriate in the 
physician’s office or outpatient setting.  Complications that occur during 
hospitalization are an adverse event.  If a c omplication prolongs hospitalization or 
fulfills any other serious criteria, the event is serious.  When in doubt as to 
whether “hospitalization” occurred or was necessary, the adverse event is to be 
considered serious.  Hospitalization for elective treatm ent of a pre -existing 
condition that did not worsen from baseline is not considered an adverse event.  
Results in persistent or significant disability/incapacity  
The term disability means a substantial disruption of a person’s ability to conduct 
normal lif e functions.  This definition is not intended to include experiences of 
relatively minor medical significance such as uncomplicated headache, nausea, 
vomiting, diarrhea, influenza, and accidental trauma (eg, sprained ankle) which 
may interfere with or prev ent everyday life functions but do not constitute a 
substantial disruption.  
Is a congenital anomaly/birth defect  
Other medically important serious event  
Medical or scientific judgment is to be exercised in deciding whether serious 
adverse event reporting  is appropriate in other situations such as important 
medical events that may not be immediately life -threatening or result in death or 
hospitalization but may jeopardize the subject or may require medical or surgical 
intervention to prevent 1 of the other  outcomes listed in the above definition.  
These events are typically to be considered serious.  
Examples of such events include invasive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias o r convulsions that do not result in hospitalization, or development of 
drug dependency or drug abuse.  
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 105 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Recording Adverse Events and Serious Adverse Events  
Adverse Event and Serious Adverse Event Recording  
 When an adverse event or serious adverse event occurs, it is the responsibility of 
the investigator to review all documentation (eg, hospital progress notes, 
laboratory, and diagnostics reports) related to the event.  
 The investigator will then record all relevant adverse event/serious adverse event 
information in the Event case report form (CRF).  
 The investigator must assign the following adverse event attributes:  
o Adverse event diagnosis or syndrome(s), if known (if not known, signs or 
symptoms);  
o Dates of onset and resolution (if resolved);  
o Did the event start prior to first dose of investigational product  
o Assessment of seriousness;  
o Severity (or toxicity defined below);  
o Assessment of relatedness to investigational product (AMG 570/placebo), 
protocol -required therapies and/or study -mandated activity/s tudy procedure;  
o Action taken  
 If the severity of an adverse event changes from the date of onset to the date of 
resolution, record as a single event with the worst severity on the Event s CRF.  
 It is not acceptable for the investigator to send photocopies of the subject’s 
medical records to the sponsor in lieu of completion of the Event s CRF page.  
 If specifically requested, the investigator may need to provide additional follow -up 
information, such as discharge summaries, medical records, or extracts from the 
medical records.  In this case, all subject identifiers, with the exception of the 
subject number, will be blinded on the copies of the medical records before 
submission to Amgen.  
 The inves tigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information.  In such cases, the diagnosis (not the 
individual signs/symptoms) will be documented as the adverse event/serious 
adverse event.  
Evalua ting Adverse Events and Serious Adverse Events  
Assessment of Severity  
The investigator will make an assessment of severity for each adverse event and 
serious adverse event reported during the study.  The assessment of severity will be 
based on:  
The Common Terminology Criteria for Adverse Events, version 5 which is available at 
the following location:  
http://ctep.cancer.gov/protocolDevelopment/electronic_ap plications/ctc.htm . 
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 106 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Assessment of Causality  
 The investigator is obligated to assess the relationship between investigational 
product (AMG 570/placebo), study -mandated activity/study procedure and/or 
other protocol -required therapies and each occurrence of each adverse 
event/serious adverse event.  
 Relatedness means that there are facts or reasons to support a relationship 
between investigational product and the event.  
 The investigator will use clinical judgment to determine the relationship.  
 Alternative causes, such as underlying disease(s), concomitant therapy, and other 
risk factors, as well as the temporal relationship of the event to investigational 
product administration will be considered and investigated.  
 The investigator will also consult the Investigator’s  Brochure  and/or Product 
Information, for marketed products, in his/her assessment.  
 For each adverse event/serious adverse event, the investigator must document in 
the medical notes that he/she has reviewed the adverse event/serious adverse 
event  and has provided an assessment of causality.  
 There may be situations in which a serious adverse event has occurred , and the 
investigator has minimal information to include in the initial report.  However, it is 
very important that the investigator always make an assessment of causality for 
every event before the initial transmission of the serious adverse event data.  
 The investigator may change his/her opinion of causality in light of follow -up 
information and send a serious adverse event follow -up report with the updated 
causality assessment.  
 The causality assessment is 1 of the criteria used when determining regulatory 
reporting requirements.  
 
Follow -up of Adverse Event and Serious Adverse Event  
 The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by 
Amgen to elucidate the nature and/or causality of the adverse event or serious 
adverse event as fully as possible.  This may include additional laboratory  tests or 
investigations, histopathological examinations, or consultation with other health 
care professionals.  
 If a subject is permanently withdrawn from protocol -required therapies because of 
a serious adverse event, this information must be submitted to  Amgen.  
 If a subject dies during participation in the study or during a recognized follow -up 
period, the investigator will provide Amgen with a copy of any post -mortem 
findings including histopathology . 
 New or updated information will be recorded in the or iginally completed Event s 
CRF.  
 The investigator will submit any updated serious adverse event data to Amgen 
within 24  hours of receipt of the information.  
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 107 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Reporting of Serious Adverse Event  
Serious Adverse Event Reporting via Electronic Data Collection Tool  
 The primary mechanism for reporting serious adverse event will be the electronic 
data capture (EDC) system.  
 If the EDC system is unavailable for more than 24  hours, then the site will report 
the information to Amgen using the electronic Serious Adver se Contingency 
Report Form (this is a paper -based form) (see  Figure  12-1) within 24  hours of the 
investigator’s knowledge of the event.  
 The site will enter the serious adverse event data into the electronic system as 
soon as it becomes available.  
 After the study is completed at a given site, the EDC system will be taken off -line 
to prevent the entry of new data or changes to existing data.  
 If a site receives a report of a new serious adverse event from a study subject or 
receives updated data on a previously reported  serious adverse event after the 
EDC has been taken off -line, then the site can report this information on the 
paper -based Serious Adverse Event Contingency Report Form ( see Figure  12-1). 
 Once the study has ended, serious adverse event(s) suspected to be related 
to investigational product will be reported to Amgen if the investigator 
becomes aware of a serious adverse event.  The investigator should use the 
paper -based Serious Adverse Event Contingency Report Form to report the 
event.  
 
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 108 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Figure  12-1.  Sample Electronic Serious Adverse Event Contingency Report Form  
 

Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 109 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
 

Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 110 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
 
 
 
 
 

Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 111 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
12.5 Appendix 5.  Contraceptive Guidance and Collection of Pregnancy 
and Lactation Information  
Study -specific contraception requirements for females of childbearing potential are 
outlined in Section  6.2. 
Contraceptive use and methods should be consistent with local regulations for subjects 
participa ting in clinical studies.  
Female subjects of childbearing potential should be advised of the pregnancy prevention 
requirements and the potential risk to the fetus if they become pregnant during treatment 
and for a period of at least 10 weeks after the last  dose of protocol -required therapies.  
Definition of Females of Childbearing Potential  
A female is considered fertile following menarche and until becoming postmenopausal 
unless permanently sterile.  Permanent sterilization methods include documented 
hyster ectomy, bilateral salpingectomy, and bilateral oophorectomy.  Females with 
documented permanent infertility due to an alternative medical cause (eg.  Mullerian 
agenesis, androgen insensitivity, and gonadal dysgenesis), can be considered not of 
childbearing potential.  
Note:  bilateral tubal ligation/occlusion is not considered a permanent sterilization 
method.  
Note:  Documentation from the following sources is acceptable to provide confirmation of 
each sterilization method:  1) review of subject’s medical records; 2) subject’s medical 
examination; or 3) subject’s medical history interview.  
A postmenopausal female is defined as:  
 A woman of ≥ 55 years with no menses for 12  months without an alternative medical 
cause OR  
 A woman age < 55 years with no menses fo r at least 12  months and with a follicle 
stimulating hormone (FSH) level within the definition of “postmenopausal range” for 
the laboratory involved.  In the absence of 12  months of amenorrhea, confirmation 
with more than one FSH measurement is required.  
 
Contraception Methods for Female Subjects  
Highly Effective Contraceptive Methods  
 Combined (estrogen and progestogen containing) hormonal contraception 
associated with inhibition of ovulation (oral, intravaginal, or transdermal)  
 Progestogen -only hormonal co ntraception associated with inhibition of ovulation 
(oral, injectable, implantable)  
 Intrauterine device  
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 112 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
 Intrauterine hormonal -releasing system  
 Bilateral tubal ligation/occlusion  
 Vasectomized partner (provided that partner is the sole sexual partner of the female 
subject of childbearing potential and that the vasectomized partner has received 
medical assessment of the surgical success)  
 Sexual abstinence (defined as refraining from heterosexual intercourse during the 
entire period of risk associated with the investigational products; the reliability of 
sexual abstinence must be evaluated in relation to the duration of the trial and the 
preferred and usual lifestyle of the subject)  
Collection of Pregnancy Information  
Female Subjects Who Become Pregnant  
 Investig ator will collect pregnancy information on any female subject who becomes 
pregnant while taking protocol -required therapies through the final safety 
assessment.  
 Information will be recorded on the Pregnancy Notification Form (see Figure  12-2).  
The worksheet must be submitted to Amgen Global Patient Safety within 24  hours of 
learning of a subject’s pregnancy.  (Note: Sites are not required to provi de any 
information on the Pregnancy Notification Form that violates the country or regions 
local privacy laws).  
 After obtaining the female subject’s signed authorization for release of pregnancy 
and infant health information, the investigator will collect pregnancy and infant health 
information and complete the pregnancy questionnaire for any female subject who 
becomes pregnant while taking protocol -required therapies through at least 
10 additional weeks after the last dose of the study drug.  This informat ion will be 
forwarded to Amgen Global Patient Safety.  Generally, infant follow -up will be 
conducted up to 12  months after the birth of the child (if applicable).  
 Any termination of pregnancy will be reported to Amgen Global Patient Safety, 
regardless of f etal status (presence or absence of anomalies) or indication for 
procedure.  
 While pregnancy itself is not considered to be an adverse event or serious adverse 
event, any pregnancy complication or report of a congenital anomaly or 
developmental delay, fetal  death, or suspected adverse reactions in the neonate will 
be reported as an adverse event or serious adverse event.  Note that an elective 
termination with no information on a fetal congenital malformation or maternal 
complication is generally not conside red an adverse event, but still must be reported 
to Amgen as a pregnancy exposure case.  
 Any serious adverse event occurring as a result of a post -study pregnancy which is 
considered reasonably related to the investigational product by the investigator, wil l 
be reported to Amgen Global Patient Safety as described in Section  12.4.  While the 
investigator is not obligated to actively seek this information in former study subjects, 
he or she may learn of a serious adverse event through spontaneous reporting.  
 Any female subject who becomes pregnant while participating will discontinue 
investigational product (see Section  8.1 for details).  
Male Subjects With Partners Who Become Pregnant  or Were Pregnant at the Time of 
Enrollment  
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 113 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
 In the event a male subject fathers a child during treatment, and for at least 
10 additional  weeks after discontinuing protocol -required therapies, the information 
will be recorded on the Pregnancy Notification Form.  The form (see Figure  12-2) 
must be submitted to Amgen Global Patient Safety within 24  hours of the site’s 
awareness of the pregnancy.  (Note: Sites are not required to provide any  
information on the Pregnancy Notification Form that violates the country or regions 
local privacy laws).  
 The investigator will attempt to obtain a signed authorization for release of pregnancy 
and infant health information directly from the pregnant femal e partner to obtain 
additional pregnancy information.  
 After obtaining the female partner’s signed authorization for release of pregnancy 
and infant health information, the investigator will collect pregnancy outcome and 
infant health information on the pre gnant partner and her baby and complete the 
pregnancy questionnaires.  This information will be forwarded to Amgen Global 
Patient Safety.  
 Generally, infant follow -up will be conducted up to 12 months after the birth of the 
child (if applicable).  
 Any termin ation of the pregnancy will be reported to Amgen Global Patient Safety 
regardless of fetal status (presence or absence of anomalies) or indication for 
procedure.  
Collection of Lactation Information  
 Investigator will collect lactation information on any female subject who breastfeeds 
while taking protocol -required therapies through at least 10 additional weeks after the 
last dose of investigational product  (Section  9.1.5 ). 
 Information will be recorded on the Lactation Notifica tion Form ( Figure  12-3) and 
submitted to Amgen Global Patient Safety within 24  hours of the investigator’s 
knowledge of event.  
 Investigational product will be discontinued if female subject breastfeeds during the 
study as described in exclusion criterion 223.  
 With the female subjects signed authorization for release of mother and infant health 
information, the investigator will collect mother and infant health information and 
complete the lactation questionnaire on an y female subject who breastfeeds while 
taking protocol -required therapies through the final safety assessment after 
discontinuing protocol -required therapies.  
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 114 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Figure  12-2.  Pregnancy Notific ation Form  
 
 

Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 115 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Figure  12-3.  Lactation Notification Form  
 

Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 116 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
12.6 Appendix 6.  Sample Storage and Destruction  
Any blood sample collected according to the Schedule of Activities ( Section  2) can be 
analyzed for any of the tests outlined in the protocol and for any tests necessary to 
minimize risks to  study subjects.  This includes testing to ensure analytical methods 
produce reliable and valid data throughout the course of the study.  This can also 
include, but is not limited to, investigation of unexpected results,  incurred sample 
reanalysis, and analyses for method transfer and comparability.  
All samples and associated results will be coded prior to being shipped from the site for 
analysis or storage.  Samples will be tracked using a unique identifier that is assig ned to 
the samples for the study.  Results are stored in a secure database to ensure 
confidentiality.  
If informed consent is provided by the subject, Amgen can do additional testing on 
remaining samples (ie, residual and back -up) to investigate and better understand the 
Inflammatory conditions, the dose -response and/or prediction of response to AMG 570 
and characterize aspects of the molecule (eg, mechanism of action/target, metabolites).  
Results from this analysis are to be documented and maintained but a re not necessarily 
reported as part of this study.  Samples can be retained for up to 20 years.  
Since the evaluations are not expected to benefit the subject directly or to alter the 
treatment course, the results of pharmacogenetic, [biomarker development, ] or other 
exploratory studies are not placed in the subject’s medical record and are not to be 
made available to the subject, members of the family, the personal physician, or other 
third parties, except as specified in the informed consent.  
The subject r etains the right to request that the sample material be destroyed by 
contacting the investigator.  Following the request from the subject, the investigator is to 
provide the sponsor with the required study and subject number so that any remaining 
blood sam ples and any other components from the cells can be located and destroyed.  
Samples will be destroyed once all protocol -defined procedures are completed.  
However, information collected from samples prior to the request for destruction, will be 
retained by  Amgen.  
The sponsor is the exclusive owner of any data, discoveries, or derivative materials from 
the sample materials and is responsible for the destruction of the sample(s) at the 
request of the subject through the investigator, at the end of the storage  period, or as 
appropriate (eg, the scientific rationale for experimentation with a certain sample type no  
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 117 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
longer justifies keeping the sample).  If a commercial product is developed from this 
research project, the sponsor owns the commercial product.  The  subject has no 
commercial rights to such product and has no commercial rights to the data, information, 
discoveries, or derivative materials gained or produced from the sample.  See 
Section  12.3 for subject confidentiality.  
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 118 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
12.7 Appendix 7.  Hepatotoxicity Stopping Rules:  Suggested Actions and 
Follo w-up Assessments and Investigational Product Rechallenge 
Guidelines  
Subjects with abnormal hepatic laboratory values (ie, alkaline phosphatase [ALP], 
aspartate aminotransferase [AST], alanine aminotransferase [ALT], total bilirubin [TBL]) 
and/or international normalized ratio (INR) and/or signs/symptoms of hepatitis (as 
described below) may meet the criteria for withholding or permanent discontinuation of 
Amgen investigational product or other protocol -required therapies, as specified in the 
Guidance for Industry Drug -Induced Liver Injury:  Premarketing Clinical Evaluation,  
July 2009 . 
Criteria for Withholding and/or Permanent Discontinuation of Amgen 
Investigational Product and Other Protocol -required Therapies Due to Potential 
Hepatotoxicity  
The following stopping and/or withholding rules apply to subjects for whom another 
cause of their changes in liver biomarkers (TBL, INR and transaminases) has not been 
identified.  
Important alternative causes for elevated AST/ALT and/or TBL values include, but are 
not limited to:  
 Hepatobiliary tract disease  
 Viral hepatitis (eg, hepatiti s A/B/C/D/E, Epstein -Barr Virus, cytomegalovirus, herpes 
simplex virus, varicella, toxoplasmosis, and parvovirus)  
 Right sided heart failure, hypotension or any cause of hypoxia to the liver causing 
ischemia  
 Exposure to hepatotoxic agents/drugs or hepatotox ins, including herbal and dietary 
supplements, plants and mushrooms  
 Heritable disorders causing impaired glucuronidation (eg, Gilbert’s syndrome, 
Crigler -Najjar syndrome) and drugs that inhibit bilirubin glucuronidation (eg, indinavir, 
atazanavir)  
 Alpha -one antitrypsin deficiency  
 Alcoholic hepatitis  
 Autoimmune hepatitis  
 Wilson’s disease and hemochromatosis  
 Nonalcoholic fatty liver disease including steatohepatitis  
 Non-hepatic causes (eg, rhabdomyolysis, hemolysis)  
If investigational product(s) is/are withheld, the subject is to be followed for possible 
drug-induced liver injury (DILI) according to recommendations in the last section of this 
appendix.  
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 119 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Rechallenge may be considered if an alternative cause for impaired liver tests (ALT, 
AST, ALP) and/or e levated TBL, is discovered and the laboratory abnormalities resolve 
to normal or baseline (see next section in this appendix).  
Table  12-2.  Conditions for Withholding and/or Permanent Discontinuation of 
Amgen Investigational Product and Other Protocol -required Therapies Due to 
Potential Hepatot oxicity  
Analyte  Temporary Withholding  Permanent Discontinuation  
TBL  3x ULN  
at any time   2x ULN  
  OR 
INR --  1.5x (for subjects not on 
anticoagulation therapy)  
 OR AND  
AST/ALT   8x ULN at any time  
 5x ULN but  8x ULN for  2 weeks  
 5x ULN but  8x ULN and unable to 
adhere to enhanced monitoring schedule  
 3x ULN with clinical signs or symptoms 
that are consistent with hepatitis (such as 
right upper quadrant pain/tenderness, 
fever, nausea, vomiting, and jaundice)  In the presence of no important 
alternative causes for elevated 
AST/ALT and/or TBL values  
 3x ULN (when baseline was  ULN)  
 OR  
ALP  8x ULN at any time  -- 
ALP  alkaline phosphatase; ALT  alanine aminotransferase; AST  aspartate aminotransferase; 
INR  international normalized ratio; TBL  total bilirubin; ULN  upper limit of normal  
Criteria for Rechallenge of Amgen Investigational Product and Other 
Protocol -required Therapies After Potential Hepatotoxicity  
The decision to rechallenge the subject is to  be discussed and agreed upon 
unanimously by the subject, investigator, and Amgen.  
If signs or symptoms recur with rechallenge, then Amgen 570 is to be permanently 
discontinued.  Subjects who clearly meet the criteria for permanent discontinuation (as 
desc ribed in Table  12-2) are never to be rechallenged.  
Drug -induced Liver Injury Reporting and Additional Assessments  
Reporting  
To facilitate appropriate monitoring for signals of DILI, cases of concurrent AST or ALT 
and TBL and/or INR elevation, according to the criteria spec ified in the above, require 
the following:  
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 120 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
 The event is to be reported to Amgen as a serious adverse event within 24  hours of 
discovery or notification of the event (ie, before additional etiologic investigations 
have been concluded)  
 The appropriate case r eport form (CRF) (eg, Event CRF) that captures information 
necessary to facilitate the evaluation of treatment -emergent liver abnormalities is to 
be completed and sent to Amgen  
Other events of hepatotoxicity and potential DILI are to be reported as serious  adverse 
events if they meet the criteria for a serious adverse event defined in Section  12.4. 
Additional Clinical Assessments and Observation  
All subjects in whom investigational product(s) or protocol -required therapies is/are 
withheld (either permanently or conditionally) due  to potential DILI as specified in 
Table  12-2 OR who experience AST or ALT elevations  3 x upper limit of normal (ULN) 
or 2-fold increases above baseline values for subjects with elevated values before drug 
are to undergo a period of “close observation” until abnormalities return to normal or to 
the subject’s baseline levels. Tests may be p erformed locally as required per 
investigator discretion.  
Assessments that are to be performed during this period include:  
 Repeat AST, ALT, ALP, bilirubin (BIL) (total and direct), and INR within 24  hours  
 In cases of TBL  2x ULN or INR  1.5, retesting of liver tests, BIL (total and direct), 
and INR is to be performed every 24  hours until laboratory abnormalities improve  
Testing frequency of the above laboratory tests may decrease if the abnormalities 
stabilize or the investigational prod uct(s) or protocol -required therapies has/have been 
discontinued AND the subject is asymptomatic.  
Initiate investigation of alternative causes for elevated AST or ALT and/or elevated TBL.  
The following are to be considered depending on the clinical situat ion: 
 Complete blood count with differential to assess for eosinophilia  
 Serum total immunoglobulin (Ig)G, antinuclear antibody anti -smooth muscle 
antibody, and liver kidney microsomal antibody -1 to assess for autoimmune hepatitis  
 Serum acetaminophen (parace tamol) levels  
 A more detailed history of:  
 Prior and/or concurrent diseases or illness  
 Exposure to environmental and/or industrial chemical agents  
 Symptoms (if applicable) including right upper quadrant pain, 
hypersensitivity -type reactions, fatigue, nausea , vomiting and fever  
 Prior and/or concurrent use of alcohol, recreational drugs and special diets  
Product:  Rozibafusp Alfa (AMG 570)   
Protocol Number:  20170588  
Date:  24 May 2022  Page 121 of 121 
 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
 Concomitant use of medications (including non -prescription medicines and 
herbal and dietary supplements), plants, and mushrooms  
 Viral serologies  
 Creatine phos phokinase, haptoglobin, lactate dehydrogenase and peripheral blood 
smear  
 Appropriate liver imaging if clinically indicated  
 Appropriate blood sampling for pharmacokinetic analysis if this has not already been 
collected  
 Hepatology consult (liver biopsy may b e considered in consultation with a 
hepatologist)  
Follow the subject and the laboratory tests (ALT, AST, TBL, INR) until all laboratory 
abnormalities return to baseline or normal or considered stable by the investigator.  The 
“close observation period” is to continue for a minimum of 4  weeks after discontinuation 
of all investigational product(s) and protocol -required therapies.  
The potential DILI event and additional information such as medical history, concomitant 
medications and laboratory results must b e captured in the corresponding CRFs.  
 
Product:  Rozibafusp Alfa ( AMG 570 ) 
Protocol Number:  20170588  
Date:  24 May 2022  Page 1 of 7 
Amgen Proprietary - Confidential  
FORM -492529 ,   Effective Date: 02 Mar 2020 ,  Version: 6.0 Amendment 3 
Protocol Title:  A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of 
Rozibafusp Alfa (AMG 570) in Subjects With Active Systemic Lupus Erythematosus (SLE) 
With Inadequate Response to Standard of Care (SOC) Therapy  
 
Amgen Protocol Number AMG 570  20170588  
EudraCT Number 2019 -000328 -16  
NCT Number 04058028  
 
Amendment Date:  24 May 2022  
 
Rationale:  
This protocol amendment removes the requirement for an independent blind joint assessor  to 
conduct joint count  assessments (number of tender and swollen joints).  There is no need to 
have a separate blinded assessor to perform joint count , since  for the primary endpoint and 
other main effica cy endpoints this assessment is performed by the investigator  from each site , 
who have the required training and are  performing all efficacy assessments .  Additional minor 
updates were incorporated into this amendment which in  general represent  clarifications and 
grammatical corrections .  The following changes were included:    
1. Efficacy Assessments:  
o Remove requirement for a separate blinded joint assesso r (section 9.2.2.5) . 
o Clarify that the same investigator must perform all efficacy assessments at every 
time point for a given subject .  In order to ensure consistency, i t is clarified that 
the same investigator/ assessor should perform  the assessments throughout the 
study for a given subject (sections  9.2.2 and 9.2.2.5) . 
o Clarify data collection  process (sections 9.2.2, 9.2.2.5, and 9.2.2.6) . 
Product:  Rozibafusp Alfa ( AMG 570 ) 
Protocol Number:  20170588  
Date:  24 May 2022  Page 2 of 7 
Amgen Proprietary - Confidential  
FORM -492529 ,   Effective Date: 02 Mar 2020 ,  Version: 6.0 o Improve clarity of the definition of Systemic Lupus Erythematosus Responder 
Index (SRI -4) response in section  9.2.2.11  and British Isles Lupus Assessment 
Group (BILAG) -based Combined Lupus Assessment (BICLA) resp onse  in 
section  9.2.2.12 . 
o Clarify events that classify joints as non -evaluable  (section 9.2.2.5).  
2. Update s to Primary Estimand include (sections 1.1 and 4.1):  
o Clarify that SRI -4 response cannot be  achieved  regardless of protocol deviations, 
since the Important Protocol Deviation list is now used to define 'more than 
protocol -allowed therapies' . 
o Remove language defining SRI -4 response  from the Objectives/Endpoints table , 
as it is described in detail in other sections of the protocol . 
3. Clarifications to Objectives  and Endpoints  include (sections 1  and 4.1) :  
o Endpoint for secondary objective aiming to evaluate efficacy of AMG 570 on joint  
count was updated to clarify that the combined tenderness and swelling of joint 
count will be conducted for joints in hands and wrists , as it is described in 
section  9.2.2.5 .   
o Clarify that the e ndpoint  for secondary objective  aiming  to describe efficacy of 
AMG 570 using patient -reported outcomes  include s the 2 component measures 
of physical and mental hea lth to be assess ed by the Medical Outcomes Short 
Form 36 version 2 Questionnaire , as it is described in  section  9.2.10.1 . 
4. Clarifications were provided on study duration and safety follow -up for subjects that 
complete the 52 -week treatment period  and for subje cts who discontinue the 

Product:  Rozibafusp Alfa ( AMG 570 ) 
Protocol Number:  20170588  
Date:  24 May 2022  Page 3 of 7 
Amgen Proprietary - Confidential  
FORM -492529 ,   Effective Date: 02 Mar 2020 ,  Version: 6.0 investigational product earlier.  These clarifications were incorporated to multiple 
sections of the protocol  (sections 5.1, 5.3.2 , 9.1.3 , 9.1.5.1 , and Table 2 -2).   
o Timing of sample collection for pharmacokinetic ( PK) and  
assessments during safety follow -up was described for clarity purposes 
(section  9.1.3).  
o Additionally, for simplification and improve d clarity , information pertaining to 
safety follow -up was removed from protocol synopsis , overall design de scription , 
and treatment period  (section s 1.1, 5.1, and 9.1.2 )  
5. Clarification of when an individual subject is considered to have completed the study 
(sections 5.3.2 and 9.1.5.1).  
6. Clarify within the table for Analyses Schedule that after the 7th interim an alysis , 
additional interim analyses are planned after every 32 subjects are randomized and 
have had the opportunity to complete the week 24 assessment until full enrollment  
(Table 1 -1).   
7. Interim analysis language was updated to remove details related to the hypothetical 
Phase 3 study as they do not impact the conduct of this study and will be pre -specified in 
the study data monitoring committee charter, statistical analysis plan, and simul ation 
report, as appropriate (section 10.3.1).  
8. Clarify that the  adjudication reviews occur  at study entry to determine eligibility and  
throughout the study period on blinded endpoint data from enrollment to week 52 for all 
randomized subjects and for all visits  (section 5.1) . 
9. Clarify that s ubjects taking more that protocol -allowed therapies are considered 
treatment failure s for the prima ry efficacy endpoint analyses  but will be allowed to 
continue investigational product and/or the study at the investigator’s discretion except 
those initiating  specific  treatments with immunosuppressant/immunomodulators  
(sections 5.1, 7.1.4. 1, and 7.1.7 ). 
o Section 7.1.7 is listing all the treatments preventing a subject from continuing 
treatment with investigational product.   

Product:  Rozibafusp Alfa ( AMG 570 ) 
Protocol Number:  20170588  
Date:  24 May 2022  Page 4 of 7 
Amgen Proprietary - Confidential  
FORM -492529 ,   Effective Date: 02 Mar 2020 ,  Version: 6.0 10. Title of section 9.2.6.1 was changed to Biomarker Assessment During the Study given 
that not all biomarkers listed in that section ha ve established pharmacodynamic activity .  
11. Specify that all subjects who at the end of study visit have clinical sequelae considered 
potentially related to an  response will be asked to return for 
additional testing.  Additionally, it w as clarified that follow -up results will be 
communicated to sites after database is locked  to prevent potential risk of unblinding the 
sites for treatment assignment  (section 9.2.8).  
12. Clarify what is included in baseline covariates (section 10.2.2).  
13. Inclusi on criteria:  
o Clarify i nclusion criterion 105 by re-organizing  Systemic Lupus Erythematosus 
(SLE)  treatments that subjects must be taking to meet protocol -specific rules 
applied during screening.  One treatment was included  to this criterion, 
leflunomide  (update also incorporated in section 7.4.2.2).  
14. Exclusion criteria:    
Other Medical Conditions  
o For consistency, criterion 208 was updated to align with the updates made to 
Schedule of Activities regarding monitoring of viral load frequency  to evaluate 
hepatitis B and C .  
Prior/Concomitant Therapy was updated to:  
o Add thalidomide  treatment  within 4 weeks prior to screening to the treatment 
listed in exclusion criterion 212 .  For consistency, thalidomide was also added as 
an excluded treatment during study pe riod (section 7.1.7).  
o Decreased  washout period for Janus kinase ( JAK) inhibitor from 3 to 1 month 
prior to screening  based on information available for the 
pharmacokinetic /pharmacodynamic  profile of these drugs  (criterion  213). 
o Clarify criterion 215 by a dding immunosuppressive or immunomodulatory activity  
to treatment with a biologic agent , reduc e washout period for abatacept to 

Product:  Rozibafusp Alfa ( AMG 570 ) 
Protocol Number:  20170588  
Date:  24 May 2022  Page 5 of 7 
Amgen Proprietary - Confidential
FORM -492529 ,   Effective Date: 02 Mar 2020 ,  Version: 6.0 3 months prior to screening  based on its pharmacokinetic/pharmacodynamic 
profile , and clarify that pharmacodynamic activity of oth er biologics at screening 
should be considered when evaluating washout periods . 
oClarify  the timeframe within which a subject must not plan to receive a live
vaccine (criterion 217).
Prior/Concurrent Clinical Study Experience : 
oRevise washout period for tr eatment with an investigational product or device to
consider the pharmacokinetic  and pharmacodynamic  profile of those products at
screening  (criterion 219).
Diagnostic Assessment s: 
oInclude  Gilbert’s Syndrome as an exception for presence of laboratory
abno rmalities during screening in serum total bilirubin  since these patients
present  non clinically relevant  elevated bilirubin levels ( criterion 221).
Other Exclusions  was updated to : 
oClarify that serum pregnancy test is required at screening and urine pregnancy
test is required at day 1 visit  (criterion 225).
15. Schedule of Activities -Safety Follow -up Period was updated to (Table 2 -2):
oClarify that this table applies for the subset of subjects that completed the
planned 52 -week treatment period and emphasize that subjects are required to
attend as many visits as necessary to ensure a minimum of 16 weeks of safety
follow -up after last dose of the investigational product.
oClarify that  safety follow -up visits should be schedul ed in relation to last
administration of the investigational product and not visit week 52.
oAdd frequency for monitoring viral load to evaluate hepatitis B and C .
oRemove urine pregnancy tests from the last two safety follow -up visits.
Product:  Rozibafusp Alfa ( AMG 570 ) 
Protocol Number:  20170588  
Date:  24 May 2022  Page 6 of 7 
Amgen Proprietary - Confidential  
FORM -492529 ,   Effective Date: 02 Mar 2020 ,  Version: 6.0 16. Minor updates were in cluded in the footnotes of the Schedule of Activities Treatment 
Period to clarify information regarding starting time of home health care visits, the option 
of conducting a QuantiFERON -TB test locally, assessment frequency of serum viral 
DNA and RNA for he patitis B and C, and .  Additionally, for 
clarity purposes details no longer relevant to the assessments were removed (Table 2 -1 
footnotes e, f, g, i, q, and r).  
17. Accountability instructions for AMG 570 was updated to remove requir ement to record 
the amount used in AMG 570 preparation on the electronic case report form for each 
subject (Table 7 -1). 
18. Simplify language around disease flares as a p ossible reason to discontinue 
protocol -required investigational product or procedural asse ssments (section 8.1).  
19. The description of AMG 570 was updated (section 3.2.2).  
20. For rescreening, it was clarified that tuberculosis tests and serologies for hepatitis B 
virus, hepatitis C virus , and human immunodeficiency virus ( HIV) are not required to be 
repeated when rescreening occurs within 12 months of screening visit, provided that 
those test results were negative and there is no patient’s medical/epidemiological history 
suggestive of infection or recent exposure to cases of infection (section 9.1.1).  
21. Clarify the types of corticosteroid treatments that are allowed in the study and specify 
that subjects requiring such treatments can continue the investigational product at the 
investigator’s discretion (section 7.1.4.2).   
22. Simplify Treatment Period section by removing  information outside the scope of this 
section  (section 9.1.2) . 
23. Include the option for local laboratory to conduct the QuantiFERON -TB test for eligibility  
using a local kit procured by the site (section 9.2.4.3.2).  
24. Clarify the rating sca le used for patient global assessment of disease activity  
(section  9.2.10.4) . 

Product:  Rozibafusp Alfa ( AMG 570 ) 
Protocol Number:  20170588  
Date:  24 May 2022  Page 7 of 7 
Amgen Proprietary - Confidential  
FORM -492529 ,   Effective Date: 02 Mar 2020 ,  Version: 6.0 25. Information collected for screen failure was updated to remove medical history and prior 
therapies as these are not considered required forms for screen failure per electronic 
case report form standard instructions (section 6.5).   
26. Remove the  efficacy analysis set  (section 10.2.1.2).  
27. Include a footnote in Analyte Listing table to instruct that local lab testing may be 
conducted if central lab testing is unavailable and add that Qu antiFERON -TB test can 
also be conducted locally .  For clarity purposes , details no longer relevant to the analyte 
listing  were removed  (Table 1 2-1 footnote s a, b, and f). 
28. Add a clarification note that clinical assessments to evaluate hepatoxicity  in subjects for 
whom investigational product is withheld due to potential drug -induced liver injury can be 
performed locally as required per investigator discretion  (section 12.7) . 
29. Updates have been implemented to align collection and reporting of safety events with 
current procedures (Table 2 -1, Table 2 -2, sections 7.1.6, 9.2.3.1.1.2, 9.2.3.1.1.3,  and 
12.4). 
30. Clarify that  tapering of oral corticosteroids is allowed before week 24 at the  investigator ’s 
discretion  (sections  1.1 and 7.1.4.2).  
32. The definition of the  alphabetical score used to evaluate disease activity in 9 separate 
organ system was updated only for D by replacing stable with no activity 
(section  9.2.2.2).   
33. Administrati ve, typographical , abbreviations,  and formatting changes were made 
throughout the protocol.  

Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  11 Novem ber 2020  Page 1 of 2 
Amgen Proprietary - Confidential  
FORM -492529 ,   Effective Date: 02 Mar 2020 ,  Version: 6.0 Superseding Amendment 2  
Protocol Title:  A Phase 2b Dose Ranging Study to Evaluate the Efficacy and 
Safety of Rozibafusp Alfa (AMG 570) in Subjects with Active Systemic Lupus 
Erythematosus (SLE) with Inadequate Response to Standard of Care (SOC) 
Therapy  
 
Amgen Protocol Number AMG 570 20170588  
 
Amendment Date:  13 October 2020  
Superseding Amendment Date:  11 November  2020  
 
Superseding Amendment 2 Summary of Changes:  
 Incorporate changes to align with the Data Monitoring Committee (DMC) Charter:  
 Change ‘Futility’ to ‘Administrative Success’ in Table 1 -1. 
 Revise administrative success cutoff value from 85 to 80 . 
 Remove ‘moderate to severe’ from BILAG flare endpoint.  
 Relocate the SL EDAI -2K proteinuria definition for clarity.  
 Clarify efficacy assessment data will be captured either on an electronic or paper 
source and transmitted or entered into the study database.  
 Clarify SLE -related eligibility will be reviewed and confirmed by the adjudication 
team.  
 Delete Appendix 8. Data Collection to align with the updated Amgen protocol 
template.  
Amendment 2 Summary of Changes:  
 Incorporate changes to the study design to enable the study to support registration, if 
the results are positive ; these  changes include : 
 Update study from phase  2 to phase  2b. 
 Revise primary endpoint to SRI -4 response rate at week  52 and make SRI -4 
response rate at week 24 a secondary endpoint . 
 Change all key secondary endpoints to secondary endpoints  and add secondary 
disease flare endpoints . 
 
 Revise statistical methods, including sample size estimate, planned analyses, 
and efficacy analyses methods for primary and secondary endpoints.  

Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  11 Novem ber 2020  Page 2 of 2 
Amgen Proprietary - Confidential  
FORM -492529 ,   Effective Date: 02 Mar 2020 ,  Version: 6.0  Clarify options for a subject to proceed in the study if the subject discontinues 
investigational product prior to week 52.  
 Clarify contrac eptive guidance and pregnancy and lactation information:  
 Adjust the duration for contraceptive requirements and collection of pregnancy 
and lactation information to at least 10 additional weeks after the last dose of 
investigational product for female subj ects of childbearing potential.  
 Specify that pregnancy testing should be performed monthly during both the 
treatment period and at the first 2 safety follow -up visits.  
 Clarify the definition of females of childbearing potential.  
 Specify home health care vi sits will be centrally provided by the sponsor starting a t 
week  22 and will be optional for subjects who have not experienced adverse effects 
from investigational product administration.  
 Clarify initiation or increase in oral corticosteroid dosing.  
 Add Independent Data Monitoring Committee description.  
 Administrative, typographical, and formatting changes were made throughout the 
protocol.  

Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  13 October 2020  Page 1 of 2 
Amgen Proprietary - Confidential  
FORM -492529 ,   Effective Date: 02 Mar 2020 ,  Version: 6.0 Amendment 2  
Protocol Title:  A Phase 2b Dose Ranging Study to Evaluate the Efficacy and 
Safety of Rozibafusp Alfa (AMG 570) in Subjects with Active Systemic Lupus 
Erythematosus (SLE) with Inadequate Response to Standard of Care (SOC) 
Therapy  
 
Amgen Protocol Number AMG 570 20170588  
 
Amendment Date:  13 October 2020  
 
Summary of Changes:  
 Incorporate changes to the study design to enable the study to support registration, if 
the results ar e positive ; these changes include : 
 Update study from phase  2 to phase  2b. 
 Revise primary endpoint to SRI -4 response rate at week  52 and make SRI -4 
response rate at week 24 a secondary endpoint . 
 Change all key secondary endpoints to secondary endpoints  and add secondary 
disease flare endpoints . 
 Revise statist ical methods, including sample size estimate, planned analyses, 
and efficacy analyses methods for primary and secondary endpoints.  
 Clarify options for a subject to proceed in the study if the subject discontinues 
investigational product prior to week 52.  
 Clarify contraceptive guidance and pregnancy and lactation information:  
 Adjust the duration for contraceptive requirements and collection of pregnancy 
and lactation information to at least 10 additional weeks after the last dose of 
investigational product f or female subjects of childbearing potential.  
 Specify that pregnancy testing should be performed monthly during both the 
treatment period and at the first 2 safety follow -up visits.  
 Clarify the definition of females of childbearing potential.  
 Specify home health care visits will be centrally provided by the sponsor starting a t 
week  22 and will be optional for subjects who have not experienced adverse effects 
from investigational product administration.  

Product:  Rozibafusp Alfa (AMG 570)  
Protocol Number:  20170588  
Date:  13 October 2020  Page 2 of 2 
Amgen Proprietary - Confidential  
FORM -492529 ,   Effective Date: 02 Mar 2020 ,  Version: 6.0  Clarify initiation or increase in oral corticosteroid dosing.  
 Add Independent Data Monitoring Committee description.  
 Administrative, typographical, and formatting changes were made throughout the 
protocol.  

Product:  AMG 570  
Protocol Number:  20170588  
Date:  28 February 2020  Page 1 of 70 
CONFIDENTIAL  
  Amendment 1 
Protocol Title:  A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety 
of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) With 
Inadequate Response to Standard of Care (SOC) Therapy  
 
Amgen Protocol Number 20170588  
 
Amendment Date:  28 February 2020  
 
Rationale  for Major Changes : 
 Remove detectable systemic lupus erythematosus  (SLE) standard of care  
(SOC ) drug levels from the inclusion criteria list  - recent evidence of 
important technical limitations in the methods use d to assess levels of those 
therapies that may lead to a high rate of false negative results (which are 
particularly significant for some SLE SOC therapies).  Therefore, assessments of 
drug levels of methotrexate, chloroquine and dapsone will be removed fr om 
protocol, while assessment of drug levels of hydroxychloroquine, mycophenolate 
mofetil and azathio prine will remain.  Results of those assessments will be used 
only for exploratory analyses and not for eligibility purposes, as current available 
evidence  is still insufficient to establish a clear correlation between drug levels 
assessed by the methods used in this protocol and adherence to those therapies.  
 Substitute Systemic Lupus Erythematosus Disease Activity Index 2000  
(SLEDAI 2K ) by hybrid SLEDAI as part of the efficacy assessment  - hybrid 
SLEDAI was the SLEDAI version used to validate Systemic Lupus 
Erythematosus Responder Index  (SRI) 4 index (Navarra et al, 2011; 
Furie  et al, 2011 ).  The arthritis definition in the hybrid SLEDAI improves th e 
specifi city of the instrument for inflammatory arthritis, reducing the probabi lity of 
false positive scores at baseline and throughout the study.  
 Simplify and reduce screening period  - removal of SLE drug levels from 
eligibility criteria allows shortening screeni ng period, which simplifies screening 
process and reduce timelines.  
 Introduce home health care visits  - frequent number of visits to the site 
(every  2 weeks) has been pointed out by many patients and investigators as a 
barrier for enrollment.   The offer o f home care visits is expected to increase study 
participation.  
Rationale for Minor Changes:  
 Add Lupus Low Disease Activity State  (LLDAS ) to key secondary endpoints . 
 Reduce period required for oral corticosteroids  (OCS ) stable dose prior to 
screening visit  - from 4 to 2 weeks . 
Product:  AMG 570  
Protocol Number:  20170588  
Date:  28 February 2020  Page 2 of 70 
CONFIDENTIAL  
   Changes to OCS dose permitted between 0  to 4 weeks - from up to 20 mg/day 
increase in prednisone dose (or equivalent) over baseline to up to 5 mg/day 
increase (10 mg/day of prednisone or equivalent allowed if OCS being 
temporarily ini tiated between 0  to 4 weeks).  In both cases, return to baseline 
dose within 2 weeks is required.  
 Remove body surface requirements for rash sore in SLEDAI at screening 
visit-rash is being evaluated through Cutaneous Lupus Erythematosus Area and 
Severity In dex (CLASI ) instrument and there is no need to impose restrictions 
relatively to the extension of rash (which are difficult to achieve in SLE patients).  
 Add language relative to management of Non-steroidal Anti -inflammatory Drugs 
(NSAIDs ) and analgesic the rapies throughout the study  - Initiation or increases in 
the NSAIDs or other analgesic therapy dose during the study are allowed if: 
1) not initiated within 24  hours of the scheduled monthly efficacy assessments 
and 2) the subject returns to baseline dose within the subsequent 2  weeks.  For 
patients taking these therapies at baseline, stable dose is recommended 
throughout the study.  
 Substitute FACIT -Fatigue by Patient -Reported Outcome Measurement 
Information System  (PROMIS )-Fatigue scale as part of Patient  Reported 
outcomes ( PROs ) – PROMIS able to assess impact of fatigue.  
 Revise washout period for prior biologic drugs –abatacept 6 months, belimumab 
and anifrolumab 3 months prior to screening.  
 Add additional lab parameters  – added CRP, ESR, GGT as part of regular 
chemistry assessments, add lipid profile ( baseline and week 52 only), add 
(baseline, week 24 and 52), add aPTT as part of 
regular coagulation assessments.  
